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 Abstract	
Bipolar Disorder (BD) is a severe chronic mood disorder with typical onset in late adolescence to 
early adulthood. A large proportion of individuals with BD experience onset of symptoms prior to 
adulthood and it is commonly reported that an earlier onset is associated with more negative outcomes. 
Delays in diagnosis and appropriate treatment are also associated with poorer prognosis for patients with 
BD. Early identification is therefore imperative for more favourable outcomes, however, the heterogeneity 
of bipolar presentations mean that diagnosis remains a complicated process. The aims of this thesis were 
threefold: To summarise and synthesise the current empirical and theoretical research into BD; to critically 
evaluate the literature investigating early onset of BD to ascertain whether age of onset is indeed 
associated with poorer outcomes; and to examine whether individual symptoms associated with BD may 
be clinically useful as risk markers in childhood and adolescence.  
Study one systematically evaluated and analysed data from existing research investigating 
outcomes associated with an early onset of bipolar disorder. Analysis included data from fifteen empirical 
papers that compared clinical presentation and outcomes for individuals with BD grouped according to 
age of onset (Total n = 7370). Results indicated there was insufficient evidence to support commonly 
reported associations between early onset and clinical characteristics indicative of greater severity such as 
psychotic symptoms or mixed episodes. Clinical features found to have the strongest relationship with an 
earlier age of onset were those that may potentially be amenable to intervention such as comorbid anxiety, 
substance use, and treatment delay. Results highlight the importance of early identification in BD and 
provide potential areas of focus for the development of early intervention.  
In the second study, the potential clinical usefulness of individual symptoms was examined using 
a novel analytical approach based on Item Response Theory (IRT). The main objective of this study was 
to evaluate whether individual symptoms differed in their capacity to discriminate between those scoring 
high and low on underlying latent traits of depression and mania, and in the information they provided in 
relation to severity. The sample consisted of n=186 participants aged 12 – 21yrs including n = 105 with a 
first degree relative who has a diagnosis of BD (At Risk); n = 63 control participants (C); and n = 18 with 
a confirmed diagnosis of bipolar disorder (BD). Depressive symptoms found to be the most informative 
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were Anhedonia, Hopelessness, and Thoughts of Death. The least discriminating items were Insomnia and 
Irritability. From the mania scale, the most informative items were Increased Energy, Hyperactivity and 
Elevated Mood. Symptoms providing least information were Mood Lability and again, Irritability. Results 
support hypotheses from previous research that specific mood symptoms are more informative of risk in 
BD than general symptoms. Results are also in line with previous findings that indicate that increased 
energy is a core feature of mania. These findings are important in relation to ongoing controversy around 
diagnoses of paediatric BD and the broadening of diagnostic criteria. 
Overall, the studies in this thesis provide information useful to clinicians in the identification of at 
risk populations that may benefit from early support, monitoring and intervention. They provide a basis 
for the creation of developmentally appropriate clinical screening tools that assist in differentiating normal 
adolescent stress from clinically relevant risk, and development of early intervention programs for 
individuals considered at risk. From a theoretical perspective, these studies identify key risk areas in 
adolescent populations and inform areas of future research important for this group.  
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Chapter	1:	Introduction	
Over the last two decades there has been a drive in mental health care and support services to 
move from a crisis care model to a more preventative approach. The aims of this approach are to use early 
identification to minimise diagnostic delays, allow for appropriate and timely intervention, and thus 
improve prognosis and outcomes. There has been some evidence of success with this approach in 
schizophrenia and psychotic disorders. For example, positive outcomes have been found for those with 
early (EOS) and very early-onset (VEOS) schizophrenia following psychosocial intervention and 
cognitive remediation (Armando, Pontillo, & Vicari, 2015); and specialised assertive early intervention 
has been found to have positive effects on positive and negative symptoms as well as comorbid substance 
use (Nordentoft, Rasmussen, Melau, Hjorthøj, & Thorup, 2014). Given the commonalities that have been 
identified by genetic and epidemiological research between schizophrenia and bipolar disorder (BD) in 
certain symptoms, susceptibility markers, and neurotransmitter dysfunction (Möller, 2002; Murray et al., 
2004) these results may provide promise for early intervention outcomes in bipolar BD. Unfortunately, 
many psychological disorders, BD included, are heterogeneous in their presentations often making 
accurate and reliable diagnosis complex. As such, early identification when symptoms are less pronounced 
is very challenging. The aims of this thesis were threefold: First, to summarise and synthesise the current 
empirical and theoretical research relating to onset, diagnosis and prognosis in BD. Second, to 
systematically review and analyse empirical data specific to studies of early onset of BD and resulting 
outcomes; and finally, to apply a novel statistical approach to symptom measures from commonly used 
standardised interviews to identify individual symptoms that may be clinically useful in identifying risk of 
later disorder development.  
The following literature review provides an overview of the relevant theoretical and empirical 
research as rationale for the two studies included in the thesis. This includes an introduction to the recent 
history of BD research; diagnostic difficulties in BD; changes to key focus areas over time; and current 
opinions. Also addressed are the parallels and overlap between BD and schizophrenia research, and the 
relevant advances in schizophrenia research that, it is argued, may inform developmental research into 
BD. Finally, a brief overview of Item Response Theory is provided, as background to the examination of 
adolescent symptoms of BD in study two.  
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Background	
Bipolar disorder (BD) is a clinically severe, chronic mood disorder with onset commonly around 
late adolescence and early adulthood (Joyce, 1984; Merikangas et al., 2007).  It is linked with high rates of 
comorbidity (Oswald et al., 2007), and is a leading cause of premature mortality due to suicide and 
associated medical conditions such as diabetes and cardiovascular disease (Coryell et al., 1993c). BD 
causes widespread role impairment, and is associated with a significant economic burden, both to the 
individual, and to society due to the direct costs of medical expenditure, and indirect costs such as loss of 
productivity and increased mortality (Fagiolini et al., 2013). Although severity and course vary among 
individuals affected with BD, overall it is a grave psychiatric illness that is a leading cause of disability 
worldwide (Azorin et al., 2013; World Health Organisation, 2001). 
The defining feature of BD is the occurrence of episodes of mania, or hypomania, that alternate, 
or occur concurrently with, episodes of depression (Fagiolini et al., 2013). A manic episode is defined by a 
significant, persistent, abnormal change in mood (becoming highly euphoric, elated, or irritable) 
accompanied by an increase in behaviours that signify an activated state (Blader & Carlson, 2013). Such 
behaviours may include rapid speech, increases in goal directed activity and risk taking behaviours, 
impulsivity, and hyper-sexuality. Hypomania also represents a marked change from an individual’s 
standard mood and functioning, differing from mania primarily with regard to severity and level of 
impairment (Blader & Carlson, 2013). In BD, episodes are usually separated by periods of recovery 
involving a return to normal functioning. However, recurrence rates are high (Oswald et al., 2007), and 
residual sub-syndromal symptoms often persist between major episodes  (Gitlin, Swendsen, Heller, & 
Hammen, 1995; Goldberg & Grossman, 1995; Keller et al., 1992). 
Diagnosis	
The classification and diagnosis of affective disorders has had a long and eventful history (see 
Angst and Marneros (2001) for a detailed outline). Although all affective disturbances were originally 
believed to be varying presentations of the same underlying disorder, in the 1960s and 1970s key work by 
Perris and D'Elia (1966a), and Cadoret, Winokur, and Clayton (1970) demonstrated that unipolar and 
bipolar depression differed significantly across a number of characteristics including genetics (Perris, 
1966a; Winokur, 1970), course (Perris & d'Elia, 1966b) and premorbid personality (Perris, 1966b). 
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Further support for this differentiation between unipolar and bipolar depression has also been provided by 
neuroimaging studies (de Almeida & Phillips, 2013). However, there remains a relationship between 
unipolar and bipolar disorders in depressive symptomatology, which is frequently misdiagnosed as 
unipolar depression in those with BD.     
BD is commonly misdiagnosed. A survey study conducted by the Depression and Bipolar support 
alliance (Hirschfeld, Lewis, & Vornik, 2003), found that 69% of their members had experienced initial 
misdiagnosis, most frequently as major depression, followed by anxiety disorders, schizophrenia and 
substance use disorders. Moreover, a prospective longitudinal study of 550 individuals originally 
diagnosed with major depression (Fiedorowicz et al., 2011), found that over the course of 17.5 years 
approximately 20% of the sample experienced mania or hypomania, resulting in a revision of diagnosis to 
bipolar I disorder (7.5%) or bipolar II disorder (12.2%). Misdiagnosis can have major implications for 
appropriate treatment and long term clinical course for individuals with BD. For example, antidepressant 
medications, a common first line treatment for major depression, have been found to induce mania or 
hypomania in a proportion of individuals susceptible to BD if provided without accompanying mood 
stabiliser medication (Goldberg & Ernst, 2002c; Goldberg & Truman, 2003; Henry, Sorbara, Lacoste, 
Gindre, & Leboyer, 2001). Incorrect diagnosis of BD can also have negative consequences including 
increased risk of harm due to unnecessary treatments; stigma associated with the diagnostic label; and the 
inappropriate use of health care resources (Ghouse, Sanches, Zunta-Soares, Swann, & Soares, 2013). 
Perhaps due to the complexities of diagnosis in BD, delays in diagnosis are also common with 
patients reporting up to 10 years between the onset of affective symptoms and formal diagnosis 
(Drancourt et al., 2013; Schneck, 2011b). This is thought to be even more pronounced in those with an 
earlier onset of BD (Azorin et al., 2013; Drancourt et al., 2013). Such delays in diagnosis, and therefore 
appropriate treatment, are associated with poorer prognosis for individuals with BD, having been linked to 
higher rates of suicidal behaviour, poorer social adjustment and higher hospitalisation rates (Goldberg & 
Ernst, 2002b). There is also evidence to suggest that patients with a greater number of affective episodes 
prior to the institution of lithium prophylaxis have a less favourable prognosis than those who begin 
prophylaxis after fewer episodes (See Coryell, Fiedorowicz, Leon, Endicott, and Keller (2013) for a 
review). Early identification is therefore imperative for more favourable outcomes in BD; however, due to 
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the heterogeneity of bipolar presentations, along with the frequent occurrence of depression as the onset 
episode, diagnosis remains a complicated process.  
To account for the heterogeneity of bipolar disorder presentations, the Diagnostic and Statistical 
Manual of mental disorders (DSM) has separated BD variations into categories according to different 
clinical and diagnostic criteria. In the 3rd edition (DSM-III) (Drancourt et al., 2013) the category of bipolar 
mood disorders included: bipolar disorder, cyclothymic disorder and atypical bipolar disorder. DSM-3-
revised addition (American Psychiatric Association, 1987) altered these categories slightly by removing 
the duration criterion for manic episodes, thereby loosening the diagnostic criteria; and replacing atypical 
bipolar disorder with bipolar disorder not otherwise specified (NOS). At this time, bipolar II was 
subsumed under bipolar NOS and was not classified as a separate disorder, and rapid cycling was not 
included at all (Vieta, Reinares, & Bourgeois, 2005). In DSM-IV (American Psychiatric Association, 
1994) and DSM-IV-TR (American Psychiatric Association, 2000), BD was classified into the following 
diagnostic categories: bipolar I disorder, characterised by one or more manic or mixed episodes, usually 
accompanied by major depressive episodes; bipolar II disorder, characterised by one or more major 
depressive episodes, accompanied by at least one hypomanic episode; cyclothymic disorder, characterised 
by at least two years of numerous periods of hypomanic symptoms that do not meet criteria for a manic 
episode, and numerous periods of depressive symptoms that do not meet criteria for a major depressive 
episode; and bipolar disorder NOS, included for coding disorders with bipolar features that did not meet 
criteria for any of the specific bipolar disorders, and for bipolar symptoms about which there was 
inadequate or contradictory information.  
In the change from DSM-III to DSM-IV, bipolar disorders were no longer recognised as a unique 
category unto themselves. They became grouped under the category of “mood disorders” with unipolar 
depressive disorders and other mood disorders such as substance induced mood disorders, and mood 
disorders NOS. With the recent development and release of DSM-5 (American Psychiatric Association, 
2013a) bipolar disorders have again been separated from depressive disorders, presumably in recognition 
of the identified differences between bipolar and unipolar disorders. The diagnoses included under the 
category of bipolar disorders in DSM-5 include: bipolar I disorder, bipolar II disorder, cyclothymic 
disorder, substance / medication-induced bipolar and related disorder, bipolar and related disorder due to 
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another medical condition, other specified bipolar and related disorder, and unspecified bipolar and related 
disorder (American Psychiatric Association, 2013a).   
 The recent changes in BD classification have prompted both positive and negative responses from 
clinicians and researchers. Those who have argued previously that BD has been underdiagnosed due to 
overly stringent diagnostic criteria have praised some of the changes, such as the recognition / inclusion of 
more variations of the disorder and the removal of substance induced mania as an exclusion criteria 
(Angst, 2013). However, they have expressed concerns about the addition of the diagnostic specifier for 
mania that increased energy and activity must be included for a diagnosis. The argument is that this 
change excludes individuals who present primarily with symptoms of irritability, and who previously 
would have met criteria for diagnosis (Angst, 2013). However, others have argued that this change is an 
important addition to avoid over-loosening of diagnostic criteria that would impact BD treatment and 
research (Severus & Bauer, 2013). They argue that such loosening of diagnostic criteria can undermine the 
core conceptualisation of BD and result in an increase in false positive diagnoses with concerning 
consequences. For example, a young person presenting with a depressive episode who is suspected of 
having BDII may be treated with a prophylactic mood stabiliser in the absence of an observed hypomanic 
episode. Such treatment may then continue indefinitely as assessment of efficacy involves seeking the 
prevention of new manic episodes, which would be unlikely to occur if the individual is suffering from 
unipolar, not bipolar depression (Severus & Bauer, 2013). This kind of inappropriate and unnecessary 
treatment is likely to have long-term physical health effects as well as a financial impact for the individual. 
Moreover, it is a potential misuse of health resources. There is already concerning evidence to suggest that 
whereas a decade ago BD, particularly BDII, was perhaps underdiagnosed, the trend is now toward an 
over diagnosis with the label BDII applied incorrectly to presentations such as unipolar depression, 
borderline personality disorder, and impulse control disorders (Mitchell, 2013). Unfortunately, this kind of 
shift from under- to over-diagnosis does not address the diagnostic issues identified in BD, and may in fact 
create more confusion than clarity around BD diagnosis. 
The concerns raised by Severus and Bauer (2013), relate primarily to the potential adverse 
consequences of incorrect pharmacological treatment, and rightly so. The current primary treatment for 
BD is pharmacological. For some this is extremely effective, however, recurrence rates for patients on 
active medications are unfortunately high (see Gitlin and Frye (2012) for a review). A substantial 
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proportion of patients treated for BD report significant levels of residual depressive symptoms despite 
having high levels of adherence to using prophylactic medication and being rated as euthymic by 
clinicians (Scott, Stanton, Garland, & Ferrier, 2000). Given that individual medications have some 
efficacy, when one is insufficient, the approach to treatment is often to assume a cumulative benefit will 
be obtained by adding additional medications. In many cases, this strategy does provide more optimal 
treatment. It can, however, also result in patients being treated with up to six mood stabilisers, each of 
which contributes to side effects and patient burden, and of which none has any demonstrated efficacy for 
the individual (Gitlin & Frye, 2012). Moreover, we know little about the long-term effects of many of 
these medications and the resulting impacts on physical health and outcomes for the individual.  
It could be argued that from a psychological intervention perspective, increased sensitivity at the 
cost of increasing probability of false positives may be of greater benefit than concern. Appropriate 
application of early psychological support and interventions involves far less risk of increased harm and 
fewer unknown outcomes. Unfortunately, the psychological investigation of bipolar disorder has been 
severely neglected. It is only in the last few decades that researchers have begun to investigate the 
potential contribution of psychosocial factors to the onset and course of the disorder, and thus far the 
research has been limited. According to some researchers, the lack of strong psychological models for 
bipolar disorder has been a major impediment to the development of new therapeutic approaches, and also 
to the enhancement of current treatment options (Jones & Tarrier, 2005). Psychological therapies have the 
potential to address a number of concerns in BD, particularly in conjunction with pharmacological 
treatment.   
Support for the potential of psychological therapies for complex disorders previously treated 
primarily with medication again comes from schizophrenia research. For example, a meta-analysis of 26 
randomised controlled trials found clear improvements in mental state and reduction of relapse risk for 
individuals with schizophrenia receiving psychological treatment (Bellivier, Golmard, Henry, Leboyer, & 
Schurhoff, 2001b). For patients with BD, psychological therapies including CBT, family-focused therapy, 
and interpersonal social rhythm therapy have been shown to promote treatment adherence and provide 
positive benefits such as reduction in symptom severity, and prolonging time to relapse (Schneck, 2011b). 
Moreover, a review examining outcomes from studies of psychotherapy for BD (Bellivier et al., 2003) 
found a range of approaches were able to provide treatment benefits, with the clearest evidence for 
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individual cognitive-behavioural therapy (CBT) which was found to impact social functioning, symptoms, 
and risk of relapse. Nevertheless, research into the effectiveness of psychological therapies for bipolar 
disorder is limited and improvements are needed in the quality of studies before we will have a clear 
picture of the treatments that provide the greatest improvements in management and prognosis.   
It is, as yet, unclear whether psychological strategies can prevent, delay or minimise full 
expression of mood disorders, however, they do offer promise in lowering the long-term morbidity and 
mortality associated with this severe disorder. Current psychological strategies for reducing relapse in BD 
include: psychoeducation on the signs and symptoms of mood dysregulation; the protective effects of 
daytime routine and well-regulated sleep-wake cycles; and the importance of managing stress. Adapting 
core features of these treatments may also help those at heightened risk of developing BD recognise early 
warning signs of affective change and implement protective strategies. This has the potential to alter the 
trajectory and minimise the severity of impending mood disturbance, despite our current inability to 
definitively diagnose the disorder in early stages (Schneck, 2011b). Of	 course,	 accurate	 identification	 of	
individuals	at	increased	risk	is	necessary	before	interventions	can	be	provided.	Similarly,	identification	of	
the	most	 informative	early,	or	high	risk	symptoms	 is	needed	to	facilitate	development	of	 interventions	
that	are	likely	to	be	most	effective	and	appropriate	for	those	identified	as	at	heightened	risk. 
Category	vs.	Continuum	
Although reassessment of the categories of BD may be progressing, as with many psychological 
diagnoses, the argument against a categorical approach using symptom checklists persists. This discussion 
of whether psychological disorders are better accounted for by categorical or dimensional models is not a 
new one. Limitations and complications engendered by the categorical approach to diagnosis, such as 
excessive diagnostic comorbidity and problematic boundary disputes, are well recognised and have driven 
an escalation in the importance placed on developing an answer to the categorical / dimensional dilemma 
(Widiger & Samuel, 2005). The issues identified with the categorical approach suggest that a dimensional 
model may provide a more valid description of psychopathology, as it would effectively address the 
illusory boundaries and extensive comorbidity created by existing diagnostic categories (Widiger & 
Samuel, 2005). 
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Psychiatric symptoms have been found to be dimensional in patient populations (Goldberg, 2000), 
and research into a range of psychological symptomatology using population samples has shown 
continuous distributions. For example, using data collected prospectively in the general population of 
Zurich over twenty-years, Rössler et al. (2007) found expression of psychotic symptoms to be continuous 
and characterised by different levels of persistence and severity. A review of earlier literature conducted 
by Johns and Van Os (2001) also found evidence to indicate that psychosis exists as a continuum of 
experiences with a distribution in the general population. Further, research into personality disorders has 
found that the functioning represented by symptoms of these disorders is not qualitatively different to 
typical functioning. Rather, personality disorders appear to be maladaptive variants of the domains and 
facets of normal personality factors (Widiger & Samuel, 2005).   
Clinical and epidemiological studies have demonstrated a continuous distribution of symptoms 
from normal to pathological in both depressive and hypo / manic symptoms (Angst, 2007).  In a 20-year 
follow up study of patients with BDI and BDII, patients were found to spend approximately half the time 
in sub-threshold affective conditions that were found to be dimensional, involving the full range of 
symptom severity for both depression and hypomania (Judd & Akiskal, 2003). On the other hand, Akiskal 
and Benazzi (2007) found evidence for a categorical distinction between major depressive disorder and 
bipolar II disorder identifying features that distinguish unipolar depression from BP-II  such as earlier age 
of onset, family history of BD, higher rate of depressive recurrences and atypical depression symptoms. It 
should be noted however, that the same study also found a continuous distribution of the number of 
atypical depressive symptoms between MDD and BP-II which they argued provided support for a 
dimensional view of depressive disorders (Akiskal & Benazzi, 2007).   
The	Bipolar	Spectrum	
It has been suggested that current diagnostic criteria lack the sensitivity to detect the full range of 
conditions in what could be seen as a bipolar spectrum (Vieta et al., 2005).  Evidence for this comes from 
studies showing that large proportions of bipolar II patients are misdiagnosed as having unipolar 
depression due to stringent diagnostic criteria for mania, and failure to recognise minor elated states 
(Ghaemi, Boiman, & Goodwin, 2000; Vieta, Gasto, Otero, Nieto, & Vallejo, 1997). Again, such incorrect 
diagnoses guide treatment and can have a detrimental impact on the clinical course and prognosis for 
individuals with BD (Vieta et al., 2005). As identified by Angst and colleagues (Angst & Gamma, 2002; 
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Angst et al., 2003a), individuals with BD identified by both the diagnostic criteria of DSM-IV (American 
Psychiatric Association, 2000) and ICD10 (World Health Organization, 1992), form only the tip of the 
iceberg of the bipolar spectrum. Below the surface of these diagnostic thresholds are significant numbers 
of individuals with unidentified BDII, hypomania, and minor bipolar disorders (Angst & Cassano, 2005).  
In the 1990s Goodwin and Jamison argued that the exploration of spectrum models of BD had the 
potential to enhance research on genetic markers and modes of transmission, provide an approach for 
identifying at risk individuals, and permit the evaluation of early intervention treatments and treatments 
for milder forms of the disorder (Goodwin & Jamison, 1990; Vieta et al., 2005). In 1978 Wing and 
colleagues argued that the question of correct cut-off levels for “caseness” was raised by the dimensional 
nature of the mood disorders (Wing, Mann, Leff, & Nixon, 1978). Yet the attempts to address the 
diagnostic complications that persist in BD continue to come from a categorical perspective.  
Importance	of	sub-clinical	symptoms	
Sub-syndromal symptoms outside an episode are common in bipolar disorder (Fava, 1999). These 
are symptoms that, though not reaching the severity of an episode, can cause significant distress and 
disruption in patients’ lives (Lam & Wong, 2005), and can develop into prodromal symptoms that herald 
the onset of a full episode. Several studies report that more than 50% of bipolar patients suffer from 
significant sub-syndromal symptoms between episodes (Gitlin et al., 1995; Goldberg, Harrow, & 
Grossman, 1995; Keller et al., 1992) and amelioration of sub-syndromal symptoms is a vital component of 
maintenance treatment in BD (Gitlin & Frye, 2012). Sub-syndromal symptoms are associated with 
functional impairment for those with BD.  They have also been found to be predictive of earlier relapse of 
both manic and depressive episodes (Frye et al., 2006; Judd et al., 2008; Perlis et al., 2006), and the 
psychosocial impact of relapse persists for years in a great number of bipolar patients (Coryell et al., 1995; 
Keck, McElroy, & Arnold, 2001). It stands to reason that such sub-clinical symptoms may have a similar 
impact for those aware of their own increased familial risk of BD, particularly those who have been 
exposed to the impact of the disorder on family members. Such individuals may be pre-disposed to 
anxiety around the development of BD related symptomatology in the same way that those with remittent 
BD may be anxious about relapse.   
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Symptoms that do not reach threshold for diagnosis of BD may also be useful indicators of later 
risk, as has been demonstrated in the depression literature. The results of studies of adults with depression 
suggest that subclinical symptoms are associated with a high risk of later development of full depressive 
episodes (Eaton, Badawi, & Melton, 1995). Moreover, a predictive relationship has been found between 
subclinical depressive symptoms in adolescence and major depression in adulthood (Pine, Cohen, Cohen, 
& Brook, 2014), and adolescents with major depression have a two to four-fold greater risk of 
experiencing depression as young adults (Pine et al., 2014). Some studies have found only specific sub-
threshold symptoms associated with depression predict later development of major depressive disorder. 
For example, (Pine, Cohen, & Brook, 2001) identified anhedonia and suicidal ideation as two key 
predictors of later development of major depression over and above other associated symptoms. In the 
attempt to identify potential bipolarity in those diagnosed with major depression, it has also been 
suggested that sub-threshold symptoms of mania may be useful (Angst et al., 2003b; Goldberg et al., 
2009; Merikangas et al., 2007). Although the predictive validity of such symptoms has not yet been 
established (Fiedorowicz et al., 2011), at least one recent study supports this hypothesis (Zimmermann et 
al., 2009). The findings outlined above highlight the potential significance of symptoms of 
psychopathology below the threshold of disorder. They also highlight differences in the potential utility of 
individual symptoms and their usefulness in identifying risk. 
The	Prodromal	Phase	
There is evidence to suggest that during preadolescence or adolescence, individuals who go on to 
develop bipolar disorder show sub-syndromal, premorbid symptoms or signs that may be useful indicators 
of risk. Such a period where symptoms or behaviours that are clear changes from an individual’s ordinary 
functioning emerge months or years prior to onset of a full disorder is known as a prodromal phase.  
Prodromal phases are notable in other serious disorders such as unipolar depression (Fava, Grandi, 
Canestrari, & Molnar, 1990; Fava & Kellner, 1991; Jackson, Cavanagh, & Scott, 2003) and schizophrenia 
(Cornblatt et al., 2003; Yung & McGorry, 1996) and have been found to be useful in identifying groups at 
high risk of later development of disorder. Once identified, these groups can be more closely monitored 
and provided with greater support, early targeted interventions and family education.  
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The word prodrome comes from the Greek word “prodromos” meaning the forerunner of an event 
(Lam & Wong, 2005). In mental health, the term prodrome is used to describe the symptoms that patients 
may experience and warning signs they may be at the early stages of an episode. Such prodromal 
symptoms can be strikingly different to full-blown episodes or can be similar but less intense. They tend to 
be idiosyncratic, and are thought to be the result of complex mixture of psychological makeup, biology 
and past experiences (Lam & Wong, 2005). Prodromal symptoms for individuals with BD have been 
identified that indicate impending relapse and can be reliably recognised and reported (Joyce, 1984; 
Keitner et al., 1996; Lam, Wong, & Sham, 2001; Molnar, Feeney, & Fava, 1988; Smith & Tarrier, 1992). 
Common depression prodromes include anhedonia, interrupted sleep, and pre-occupation with worries. 
Prodromal features common to mania are increased activity and decreased need for sleep, increased 
socialisation, and racing thoughts (Lam & Wong, 2005). The emergence of such prodromal symptoms in 
BD can cause distress, and level of coping with prodromal symptoms has been found to predict relapses 
(Lam & Wong, 2005). Further, both mania and depression have been clinically observed to fuel 
themselves once started. Individuals may not be completely aware that a re-emergence of feelings of 
confidence, decreased need for sleep and increased sociability may be part of the early stages of mania, 
and may be tempted to seek more stimulation, leading to further disruption of sleep and routine. Similarly, 
individuals at the early stage of depression, who are experiencing an increase in worrying thoughts, lack of 
motivation and loss of interest, may feel guilty for being “lazy” or about their decrease in functioning, 
which can, in turn, increase depressive symptoms (Lam & Wong, 2005).   
If such sub-syndromal or subclinical symptoms have been found to infer risk of relapse in those 
with BD, the same subclinical symptoms may be useful risk indicators in those at heightened genetic risk 
of developing BD. For those with a diagnosis of BD, the identification of prodromal symptoms is hoped to 
offer the opportunity for early intervention to slow or prevent development of relapse into a full episode. 
In at risk populations, the identification of a bipolar prodrome, is hoped to provide the opportunity to slow 
or even prevent development of full blown bipolar illness, reduce diagnostic delay, and improve prognosis 
for those who do go on to develop the disorder.  
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Early	identification/	intervention	research	
Research reconstructing the prodromal stage of psychotic illnesses such as schizophrenia has 
enabled researchers to put together operational criteria that can be used prospectively to identify 
individuals at risk of transition to psychosis (McGorry et al., 2013). This has allowed for the development 
and trial of early intervention strategies that have been shown to have some impact on later outcomes for 
these at risk groups (Larsen et al., 2001; Stafford, Jackson, Mayo-Wilson, Morrison, & Kendall, 2013). 
There is hope that, in a similar way, identification of specific sub-threshold symptom clusters or patterns 
in BD may help predict who is at greater risk of developing the disorder and allow the development of 
targeted interventions that parallel those in schizophrenia research.  
Research	with	High	Risk	Populations	
An important factor in identifying high risk populations is of course genetic loading or 
predisposition. BD is highly heritable (McGuffin et al., 2003; Schneck, 2011a), and there is substantial 
genetic overlap with unipolar depression (McGuffin et al., 2003). It has been suggested that positive 
family history is in fact the most potent risk factor for mood disorders, particularly BD. As such, much of 
the recent research in BD has focused on the genetic contribution to the development of the disorder. It is 
acknowledged, however, that the specific factors transmitted in families are still unknown (Merikangas & 
Low, 2004) and more recently researchers have begun to investigate the contribution of other potential 
risk factors outside of heritability.  Genes confer vulnerability to illness by impacting on an individual via 
biochemical, endocrinological, neuroanatomical and psychological processes that are more closely related 
to the onset of symptoms (Egeland, Blumenthal, Nee, Sharpe, & Endicott, 1987). Therefore, psychological 
characteristics associated with high risk or development of BD may serve as endophenotypic components 
that can assist in understanding the family transmission of the disorder through genes and gene-
environment interactions (Hasler, Drevets, Gould, Gottesman, & Manji, 2006).  
Awareness of the genetic contribution to BD allows for the investigation of such additional risk 
factors with samples of individuals identified as having increased risk due to their family history. 
Comprehensive prospective studies with groups of individuals such as this have been found to be useful in 
identifying key differences between those considered at genetic risk and those with no family history of 
mood disorder (Nurnberger et al., 2011; Perich et al., 2015; Perich et al., 2013). Moreover, similar 
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research in schizophrenia has demonstrated the interplay between genetic factors and other important 
areas contributing to risk and development of psychopathology (Yung et al., 2008). Important factors 
identified in this research include environmental and psychosocial factors, as well as subclinical 
psychological and behavioural symptoms such as affective changes, disturbances in thinking and 
perception, and decline in social functioning (Simon et al., 2006). 
  Research findings of poor outcomes in BD highlight the need for further exploration of the role 
of psychosocial factors in the development and course of the disorder (Prien & Potter, 1989; Scott, 1995).  
The exploration of similar factors in schizophrenia research has resulted in development of interventions 
aimed at prevention and improving prognoses for individuals identified as at risk or in the prodromal 
phases of the illness (Morrison et al., 2004).  It is hoped that identification of additional key risk indicators 
for BD may bring us closer to prevention, early intervention, and improved outcomes. 
Adolescence	
Although established diagnostic criteria for bipolar disorder come primarily from clinical and 
research data derived from affected adults, onset of bipolar disorder in adolescence is common (Kessler et 
al., 2005), and it is believed that the first presentation of symptoms or indicators of later disorder is often 
even earlier. Retrospective examination of prospectively collected data in a study by Egeland, Hostetter, 
Pauls, and Sussex (2000), found a number of common early symptoms experienced by children who later 
went on to develop bipolar disorder. These symptoms were: depressed mood, irritability, increased 
sensitivity, increased energy and agitation / anger. Unfortunately, as fluctuations in mood are understood 
to be common during this stage of development, it can be difficult to differentiate normal adolescent 
emotional development from early indications of later mood disorder. 
Adolescence is a unique period marked by developmental change in biological, psychological and 
social systems. Evidence suggests that hormonal changes during adolescence are linked to disruptions in 
mood and behaviour that typically generates more emotional turmoil than either childhood or adulthood 
(Larson, Csikszentmihalyi, & Graef, 1980). Epidemiological studies have reported depression prevalence 
rates as high as 8% in adolescents (Fleming & Offord, 1990; Lewinsohn, Hops, Roberts, Seeley, & 
Andrews, 1993), and the lifetime prevalence of depression in adolescents is comparable to that in adults, 
at around 15 to 20% (Muris, Schmidt, Lambrichs, & Meesters, 2001). It is believed, however, that healthy 
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adolescents are prone to hyper-emotionality that is both normative and developmentally specific (Arnett, 
1999; Casey, Jones, & Hare, 2008; Casey et al., 2010; Casey, Jones, & Somerville, 2011) and most 
adolescents cope successfully with the developmental demands of this period without extremes of 
maladaptation. Further, greater mood variability and instability does not necessarily mean greater 
disequilibrium or “turmoil”. A study by Larson et al. (1980) found that although adolescents experienced 
wider mood extremes and less mood stability than adults, this mood variability was not positively 
associated with social maladjustment as had been predicted. In fact, adolescents reporting wider mood 
variation were less alienated from their peers and more likely to be leaders in organisations. Moreover, 
mood variation was associated with a peer-oriented life style, and more time spent with friends and in 
public (Larson et al., 1980).  
The fact that behaviours associated with internalizing and externalizing forms of 
psychopathology, such as mood disruptions and increased risk taking are not atypical during adolescence, 
makes it difficult during this period to clarify the boundaries between normative struggles and 
psychopathology (Cicchetti & Rogosch, 2002). Although the importance of early identification in mental 
health is clear, it is equally important not to over-pathologise what may simply be part of normal 
adolescent development. Unfortunately, it may be no less damaging to dismiss potential signs of risk in 
someone who is experiencing the beginnings of disruption and who may benefit from increased 
monitoring or early intervention. In fact, it is commonly reported that BD with an earlier than typical onset 
is associated with more severe illness course and significantly poorer prognosis although the results of 
research investigating this relationship are mixed (Azorin et al., 2013; Baldessarini et al., 2012; Goldstein 
& Levitt, 2006; Leverich et al., 2007; Post et al., 2010; Suominen et al., 2007). 
Summary	
In summary, Bipolar disorder is a complex psychiatric illness that is a leading cause of disability 
worldwide (Azorin et al., 2013). Accurate diagnosis of BD is complex, and this frequently results in long 
delays in diagnosis (Drancourt et al., 2013; Schneck, 2011b) or misdiagnosis (Fiedorowicz et al., 2011; 
Hirschfeld et al., 2003). Evidence suggests, that subsequent delays to appropriate treatment for those with 
BD can have severe negative impacts and increase adverse outcomes (Coryell et al., 2013; Goldberg & 
Ernst, 2002c). This would imply that improved early identification and intervention is important for 
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improving outcomes in BD. Moreover, such improvements may be of particular importance for those with 
an earlier onset, which is often reported to be associated with especially poor prognoses. However, results 
of studies investigating these relationships are mixed (Azorin et al., 2013; Baldessarini et al., 2012; 
Goldstein & Levitt, 2006; Leverich et al., 2007; Post et al., 2010; Suominen et al., 2007) and the true 
relationship unclear. Identification of emerging BD is likely to be fraught with difficulties as many 
diagnostic indicators that may be helpful at other developmental stages are difficult to differentiate from 
emotional and behavioural changes typical during adolescence (Cicchetti & Rogosch, 2002). 
Pathologising of normal developmental processes, or shifting to over-diagnosis is unlikely to address 
current issues, and may create its own difficulties (Mitchell, 2012).  
BD has been demonstrated to have high heritability (McGuffin et al., 2003; Schneck, 2011a) and 
family history is therefore a useful risk indicator in BD; however, it is not sufficient to predict later 
development of the disorder. In other related disorders, such as schizophrenia, sub-threshold symptoms 
have been found to be useful in the identification of high risk groups that are likely to benefit from early 
intervention. Results of this research also suggest that there are differences in the usefulness of individual 
symptoms in the prediction of risk.  
Despite the extent and high quality of research into BD, there remain important areas of 
investigation that have not been addressed. Research into psychological and social factors contributing to 
development and outcomes in BD has been very limited and there is clear need for further exploration of 
psychological symptoms and other psychosocial factors in the expression of risk, development and course 
of the disorder (Prien & Potter, 1989; Scott, 1995). The exploration of similar factors in Schizophrenia 
research has proven helpful in development of early intervention and improvement of prgognoses 
(Morrison et al., 2004). Applying these same principles to BD research may bring us closer to prevention, 
early intervention, and improved outcomes. In addition, although it is commonly reported that an earlier 
onset of BD is associated with poorer prognosis and greater adverse outcomes, the results of studies 
investigating these relationships have found mixed results. There are no published reviews of this research 
that draw together the disparate findings and assist in clarifying the relationship between age of onset and 
outcomes. Yet the relationship is widely reported in the research as though it were common knowledge. 
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Introduction	to	thesis	studies	
 The aims of the research conducted as part of this thesis were as follows: Chapter 2 comprises a 
meta-analysis designed to systematically review and analyse empirical findings that have been published 
to date regarding associations between age of onset of BD, prognoses and outcomes. This meta-analysis 
analysed existing evidence from empirical research to ascertain whether an earlier onset of BD is in fact 
associated with poorer prognoses and greater adverse outcomes as has commonly been reported. Further, 
this paper aimed to identify the specific adverse outcomes shown to have the strongest relationship to an 
earlier age of onset of BD. Chapter 3 comprises an empirical study based on novel data including 
participants with a heightened genetic risk of BD. The aims of this study were to characterize the 
individual symptoms of BD that may be most informative during adolescence and early adulthood 
regarding risk for the disorder. Using a standardised clinical interview, the endorsement of individual 
clinical and sub-threshold symptoms was examined in participants from three groups: those with a 
diagnosis of BD (BD); those with a first-degree relative with BD (At-Risk); and controls (C). Patterns of 
endorsement were then examined using novel analysis based on Item Response Theory (IRT) to assess 
whether differences could be identified in the information provided by individual symptoms in relation to 
discrimination and severity.  
Item Response Theory (IRT) comprises a collection of mathematical models and statistical 
methods that explore the way in which underlying, unobserved or latent constructs manifest as observable 
item responses (Harvey & Hammer, 1999). IRT procedures are well established and well researched in the 
field of achievement and aptitude testing, however, the application of IRT models to personality and 
attitude measurement, and measurement of psychopathology is less well explored. In clinical research IRT 
has been applied to analyses using the SADS-C to identify the level of information provided by each 
symptom in terms of syndrome severity in bipolar mania (Cheniaux et al., 2014). It has also been used to 
develop understanding of comorbidity among anxiety and unipolar mood disorders (Krueger & Finger, 
2001), compare measures of depressive symptomatology (Olino et al., 2012), and to identify differences in 
depressive symptoms between patients with unipolar and bipolar depression (Weinstock, Strong, 
Uebelacker, & Miller, 2009).  
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In the present study it was anticipated that individual symptoms from scales of depression and 
mania would provide varying levels of information relating to risk for, and severity of, psychopathology. 
Further, it was anticipated that symptoms found to be most informative at lower levels of severity would 
be different to those found to be most informative at higher levels of severity. The findings of this study 
may be useful in the identification of high risk individuals who may benefit from early support and 
intervention. Moreover, this information has the potential to inform areas of further research with 
adolescent and young adult populations. Identifying key items or patterns of endorsed responses may help 
inform development and assessment of early intervention treatments for youth with BD. Moreover it may 
also inform areas of focus for developing early interventions to ameliorate or minimise severity of later 
development of dysfunction / disorder.  
The final chapter presents a general discussion of key findings included in this thesis. Findings of 
both the meta-analysis and empirical study are discussed. This chapter also covers a discussion of the 
clinical and theoretical implications of the findings of the present research, and recommendations for 
future research.  
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Abstract	
Objectives: To identify clinical characteristics and adverse outcomes associated with an earlier age of 
onset of bipolar disorder.   
Methods: A comprehensive search yielded 15 empirical papers comparing clinical presentation and 
outcomes in individuals with bipolar disorder grouped according to age of onset (Total N: 7370). The 
following variables were examined to determine odds ratios (ORs) and 95% confidence intervals (CI):  
presence of axis 1 comorbidity, rapid cycling, psychotic symptoms, mixed episodes (DSM-IV), lifetime 
suicide attempts, lifetime alcohol and substance abuse, symptom severity and treatment delay. 
Results: Early age of onset was found to be associated with longer delay to treatment (Hedges g = 0.39, p 
= 0.001), greater severity of depression (Hedges g = 0.42, p<0.001), and higher levels of comorbid anxiety 
(OR = 2.34, p<0.001) and substance use (OR = 1.80, p<0.001). Surprisingly, no association was found 
between early age of onset and clinical characteristics such as psychotic symptoms or mixed episodes as 
defined by DSM-IV. 
Conclusions: Earlier age of onset of BD is associated with factors that can negatively impact long term 
outcomes such as increased comorbidity. However, no association was found between early onset and 
indicators of severity or treatment resistance such as psychotic symptoms. Clinical features found to have 
the strongest relationship with early age of onset were those potentially amenable to pharmacological and 
psychological treatment. Results highlight the importance of early identification and provide potential 
areas of focus for the development of early intervention in BD. 
 
Key Words: Bipolar disorder, Meta-Analysis, Age of onset, Prognosis, Outcomes, Severity, Comorbidity  
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Introduction	
 Bipolar disorder (BD) is a severe, chronic mood disorder with a population prevalence of around 
1-5% (Fagiolini et al., 2013; Ketter, 2010).  It is associated with high rates of comorbidity and is a leading 
cause of premature mortality due to suicide (da Silva Costa et al., 2015; Hayes, Miles, Walters, King, & 
Osborn, 2015).  BD often results in enduring work and social impairment (Coryell et al., 1993a), and is 
associated with a significant economic burden, to the individual and society, due to both direct and 
indirect costs such as medical expenditure, loss of productivity and increased mortality (Fagiolini et al., 
2013). The typical onset of BD occurs in late adolescence to early adulthood (Joyce, 1984). However, a 
large proportion of adults with BD experience the onset of the disorder prior to adulthood (Chengappa et 
al., 2003) and, although it remains controversial, some have argued that incidences of prepubescent and 
childhood onset BD are increasing (Axelson et al., 2006; Birmaher & Axelson, 2006; Wozniak et al., 
2011).   
A strong birth cohort effect has been detected in bipolar disorder whereby higher overall rates of 
the disorder as well as earlier ages of onset have been found over successive generations (Bauer et al., 
2015; Chengappa et al., 2003).  Much of this research has focused on differences between those born prior 
to and after 1940 (Chengappa et al., 2003; Lasch, Weissman, Wickramaratne, & Bruce, 1990), however, 
several studies have also found a similar continuing trend for later decades (Bauer et al., 2015; Da Silva 
Magalhaes, Gomes, Kunz, & Kapczinski, 2009; Gershon, Hamovit, Guroff, & Nurnberger, 1987). At least 
one study using a US based community sample detected this trend for major depression but not for BD 
(Burke, Burke, Rae, & Regier, 1991). However, a wealth of evidence, including a large study with data 
from 36 international sites, supports these cohort effects (Bauer et al., 2015; Da Silva Magalhaes et al., 
2009; Gershon et al., 1987). Changes in the development and detection of BD over time are perhaps not 
unexpected, particularly as our understanding of the disorder develops, however, whether these effects are 
the result of genetic, environmental or cultural / educational influences is as yet unclear. 
It has been suggested that increases in the prevalence of BD in younger populations are mainly 
due to changes in diagnostic criteria, with claims that diagnostic rates are significantly higher in the 
United States compared to other countries (James et al., 2014). Studies comparing hospital discharge rates 
for children and adolescents (under 20years) diagnosed with BD have found significantly higher rates in 
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the US compared to other countries such as England, Australia, New Zealand, and Germany (Clacey, 
Goldacre, & James, 2015; James et al., 2014). Further, rates of diagnosis of BD in general, but particularly 
in children have been found to be increasing significantly within U.S. over time (Blader & Carlson, 2007; 
Moreno et al., 2007). There are a number of possible explanations for these discrepancies. Patient 
expectations and medical system differences can influence the acceptance of particular diagnoses and 
treatment (Stringaris & Youngstrom, 2014b). Differences in the way clinicians in different countries 
interpret symptoms in children, and use of non-specific symptoms such as irritability as core features can 
also impact rates of diagnosis (Dubicka, Carlson, Vail, & Harrington, 2008).  
It is important to note here the difference between epidemiological prevalence and administrative 
prevalence. What is generally reported in studies where these differences between countries have been 
identified are numbers of diagnoses made by health care professionals during a particular period in a 
defined region (administrative prevalence). Epidemiologic prevalence estimates on the other hand, use 
standardized instruments and random population samples (Stringaris & Youngstrom, 2014b). A meta-
analysis of epidemiologic studies of pediatric bipolar disorder conducted by Van Meter et al. in 2011 (Van 
Meter, Moreira, & Youngstrom, 2011) found no significant differences between US and non-US samples 
in average rates of pediatric mania and hypomania in the community. This would suggest that differences 
in detection rates are primarily driven by different application of diagnostic criteria (Van Meter et al., 
2011). Improving accuracy of BD diagnoses is of utmost importance, and over-diagnosis is a grave 
concern (Mitchell, 2012). However, to deny the possibility of early onset BD is not necessarily an 
appropriate solution. BD has been diagnosed in children as young as 12yrs, and it is recognized that 
particular symptoms should be closely monitored by clinicians for early signs of mania (Kessing, Vradi, & 
Andersen, 2015).  
The definitive diagnosis of BD is often difficult and misdiagnosis is common particularly for 
younger individuals. As a result, long delays in diagnosis frequently occur. Patients report up to 10 years 
between the onset of affective symptoms and formal diagnosis (Lish, Dime-Meenan, Whybrow, Price, & 
Hirschfeld, 1994) and there is evidence to suggest that an earlier age of onset is associated with the longest 
delays to appropriate diagnosis and treatment (Drancourt et al., 2013; Leverich et al., 2007; Post et al., 
2010; Suominen et al., 2007). These delays are associated with poorer prognosis and more adverse 
outcomes for individuals such as more time depressed, greater severity of depression (Post et al., 2010), 
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elevated risk for suicidal behavior (Drancourt et al., 2013; Goldberg & Ernst, 2002a; Nery-Fernandes et 
al., 2012), poorer social adjustment, and greater number of hospitalizations (Goldberg & Ernst, 2002a).  
One possible explanation for diagnostic difficulties in BD is the clinical heterogeneity of the 
disorder. As such, a great deal of research has focused on identifying a specific prodrome and key risk 
indicators to aid with early identification and intervention; and thereby assist in refining early diagnosis.  
Age at onset (AAO) has been proposed as one potential marker for more homogeneous subgroups of BD 
(Bellivier, Golmard, Henry, Leboyer, & Schurhoff, 2001a). It was also proposed as a course specifier for 
BD in the development of DSM-5 (Baldessarini et al., 2012; Colom & Vieta, 2009), however, was not 
incorporated in the final publication. It is often suggested that, compared to a more typical age of onset of 
BD, earlier age of onset is associated with a more severe clinical presentation and poorer outcomes. This 
appears intuitive given the potential impact that the development of BD during adolescence might have on 
critical developmental processes (Moor, Crowe, Luty, Carter, & Joyce, 2012), however, the nature of the 
relationship between age of onset and outcome in BD remains unclear.   
One limitation of early studies investigating the potential for AAO to delineate more homogenous 
subgroups of BD was that age cut-offs for AAO groups were arbitrarily chosen to define early and late 
onset (Strober, 1992). More recent investigations have used admixture analysis to overcome this limitation 
and determine the model that best fits observed AAO distributions. These studies have identified three 
subgroups defined by AAO; early, with mean onset around 17 -18yrs (SD= 2); intermediate, with mean 
onset around 24yrs (SD=6) and late, with mean onset around 40yrs (SD=10) (Azorin et al., 2013; Bellivier 
et al., 2001a; Geoffroy, Etain, Jamain, Bellivier, & Leboyer, 2013; Hamshere et al., 2009; Leboyer, Henry, 
Paillere-Martinot, & Bellivier, 2005). 
Studies of the relationship between AAO, and BD severity and prognosis have reported mixed 
results. For example, although many have found early age of onset to be associated with more severe 
clinical characteristics such as greater rates of psychotic features (Schürhoff et al., 2000; Strober et al., 
1995; Suominen et al., 2007; Yildiz & Sachs, 2003), rapid cycling (Azorin et al., 2013; Cate Carter, 
Mundo, Parikh, & Kennedy, 2003) and mixed episodes (Patel, DelBello, Keck, & Strakowski, 2006; 
Schürhoff et al., 2000), others have found no difference in rates of these characteristics between EAO and 
Adult onset groups (Goldstein & Levitt, 2006; Tozzi et al., 2011a). Moreover, some have found the 
opposite relationships. For example, Patel et al. (Patel et al., 2006) reported psychotic features to be more 
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common in those with “typical onset” (20-30yrs) compared to those with early onset. Finally, others have 
found no evidence of more severe symptomatic morbidity among juvenile onset cases but have instead 
found differences in functional outcomes such as employment, independent living and quality of life 
(Baldessarini et al., 2012). 
A number of studies have shown higher rates of psychiatric comorbidity such as anxiety disorders 
(Cassano, Pini, Saettoni, & Dell’Osso, 1999; Cate Carter et al., 2003; Ibiloglu & Caykoylu, 2011; 
McElroy et al., 2001; Mick, Biederman, Faraone, Murray, & Wozniak, 2003), and alcohol or substance 
use disorders (Azorin et al., 2013; Bashir, Russell, & Johnson, 1987; Grunebaum et al., 2006a; Lin et al., 
2014) in those with an earlier onset of BD. Others though, have found no relationship between age of 
onset and comorbid anxiety (Altindag, Yanik, & Nebioglu, 2006), or alcohol abuse (Schürhoff et al., 
2000), or have found an association between EAO and either alcohol or substance abuse but not the other 
(Cate Carter et al., 2003; Lagerberg et al., 2011). 
 Finally, many studies have suggested that earlier onset of BD is associated with more frequent 
and severe depressive episodes (Slama et al., 2004), more suicidal ideation (Biffin et al., 2009), and a 
greater likelihood of lifetime suicide attempts (Azorin et al., 2013; Cate Carter et al., 2003; Grunebaum et 
al., 2006b; Slama et al., 2004; Tozzi et al., 2011a). It is difficult, however, particularly with lifetime risk 
indicators, to clearly differentiate risk associated with age of onset from risk associated with other factors 
such as duration of illness. Studies using multiple logistic regression to examine relative associations of 
different variables with a past history of suicide attempt in BD (Leverich et al., 2007; López et al., 2001; 
Slama et al., 2004; Tondo et al., 1999; Tsai, Lee, & Chen, 1999) have consistently found a number of 
variables to be associated with suicide attempts including: earlier age of onset, depression severity 
(hospitalization) and comorbid substance use. Other studies have found no significant difference in rates 
of suicide attempts between early and adult onset age groups (Ernst & Goldberg, 2004; Schürhoff et al., 
2000). A recent meta-analysis by Schaffer and colleagues (Schaffer et al., 2015) synthesizing data on BD 
and suicide attempts between 1980 and 2013, found a wide range of factors to correlate with previous 
suicide attempts in BD such as female gender, comorbid anxiety, substance use, or alcohol use disorder 
and a family history of suicide in first degree relatives. This study included samples with an ages >13yrs 
and found a younger age at onset to be significantly associated with a history of suicide attempts. 
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 While it is frequently stated that those with early onset BD have a more severe clinical 
presentation and poorer prognosis, as yet no reviews or meta-analyses have been published on this 
relationship. Indeed, findings on the magnitude of differences in clinical characteristics and prognosis 
associated with this age group have varied markedly across studies. As such, meta-analysis is a useful tool 
for synthesizing data to identify outcomes with more robust effects. The present study aimed to review the 
current evidence regarding clinical presentation and outcomes associated with early onset of bipolar 
disorder compared with those associated with adult onset.   
Method	
This review included studies that investigated differences in clinical presentation and outcomes in 
bipolar disorder (BD) for individuals with differing ages of onset. Only studies with original data 
published in peer reviewed journals were included. Review articles, book chapters, commentaries and 
symposia were excluded. All participants were required to have a formal structured diagnosis of bipolar I 
disorder (BDI), bipolar II disorder (BDII) or bipolar disorder not otherwise specified (BDNOS) to be 
included. Samples including participants with a diagnosis of schizophrenia, schizo-affective disorder and 
major depressive disorder were excluded. Genetic studies investigating heritability and family history of 
BD were also excluded on the basis that their focus was not on differences in clinical or prognostic 
characteristics between onset age groups, but on factors that are outside the scope of the current paper. 
Age at onset (AAO) of BD ranged from younger than 13 years to older than 40 years. For the 
majority of studies, AAO was defined as the age at which the person first met diagnostic criteria for an 
affective episode of depressive, manic, hypomanic or mixed state. Studies involving both early age at 
onset (EAO) and typical (or adult) age at onset groups were included. Those that focused on age of onset 
over 65 years were considered outside the age range of focus for this paper and were therefore excluded. 
Furthermore, studies that compared pre-pubertal onset alone without an older comparison group were also 
excluded. Consistent with the majority of prior research, EAO was defined as onset less than or equal to 
18 years of age where possible, however, to account for minor differences in studies, EAO was extended 
to include participants up to 20 years of age where necessary. Studies that classified EAO outside of this 
age range were excluded.   
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As the focus of this paper was on the comparison between early and typical (intermediate) onset, 
only participants within this age range were included in the analysis. Unfortunately many of the papers 
included in the analysis did not categorize AAO groups according to the model suggested by admixture 
analysis studies. An attempt was made to recognize these recently identified AAO group cut-off ages 
while at the same time maintaining the integrity of the data from studies where AAO groups were not 
categorized according to these cut-offs. Where the original data was separated into two groups: early 
(<18yrs) and late (>18yrs) these groups were maintained. Where the original data was separated into three 
groups with early onset defined as <13yrs, adolescent 13-18yrs, and adult >18yrs the early and adolescent 
groups were combined to reflect the suggested cut-off range from admixture analysis studies. Where 
necessary, when the original data was grouped as such, the early AAO cut-off was extended as far as 
21yrs. This breakdown of age groups fits within the suggested grouping identified by admixture analyses 
where the peak age for the EAO group is between 17 and 18yrs, and the cut-off for that range has been 
suggested to be 21yrs (Geoffroy et al., 2013; Hamshere et al., 2009; Leboyer et al., 2005). 
Studies reporting on any of the following clinical characteristics and outcomes were included: 
psychotic features, rapid cycling, mixed episodes (as classified in DSM-IV), severity of depression or 
mania, comorbidity, suicidal ideation and / or attempts, treatment delay, and objective quality of life 
measures such as education, employment and independent living. Confirmation of an operationalized 
diagnosis of BD by semi-structured clinical interview or medical records was required for inclusion. 
Clinical characteristics and outcomes were also required to be established using standardized measures. 
Examples of acceptable diagnostic instruments included: Structured Clinical Interview for DSM-IV 
Disorders (SCID) (First, Spitzer, Gibbon, & Williams, 1995); Diagnostic Interview for Genetic Studies 
(DIGS) (Nurnberger et al., 1994); Schedule for Affective Disorders and Schizophrenia (SADS) (Endicott 
& Spitzer, 1978); and the Kiddie-Schedule for Affective Disorders and Schizophrenia (KSADS) (Puig-
Antich & Chambers, 1978). Acceptable rating scales for severity of symptoms included: Montgomery-
Asberg Depression Rating Scale (MADRS) (Montgomery & Asberg, 1979); Young Mania Rating Scale 
(YMRS) (Young, Biggs, Ziegler, & Meyer, 1978); Beck Depression Inventory (BDI) (Beck, Steer, & 
Brown, 1996); Beck Anxiety Inventory (BAI) (Steer & Beck, 1997); and the Hamilton Depression Rating 
Scale (Hamilton, 1960).  
35	
	
A comprehensive literature search was conducted using the databases Medline, PsychINFO, 
Embase and CINAHL using a combination of the following search terms: (bipolar disorder .mp. OR exp 
bipolar disorder) AND (onset .mp. OR exp “onset (Disorders)” OR “Age of Onset”) AND [(prognosis 
.mp. OR exp prognosis) OR (Severity .mp. OR “Severity Disorders” OR “Disease Severity” OR “Severity 
of Illness”) OR (symptoms .mp. OR exp Symptoms OR exp Psychiatric Symptoms OR “Behavioral 
Symptoms” or “Affective Symptoms” OR symptomatology) OR (disease course .mp. OR exp disease 
course OR disease progression)]. The search was limited to studies published in peer-reviewed journals in 
English and covered the period from the inception of the databases to March 2014. No further studies were 
identified via the reference lists of previously published papers review or included papers.  
After duplicates were removed, a total of 2629 papers were retrieved from the original search. An 
initial screening by title was then conducted in order to identify relevant articles, resulting in 426 papers 
being retained. Papers were then screened by title and abstract resulting in the exclusion of a further 306 
articles. A more detailed examination of the remaining 120 papers resulted in the removal of a further 105 
papers. A proportion of the papers included at the full-text level (20%) were screened by a second 
reviewer to reduce bias in the selection procedure and ensure inter-rater reliability. The resulting Cohen’s 
Kappa score was k = 0.8. Any discrepancies in the inclusion or exclusion of papers were resolved by 
consensus. 15 studies comprised the final pool available for the meta-analysis (See Table 1. for study 
characteristics). An overview of the search strategy including exclusion criteria is presented in Figure 1.   
Statistical	Analyses	
 Meta-analyses were conducted using Comprehensive Meta-Analysis (CMA) Software 
(Borenstein, Hedges, Higgins, & Rothstein, 2005). The mean rated event rate was estimated as proportions 
(number of cases / sample size), and used as effect sizes in the analyses with the exception of four 
outcome variables for which the standardized mean difference method was used, with Hedge’s g 
correction for bias. Due to expected heterogeneity, calculations were based on a random effects rather than 
a fixed effects model (Cooper & Lindsay, 1998). Homogeneity of weighted effect sizes was assessed 
using a Q-test (Higgins & Thompson, 2002) and results are reported with associated I2 (Huedo-Medina, 
Sánchez-Meca, Marín-Martínez, & Botella, 2006) statistics in Table 2. 
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Papers identified via electronic database searching: 
Medline (955), PsycInfo (1031), Embase (1546), CINAHL (70)  
Papers after duplicates removed (2629) 
Papers screened using title and abstract  
Papers excluded after title and abstract screening (306) 
Reasons:  
Not related to age at onset  
Samples include other disorders: MDD, Schizophrenia 
Review papers, letters and supplements 
Case studies, Genetic studies, MRI studies 
Not in English language, At risk sample 
Age range over 65yrs 
 Papers retained after screening by title 
= 426 
Papers retained for full-text screening 120 
Papers excluded after full-text screening (105) 
Reasons:  
Multiple publications from the same sample (14) 
Schizophrenia / Psychosis (7) 
No age group comparison (45) 
No adult comparison group (2) 
Poster / symposium / supplements (12) 
Treatment comparison (2) 
Outside required age range (21) 
Sample includes other disorders (1) 
Familial aggregation study (1) Papers added after screening reference 
lists of full-text papers (0) 
Papers added after screening reference 
lists of review papers (0) 
Final sample of included papers = 15 
Figure 1: Study Ascertainment Diagram  
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Table 1: Characteristics of Included Studies 
N
o. 
Study N Diagnosis Onset Groups Meta-Analysis 
Groups 
Definition of AAO Included Outcome Variables  List of Measures 
Included in study 
1 Azorin et al. (2013)a 723 BDI Early <= 20yrs; 
Intermediate 20-
30yrs; Late >30yrs 
<=20yrs vs. >20yrs The age at which the participant first met the 
Research Diagnostic Criteria for an affective 
episode 
Alcohol abuse / dependence; Substance 
abuse /dependence; Comorbid Anxiety; 
Mixed Episodes; Psychotic Features; Rapid 
Cycling; Suicidal Ideation; Suicide 
Attempt; Mean severity depression; Mean 
severity mania; Treatment Delay (years) 
SCID, Medical 
records, MSRS, 
MADRS, SAPS 
2 Baldessarini et al. 
(2012) a 
1665 BDI Childhood <13yrs; 
Adolescence 12-18yrs 
(also combined 
<18yrs); Adult >19yrs 
<=18yrs vs. >18yrs First clinically appreciable syndromal illness 
as indicated by patient history, recollections 
of family members and medical records 
Psychotic symptoms; Suicide attempts; Any 
psychiatric comorbidity;  
SCID; BPRS; 
GAF; CGI 
3 Biffin et al. (2009) 162 BD Early <=19yrs; 
Intermediate 20-
39yrs; Late >=40yrs 
<=19yrs vs. >20yrs The age at which participants reported 
experiencing their first major affective 
episode 
Alcohol abuse / dependence; Substance 
abuse / dependence; Comorbid anxiety; 
Mean severity depression; Mean severity 
mania ; Suicidal Ideation 
MINI; HAM-D; 
YMRS; CGI-BP 
4 Cate Carter et al. 
(2003) a 
320 BDI; BDII Early <=18yrs; Late 
>18yrs 
<=18yrs vs. >18yrs Age at which participants fulfilled diagnostic 
criteria for a major mood episode (depressive, 
manic/hypomanic or mixed) as defined by 
DSM-IV.  Determined by best estimate 
procedure involving interviewer and a senior 
psychiatrist 
Alcohol abuse / dependence; Substance 
abuse / dependence; Any psychiatric 
comorbidity; Comorbid anxiety; Psychotic 
features; Rapid cycling; Suicidal ideation  
SCID; Medical 
records; FIGS 
5 Coryell et al. (2013) 427 BDI; BDII Early <=20yrs; 
Intermediate 21-
29yrs; Late >=30yrs 
<=20yrs vs. >20yrs Age at which full criteria for disorder were 
first met 
Alcohol abuse / dependence; Substance 
abuse /dependence; Comorbid anxiety; 
Psychotic features; Suicide attempt 
SADS 
6 Drancourt et al. 
(2013) 
501 BDI; BDII Early <=21yrs; 
Intermediate 22-
37yrs; Late >37yrs 
<=21yrs vs. >21yrs Age at which the participant first met full 
syndromal DSM-IV criteria for a BD episode 
(manic, hypomanic, mixed or major 
depressive) 
Treatment delay (years) DIGS; FIGS; 
Medical records 
7 Ernst and Goldberg 
(2004) a 
56 BDI; 
BDII; BD-
NOS 
Early <19yrs;    
Typical >19yrs 
<19yrs vs. >19yrs The first distinct episode of mania, 
hypomania or major depression. 
Substance abuse / dependence, Psychotic 
features, Rapid cycling, Suicide attempt 
SCID; HAM-D; 
YMRS 
8 Goldstein and Levitt 
(2006) a 
1411 BD Child <13yrs; 
Adolescent 13-18yrs; 
Adult >=19yrs 
<19yrs vs. >19yrs The first experience of endorsed DSM-IV 
mania criteria for at least one week duration. 
Alcohol and substance abuse, Alcohol 
abuse / dependence; Substance abuse / 
dependence; Comorbid anxiety; Comorbid 
personality disorder, Mixed episodes 
AUDADIS 
9 Grunebaum et al. 
(2006a) a 
146 BDI; 
BDII; BD-
NOS 
Child <=12yrs; 
Adolescent 13-18yrs; 
Adult >=19yrs 
<19yrs vs. >-19yrs Not defined Alcohol and substance abuse, Alcohol 
abuse / dependence; Substance abuse / 
dependence 
SCID; BPRS; 
GAS 
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Table 1. (cont.) Characteristics of Included Studies 
 Study N Diagnosis Onset Groups Grouping for Meta-
Analysis 
Definition of AAO Included Outcome Variables  List of Measures 
Included in Study 
10 Leverich et al. 
(2007) 
480 BDI; BDII Child <=12yrs; 
Adolescent 13-18yrs; 
Adult 19-29yrs 
<=18yrs vs. >18yrs Age of onset of first depressive symptoms 
associated with dysfunction, first 
hypomanic or manic symptoms, or first 
treatment for mania or depression 
Alcohol abuse / dependence, Substance 
abuse / dependence, Comorbid anxiety, 
Comorbid personality disorder,  
SCID; NIMH-LCM 
11 Mick et al. 
(2003) 
44 BD Child <13yrs, 
Adolescent 13-18yrs, 
Adult >19yrs 
<=18yrs vs. >18yrs Not defined Alcohol and substance abuse, Comorbid 
Anxiety, Comorbid personality disorder 
KSADS 
12 Moor et al. 
(2012) a 
100 BDI; BDII; 
BD-NOS 
Early <13yrs; 
Adolescent 13-17yrs; 
Adult >=18yrs 
<18yrs vs. >=18yrs The first 2 week period of functionally 
impairing and pervasive depressive 
symptoms or the first 4 day hypomania or 
mania whichever was earlier. 
Alcohol abuse / dependence, Substance 
abuse / dependence, Comorbid anxiety, 
Comorbid personality disorder,  
SCID 
13 Patel et al. 
(2006)a 
161 BDI Early <18yrs; Typical 
20-30yrs; Late >35yrs 
<=18yrs vs. >18yrs The age at which participants endorsed 
enough DSM-IV syndrome criteria for an 
affective episode (either major depressive, 
manic or hypomanic). 
First polarity depression; First polarity 
mania; Alcohol and substance abuse; 
Mixed episodes; Psychotic features  
SCID, KSADS, 
YMRS, HAM-D, 
SAPS 
14 Perlis et al. 
(2004) a 
983 BDI, BDII, 
BD-NOS 
Early <13yrs; 
Intermediate 13-
18yrs; Adult >18yrs 
<=18yrs vs. >18yrs Age of onset of the first episode of 
depressive, manic, hypomanic or mixed 
type.  
Alcohol dependence; Substance 
dependence; Comorbid anxiety; Psychotic 
features; Suicide attempt 
MINI, ADE, GAF 
15 Suominen et 
al. (2007) a 
191 BDI; BDII Early <=18yrs; Adult 
>18yrs 
<=18yrs vs. >18yrs Age of first mood episode fulfilling DSM-
IV criteria 
First polarity depression; First polarity 
mania; Alcohol and substance abuse; Any 
psychiatric comorbidity; Comorbid 
anxiety; Comorbid personality disorder; 
Mean severity anxiety; Mean severity 
depression; Mean severity mania; 
Psychotic features; Rapid cycling; 
Suicidal ideation; Suicide attempt; 
Treatment delay (years) 
MDQ; SCID; Medical 
records; YMRS; 
HAM-D; BDI; BAI; 
BHS;  
ADE = Affective Disorders Evaluation; AUDADIS = Alcohol Use Disorder and Associated Disabilities Interview Schedule for DSM-IV; BAI = Beck Anxiety Inventory;   
BDI = Beck Depression Inventory; BHS = Beck Hopelessness Scale; BPRS = Brief Psychiatric Rating Scale; CGI= Clinical Global Impression Scale;   
DIGS = Diagnostic Interview for Genetic Studies; FIGS = Family Interview for Genetics Studies; GAF = Global Assessment of Functioning;   HAM-D = Hamilton Depression Scale;   
KSADS = Kiddie-Schedule for Affective Disorders and Schizophrenia;   NIMH-LCM = National Institutes of Mental Health Life Chart Method;  
MADRS = Montgomery Asberg Depression Rating Scale; MDQ = Mood Disorder Questionnaire; MINI = Mini International Neuropsychiatric Interview; MSRS = Mania State Rating Scale;  
SADS = Schedule for Affective Disorders and Schizophrenia; SAPS = Scale for the Assessment of Positive Symptoms; SCID = Structured Clinical Interview for DSM-IV Disorders;  
YMRS = Young Mania Rating Scale 
 
a indicates that multivariate analyses were included in the study 
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Table 2: Summary of results for individual outcomes 
Outcome Studies (n) 
Participants 
(n) 
Odds 
Ratio Hedges g 95% CI Q 
I2 value 
(%) 
Eggers 
Test (t) 
Trim & Fill 
(studies added) 
Study references from 
Table 1. 
Alcohol or Substance Abuse 5 1953 0.90 - 0.50 - 1.62 18.57* 78.46 1.28 0 8; 9; 11; 13; 15 
Alcohol Only* 9 4752 1.36 - 1.04 - 1.76 21.20* 62.26 1.07 5 1; 3; 4; 5; 8; 9; 10; 12; 14 
Substance Only** 10 4808 1.80 - 1.39 - 2.35 18.00* 49.99 0.62 2 1; 3; 4; 5; 7; 8; 9; 10; 12; 14 
Any Psychiatric Comorbidity 3 2176 1.62 - 0.91 - 2.87 8.10* 75.32 2.38 2 2; 4; 15 
Comorbid Anxiety** 10 4841 1.72 - 1.34 - 2.19 25.20* 64.28 1.70 2 1; 3; 4; 5; 8; 10; 11; 12; 14; 15 
Comorbid Personality Disorder* 4 1746 2.34 - 1.85 - 2.95 1.11 0.00 3.42 2 8; 11; 12; 15 
Psychotic Features 8 4526 0.83 - 0.56 - 1.24 53.45* 86.90 0.27 1 1; 2; 4; 5; 7; 13; 14; 15 
Rapid Cycling 5 1770 1.80 - 0.86 - 3.77 29.95* 86.64 1.78 1 1; 4; 7; 10; 15 
Mixed Episodes 3 2295 1.81 - 0.70 - 4.71 20.16* 90.08 1.69 0 1; 8; 13 
Mean Severity Mania 3 1076 - -0.03 -0.33 - 0.26 7.86* 74.56 8.95 0 1; 3; 15 
Mean Severity Depression** 3 1076 - 0.42 0.30 - 0.55 0.36 0.00 0.67 0 1; 3; 15 
Mean Severity Anxiety 2 618 - - - - - - - 5; 15 
Suicidal Ideation** 3 673 2.37 - 1.69 - 3.31 0.08 0.00 0.04 0 3; 4; 15 
Suicide Attempt** 6 4045 1.68 - 1.29 - 2.18 11.79* 57.59 0.56 3 1; 2; 5; 7; 14; 15 
Treatment Delay (Years)** 3 1415 - 0.39 0.15 - 0.63 8.24* 75.73 1.12 0 1; 6; 15 
First Polarity Depression 2 352 - - - - - - - 13; 15 
First Polarity Mania 3 1075 1.16 - 0.79 - 1.70 2.77 27.72 0.05 1 1; 13; 15 
*Significant	at	p=0.05	
**	Significant	at	p=0.01 
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Meta-analytic methods accept published studies as representative of all valid studies undertaken, 
however, direction and significance of results can influence the chance of submission and publication of 
studies and this can be a source of bias in results (publication bias). In the current meta-analysis, 
publication bias was tested using two methods. Egger’s regression test (Higgins & Thompson, 2002) and 
Duval and Tweedie’s trim and fill (Rosenthal, 1979) were used to assess funnel plots for significant 
asymmetry that may indicate potential publication bias. 
Results	
The total number of participants in the 15 studies included in the meta-analysis was 7370. A 
summary of the included studies, with results and assessment for bias for each outcome variable, is 
presented in Table 2. The particular clinical and prognostic features varied between studies, with the most 
common including suicide ideation and attempts, comorbid alcohol and substance abuse, comorbid 
psychopathology, treatment delay, and illness characteristics such as rapid cycling, mixed episodes (DSM-
IV), psychotic symptoms and general severity. Participants included in the studies varied in diagnosis 
from BDI, for which an individual has to have experienced at least one full-blown manic episode, to BD-
NOS; however, all studies included a greater proportion of BDI participants than any other bipolar 
disorder diagnosis. Gender representation was approximately equal across studies with a combined 
average of 57.2% female participants. Average age of onset across groups ranged from 9 to 37yrs with an 
overall average age of onset across studies of 22.79yrs. Ten of the fifteen studies used retrospective 
methods while five involved a prospective design. Duration of follow up ranged from one to 25 years, 
with a median follow up of two years.  
Suicide	Attempts	/	Suicidal	Ideation		
Six studies (n= 4045) reported rates of lifetime suicide attempts. Meta-analysis (see figure 2.) 
demonstrated that the odds of those with an earlier age of onset having attempted suicide were 
significantly greater than for those with later age of onset (OR = 1.68, 95% CI = 1.29-2.18, p<0.001). 
Egger’s regression test was not significant (B = 0.94, standard error (SE) = 1.68, t = 0.56, p = 0.607). Only 
two studies (n=511) reported rates of suicidal ideation. These studies (Cate Carter et al., 2003; Suominen 
et al., 2007) both found the early onset group to have higher rates of lifetime suicidal ideation than the 
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adult onset group (χ2 = 12.12, p = 0.002; ν2 (1) = 4.1, p = 0.04 respectively). However, results from such a 
small number of studies, each with small sample sizes are unlikely to be robust.   
Only one paper (Moor et al., 2012) reported on Parasuicidal behaviors, having assessed whether 
participants had ever deliberately harmed themselves without the intent to die, but in order to relieve 
tension or help them to feel better. Very early onset (<13yrs) was found to predict both Parasuicidal and 
suicidal behaviors. However, these are the results of one study alone and as these variables were not 
reported by other papers, they were not able to be included in the meta-analysis. 
 
 
 
 
 
 
 
 
Figure 2: Forest plot odds ratios (ORs) as shaded squares proportional to study weight, with 95% 
confidence intervals (CIs) based on random-effects meta-analysis of lifetime suicide attempts in six studies 
 
Comorbidity	
 Alcohol and Substance Abuse / Dependence.  Five studies (n=1953) reported on rates of combined 
alcohol and substance abuse or dependence, nine (n=4752) reported rates of abuse and / or dependence of 
alcohol alone, and 10 (n=4808) reported rates of substance abuse or dependence alone. Those with an 
earlier age of onset were more likely to have comorbid alcohol abuse or dependence (OR = 1.35, 95% CI 
1.04-1.76, p=0.02) (For forest plot see figure 3), and almost twice as likely to have comorbid substance 
abuse or dependence (OR=1.80, 95% CI 1.39-2.35, p<0.001) (Figure 4).  It should be noted, however, that 
assessment for publication bias suggested that the robustness of the findings relating to alcohol abuse / 
dependence is questionable. Results for comorbid substance abuse or dependence appeared to be robust 
with trim and fill of only two additional studies, and non-significant Egger’s intercept (B = -0.56, standard 
error (SE) = 0.91, t = 0.62, p = 0.55).  No significant difference was found between groups for combined 
alcohol and substance abuse. 
	42	
	
 
 
 
 
 
 
 
 
Figure 3: Forest plot odds ratios (ORs) as shaded squares proportional to study weight, with 95% 
confidence intervals (CIs) based on random-effects meta-analysis of comorbid alcohol abuse/dependence 
in nine studies 
 
 
 
 
 
 
 
 
 
Figure 4: Forest plot odds ratios (ORs) as shaded squares proportional to study weight, with 95% 
confidence intervals (CIs) based on random-effects meta-analysis of comorbid substance 
abuse/dependence in 10 studies  
 
 
Psychiatric Comorbidity. Rates of psychiatric comorbidity were reported in 11 studies, of which 10 
(n=4841) included rates of comorbid anxiety disorders, 4 (n=1746) rates of comorbid personality disorder, 
and 3 (n=2176) ratings of any lifetime psychiatric comorbidity. The odds of having comorbid anxiety were 
found to be significantly higher for those with an early age of onset (OR= 1.72, 95% CI 1.34-2.19, 
p<0.001) (see figure 5). Egger’s intercept was not significant (B = 1.76, standard error (SE) = 1.03, t = 
0.62, p = 0.13) and trim and fill of only 3 studies indicate that this result is likely to be robust.   
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Figure 5: Forest plot odds ratios (ORs) as shaded squares proportional to study weight, with 95% 
confidence intervals (CIs) based on random-effects meta-analysis of comorbid anxiety in 10 studies 
 
Comorbid personality disorders were found to be significantly more likely for those with an early 
age of onset (OR = 2.34, 95% CI 1.85-2.95, p<0.001). However, it should be noted that assessment for 
publication bias suggests that this result is not robust, perhaps due to the small number of studies included.  
No significant difference was found in rates of ‘any’ lifetime comorbidity between age of onset groups. 
Clinical	Characteristics	and	Severity	
Psychotic Features. Eight studies (n=4526) reported on the presence of psychotic features or 
symptoms.  No significant differences were found in rates of psychotic symptoms.   
Rapid Cycling and Mixed Episodes (as defined by DSM-IV). Rates of rapid cycling were reported 
in five studies (n=1770) and mixed episodes in three (n=2295). No significant differences were found in 
rates of rapid cycling or mixed episodes as defined by DSM-IV.   
Severity. A limited number of studies reported mean severity ratings for depression and mania and 
only two studies reported mean severity for anxiety symptoms, making this outcome unsuitable for meta-
analysis. It should also be noted that variation in measurement tools may lead to pooling of data 
representing similar but not identical outcomes for variables such as these. For example, one study 
(Suominen et al., 2007) found no difference between early and adult onset groups in depression severity as 
measured by the clinician-rated Hamilton Depression Scale (HAM-D) (Hamilton, 1960). However, the 
same study found a significant difference on scores of depression as measured by the patient self-rated 
Beck Depression Inventory (BDI) (Beck et al., 1996) (t (177) = 2.1, p = 0.04). As such, results should be 
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interpreted with caution. A total of three studies (n=1076) reported mean severity ratings for depression 
and mania. Mean depression severity was found to be significantly higher in the early age of onset group 
(Hedges g = 0.42, p<0.001) (See figure 6). No significant difference was found in mean mania severity 
ratings. 
 
 
 
 
 
 
 
 
Figure 6: Forest plot standard difference in means (Hedges’ g) as shaded squares proportional to study 
weight, with standard error, based on random-effects meta-analysis of mean depression severity in three 
studies 
 
Treatment Delay. Delay to first treatment in years was reported in three studies (n=1415).  The 
mean treatment delay was found to be significantly higher for those in the early onset group (Hedges g 
=0.39, p=0.001) (see figure 7). 
 
 
 
 
 
 
 
 
Figure 7: Forest plot standard difference in means (Hedges’ g) as shaded squares proportional to study 
weight, with standard error, based on random-effects meta-analysis of treatment delay (years) in three 
studies 
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Due to concerns relating to confounding bias, sensitivity analyses were conducted removing all 
studies that did not conduct multivariate analyses to control for potential confounds. For a number of 
outcomes the removal of these studies resulted in too few studies for meta-analysis. This was the case for: 
severity of anxiety, depression and mania; suicidal ideation; and treatment delay. However, for a number 
of key outcomes analyses were still viable.  
The relationship between comorbid substance abuse and age of onset remained significant and 
appeared to be a robust finding (OR = 2.03, 95% CI: 1.51-2.72, p<0.001; Trim and Fill = 0; Eggers 
intercept not significant). The same was found for comorbid anxiety (OR = 1.64, 95% CI: 1.23-2.19, p = 
0.001) and comorbid personality disorder (OR = 2.38, 95% CI: 1.88-3.01, p < 0.001). The relationship 
between previous suicide attempts and age of onset also remained significant (OR = 1.60, 95% CI: 1.20 - 
2.14, p = 0.002). A major change was found, however, in the relationship between early age of onset and 
rapid cycling, which became significant (OR = 2.27, 95% CI: 1.49-3.47, p < 0.001). This may be a 
reflection of the high heterogeneity between studies in the original analysis (I2 = 86.64) and as such, the 
results associated with this outcome should be interpreted with caution. 
Discussion	
 Although it is often stated that an earlier onset of bipolar disorder (BD) results in poorer 
prognosis, investigations of this association have reported inconsistent findings. This current paper reports 
on the first meta-analysis of clinical characteristics and prognostic outcomes associated with earlier age of 
onset and has confirmed a number of adverse clinical characteristics more prevalent in those who develop 
BD at a younger age. Psychiatric comorbidity, particularly comorbid anxiety and substance abuse, were 
much higher in those with early onset. However, contrary to the findings of some individual studies, 
(Azorin et al., 2013; Patel et al., 2006; Suominen et al., 2007) psychotic symptoms, and mixed episodes, 
do not appear to be more prevalent in this group. It is important to note that the definition and use of 
mixed episodes has changed significantly in recent years with DSM-5 incorporating ‘mixed features’ as a 
specifier, rather than including distinct mixed episodes. The current results apply only to mixed episodes 
as defined in DSM-IV, and do not generalize to current understandings of the mixed states specifier in 
DSM-5. 
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  Suicide prevention is currently an area of keen interest for researchers, particularly efforts to 
understand and interrupt processes that lead to suicide attempts in adolescents and young adults. Suicide is 
a significant contributor to increased mortality in BD (da Silva Costa et al., 2015; Hayes et al., 2015) and 
higher rates of suicide attempts have been found in BD than any other psychiatric diagnosis (Chen & 
Dilsaver, 1996). The current analysis found a significant and robust relationship between early age of 
onset in BD and occurrence of at least one suicide attempt, a finding consistent with previous research that 
has suggested age of onset may be a key risk factor for suicide behaviors in BD (see Hauser et al. (Hauser, 
Galling, & Correll, 2013) for review). The precise nature of the relationship between age of onset of BD 
and suicide, however, is unclear. Higher risk of suicide has been shown to be associated with comorbid 
anxiety and substance use disorders (Dalton, Cate-Carter, Mundo, Parikh, & Kennedy, 2003; Hayes et al., 
2015) as well as severity of depression (Oquendo et al., 2000), all factors that have also been linked to 
earlier age of onset in BD. Further, Moor and colleagues (2012) found that in a sample of 100 individuals 
with BD whose ages of onset ranged from younger than 13years to over 18years, previous suicide 
attempts were predicted by greater comorbidity but not earlier age of onset (Moor et al., 2012). The 
association between age of onset of BD and suicidality appears to be part of a more complex picture of 
severity, comorbidity, and maladaptive coping mechanisms that, in combination, translate to increased 
risk, and for which the relationships and interactions between variables have not yet been fully 
investigated. Moreover, in order to separate risk associated with age of onset, from that associated with 
duration of illness, particularly with lifetime risk indicators prospective longitudinal data is needed.  
Whereas some studies included in the meta-analysis included only data from univariate analyses, 
others used multivariate analyses where possible to control for any intercorrelation between variables and 
to adjust for potential confounds such as duration of illness. For example, Azorin and colleagues (Azorin 
et al., 2013) found lifetime suicide attempts to be associated with early age of onset in univariate but not 
multivariate analyses and suspected that this indicated intercorrelation with another variable such as 
duration of illness. Interestingly, Perlis et al. (Perlis et al., 2004) found that after controlling for duration of 
illness, a greater likelihood of making at least one suicide attempt was associated with early relative to late 
age of onset. Similarly, after adjusting for duration of illness, Suominen et al. (Suominen et al., 2007) 
found a significant higher probability of psychiatric comorbidity and suicidal ideation for the early onset 
age group; and Carter et al (Cate Carter et al., 2003), using logistic regression found that the most 
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adequate model using age of onset as the dependent variable included the following factors: lifetime 
suicidal ideation or attempt, axis I comorbidity, comorbid substance abuse and rapid cycling. Even with 
attempts to control and account for intercorrelation and confounding variables, the exact nature of the 
relationship between such factors and age of onset remains unclear. Future research exploring the 
interaction between these factors may be able to clarify the exact nature of the relationship between these 
variables and identify the most significant predictors of suicide ideation and attempts in this population. 
A significant and robust association was found between early age of onset and comorbid 
substance abuse and dependence. The odds of comorbid alcohol use and dependence was also found to be 
significantly higher for the early age of onset group, however, assessment for potential publication bias 
suggested that this was not a robust finding. These findings may be impacted by the chosen cut-offs for 
early and later age groups. While a majority of studies have reported comorbid substance abuse to be more 
prevalent in the earlier onset age groups, the adolescent age group, often defined as 13 to 18yrs, has been 
found to have higher rates of substance and alcohol abuse / dependence than earlier onset (Wilens et al., 
2004; Wilens et al., 1999). By combining the younger and adolescent groups in the current study, finer 
details of the relationship between onset age and alcohol or substance abuse may have been missed. Given 
the high rates of substance use found in BD and the association with increased risk of suicide, comorbid 
substance use is clearly an area of concern in BD, particularly for those with an earlier onset. It should be 
noted, however, that not all studies included in this meta-analysis reported age of substance use onset or 
whether substance use commenced prior to, or after BD onset. It is thus difficult to ascertain whether 
substance use is the result of an earlier age of onset of BD, or whether it is a factor that contributes to 
onset.   
An interesting and perhaps less obvious finding of the current analysis was the relationship 
between comorbid anxiety and early age of onset. Those with early onset of BD were almost twice as 
likely to report one or more comorbid anxiety disorders. Rates of comorbid anxiety are high in BD 
(McElroy et al., 2001) and high rates of anxiety have also been found in high risk populations who have 
not developed BD themselves (Decina et al., 1983; Grigoroiu-Serbǎnescu et al., 1989; Perich et al., 2015). 
However, as with other clinical features, findings of studies on the relationship between anxiety and BD 
are inconsistent. Moreover, as discussed previously in relation to substance use, higher rates of comorbid 
anxiety have also been associated with comorbid substance use and suicide attempts (Altindag et al., 2006; 
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Cassano et al., 1999); thus the intricacies of the inter-relationships between these three factors and early 
age of onset, remains to be clearly elucidated. Although a significant difference was found in rates of 
comorbid personality disorder (PD) between early and adult onset groups, this was based on a limited 
number of studies and assessment of potential publication bias suggested that the finding was not robust.  
Mean level of depression severity was found to be higher in the younger onset age group. This finding is 
consistent with previous studies suggesting that both rates and severity of depression are higher in those 
with an earlier onset (Leverich et al., 2007; Post et al., 2010).  
The findings of this study should be interpreted with a number of limitations in mind. Many of the 
samples included in the meta-analysis were comprised primarily of outpatient participants and as such 
may not be representative of the more general population of those with BD. Further, not all individual 
studies incorporated the full range of diagnostic subgroups of BD which again may affect the 
generalizability of the results. All subgroups of BD were represented across samples, however, and thus, 
the synthesis of multiple studies should increase the chance of generalizability. Insufficient information on 
the breakdown of BD diagnoses was available in the original articles to conduct analyses stratified by 
diagnostic status. Given the recognized differences between BDI and BDII in terms of severity and 
prognostic factors, conducting the analysis in this way may have provided additional information relating 
to differences between ages of onset. Provided samples have sufficient power to do so, future research 
may benefit from breaking BD groups down further in this way for analysis. It may also be useful for 
future research to examine BD alongside broader neurodevelopmental phenotypes such as ADHD and 
early onset anxiety disorders, given the difficulty identifying a homogenous phenotype in BD. Such an 
approach stands to provide useful additional information regarding potentially important factors associated 
with specific early onset disorders. 
Although the majority of studies used adequate definitions of Age at onset (AAO) (Egeland et al., 
1987), differences in the measurement and definition of AAO between studies (see Table 1. for details of 
individual studies) may impact the synthesis of the data. More broadly, Q and I2 statistics identified 
significant heterogeneity for most outcome variables suggesting variability between studies that again, can 
influence results. Unfortunately, any attempts to synthesize data from multiple studies in this way are 
likely to encounter such difficulties with heterogeneity. However, this is not to suggest that the pursuit of 
such approaches should be abandoned. What it does suggest, as recommended by Baethge (Baethge, 
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2015), is that results such as those in the current study should be interpreted with this in mind and used to 
indicate direction, rather than exact estimates. Further, the reliability of AAO information gathered 
retrospectively is questionable. It should be noted, however, that many studies attempted to address this by 
collecting information from multiple sources and corroborating information using medical records where 
possible.  
An EAO cut-off of 18 – 20yrs was used in this meta-analysis as this age cut-off is reflective of the 
broader literature. Although this method has been used in a number of previous studies (Azorin et al., 
2013; Coryell et al., 2013; Drancourt et al., 2013), recent research using admixture analysis has shown that 
the theoretical model that best accounts for observed distributions of AAO is consistent with the existence 
of three AAO subgroups with average onset ages of 17years, 25years and 38years (Azorin et al., 2013; 
Bellivier et al., 2001a; Tozzi et al., 2011a). Further, despite the controversy surrounding early diagnosis of 
BD, if studies are including cases with onset as early as 12yrs, future research investigating differences 
between  pre-adolescent and adolescent onset groups is warranted. Such research may identify severity or 
prognostic indicators not clearly delineated in the current study due to the compression of these age 
groups. 
The association with AAO and mixed episodes as defined by DSM-IV was explored to ensure a 
comprehensive summary of the data included in the papers reviewed. Given recent changes in the 
definition and use of mixed features in BD, it is important to recognize that the lack of association found 
in the current study does not necessarily apply to mixed features as currently defined as a specifier in 
DSM-5. Further research would be needed to identify whether there is a relationship between AAO and 
BD with mixed features as currently used. 
Finally, the impact of potential confounding factors such as duration of illness, particularly 
duration of untreated illness, should not be underestimated. A number of the factors found to be associated 
with earlier age of onset, such as greater comorbidity and increased likelihood of suicide attempts, have 
also been found to be associated with longer duration of untreated illness, which itself has been linked to 
earlier age of onset.  As such, the true nature of many of the relationships identified in this paper is not yet 
clear.  Follow up data from longitudinal studies may offer opportunities to investigate this more 
thoroughly.  
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Conclusions	
 An earlier age of onset has long been reported to be associated with greater severity and a 
particularly poor prognosis in BD, yet the evidence to support many of these claims is variable. This is 
possibly due to difficulties differentiating the contribution of AAO over and above other factors such as 
length of untreated illness. The present study found that an earlier age of onset is indeed associated with 
features that can negatively impact long term outcomes. However, no association was found with 
indicators of severity and treatment resistance such as psychotic symptoms or mixed episodes (DSM-IV). 
Although this alone cannot rule out a possible link between AAO and these factors, it does highlight the 
need to for caution in drawing conclusions regarding such associations. Clinical features found to have the 
strongest relationship with early age of onset such as comorbid anxiety and substance use are those that 
may have greater potential for response to treatment. This suggests that with early identification, careful 
monitoring, and further development of early interventions, there may be hope for improvements in 
prognosis.  
Whether early intervention can in fact lead to prevention and improved prognosis in mental health 
in general remains to be seen. However, in order to further our knowledge in this area, development and 
assessment of early intervention strategies is necessary. Our results contribute to growing evidence that 
highlights the importance of early identification and provide potential areas of focus for the development 
of early intervention for young people with BD. Although the relationships identified in this study are 
complicated by confounding factors, particularly duration of untreated illness, it could be argued that the 
support for early identification remains the same.  
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Chapter	3:	Empirical	Study	
 
 
Investigating the clinical utility of individual symptoms of depression and mania in the identification 
of risk of bipolar disorder: An IRT analysis 
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As previously outlined, Bipolar disorder (BD) is a clinically severe, chronic mood disorder with 
typical onset around late adolescence, early adulthood (Leboyer et al., 2005). Diagnosis of BD is complex 
and delays in diagnosis are common (Drancourt et al., 2013), particularly for those with an earlier onset of 
the disorder (Joslyn, Hawes, Hunt, & Mitchell, 2016). Delays in diagnosis and appropriate treatment are 
also associated with poorer prognosis for patients with BD, having been linked to higher rates of 
hospitalization, and poorer social adjustment (Goldberg & Ernst, 2002c). Early identification is therefore 
imperative for more favourable outcomes, however, the heterogeneity of bipolar presentations mean that 
diagnosis remains a complicated process.  
Researchers have attempted to establish a BD prodrome that reliably identifies those who will go 
on to develop the disorder; however, it has been difficult to delineate specific prodromal features that 
apply across the spectrum of BD. Genetic, neuropsychological and brain imaging studies have also 
attempted to identify key risk indicators for early identification in BD using high risk participants (Corry 
et al., 2013; Mitchell, Roberts, & Green, 2013; Nurnberger et al., 2011; Shaw, Egeland, Endicott, Allen, & 
Hostetter, 2005). These samples include individuals who are not symptomatic, yet have been identified as 
at heightened genetic risk as they have a first degree relative with a confirmed diagnosis of BD. Such 
‘high risk’ individuals, although not meeting diagnostic thresholds, have been shown to endorse increased 
symptoms of psychopathology compared to control participants (Perich et al., 2015).  
Accurate differentiation between those whose changes in behaviour indicates a prodromal phase 
and those who will not go on to develop a disorder is important for early intervention and improved 
prognoses. Yet the same behaviour changes may represent very different processes across individuals, 
particularly during different developmental periods. Importantly, during adolescence, the emotional and 
behavioural features that could be indicative of risk for BD may at times resemble developmental changes 
that are typical during this period. For example, recent epidemiological research based on both parent and 
youth self-report, has indicated high prevalence of brief distinct periods of euphoria and elation in 
adolescents (Stringaris, 2011; Stringaris et al., 2010), mood states previously thought to be primarily 
specific to mania (Geller et al., 2002). Irritability, also commonly associated with both manic and 
depressive states (Stringaris, 2011), particularly in younger individuals (Wozniak et al., 2005) has also 
been found to be common in adolescents (Brotman et al., 2006; Pickles et al., 2010). Moreover, evidence 
suggests that healthy adolescents are prone to hyper-emotionality that is normative and developmentally 
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specific, and is believed may intensify periods of irritability (Arnett, 1999; Casey et al., 2008; Casey et al., 
2010; Casey et al., 2011).  
The complexity of distinguishing atypical versus typical trajectories during adolescence has 
received growing attention in recent years (Cicchetti & Rogosch, 2002), and there has been an alarming 
shift to over-diagnosis in BD (Mitchell, 2012), particularly in young people (Blader & Carlson, 2007; 
Moreno et al., 2007). Over-diagnosis is as much, if not more of a concern as diagnostic delays. We know 
little about the long term impact psychiatric medication has for adults, let alone when it is administered at 
such an important developmental period as adolescence. A rapid shift such as this from one extreme to 
another is unlikely to be helpful. Such shifts highlight the importance of the move toward a dimensional 
approach in developmental research, considering not only the stark differences between typical 
development and disorder, but also everything in between those two extremes.  
There has been growing evidence regarding the relative importance of particular sub-threshold 
symptoms in the prediction of various mood disorders in recent years. For example, Pine, Cohen, Cohen, 
and Brook (1999) found that two specific sub-threshold depressive symptoms; anhedonia, and suicidal 
ideation, were helpful in predicting later development of major depression over and above other 
symptoms. In addition, exploration of factors outside of those associated with standard diagnostic criteria 
may also assist in the identification of endophenotypic markers for mood disorders. In an analysis of 
sibling pairs, Papolos, Hennen, Cockerham, and Lachman (2007), identified five symptoms which most 
efficiently differentiated affected from non-affected participants in their study of childhood-onset BD. 
These were: fear of harm, aggression, anxiety, sensory sensitivity, sleep-wake cycle disturbances, and 
attention/executive functioning deficits. Results such as these suggest that threshold and sub-threshold 
symptoms, both those directly related to mood disturbance, and those not considered to be directly related, 
may have clinical utility in the prediction of risk in mood disorders.  
It may also be valuable to identify whether there are differences in how informative individual 
symptoms are in relation to severity. Many current diagnostic tools have been developed to fit within a 
categorical diagnostic system. As such, they are designed to tally endorsed symptoms up to a diagnostic 
threshold, with little attention paid to the weight carried by each individual symptom. With clinical 
judgment, it seems clear that there are symptoms that are indicative of greater severity, and perhaps 
therefore greater potential risk than others. Clinical judgment, however, can be subjective and vary 
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according to level of experience. This has led to growing interest in the application of analytic methods 
such as Item Response Theory (IRT) that can be used to examine risk based on patterns of individual 
symptoms rather than total symptom clusters.  
Aims	
The major aim of the current study was to characterize the individual symptoms of depression and 
mania that may be most informative during adolescence and early adulthood regarding risk for the 
disorder. Using novel analyses based on Item Response Theory, individual items (symptoms) included in a 
diagnostic clinical interview were examined to assess whether identifiable differences could be found in 
the information they provided in relation to discrimination and severity. It was anticipated that individual 
symptoms from scales of depression and mania would provide varying levels of information relating to 
risk for, and severity of, psychopathology among offspring of parents with BD. It was further anticipated 
that symptoms found to be most informative at lower levels of severity would be different to those found 
to be most informative at higher levels of severity.   
Item	Response	Theory	
Item Response Theory (IRT) comprises a collection of mathematical models and statistical 
methods that explore the way in which underlying, unobserved or latent constructs manifest as observable 
item responses (Harvey & Hammer, 1999). IRT provides ways to assess the extent to which individual 
differences in a specified latent construct can be measured by items on a scale designed to measure that 
construct (Thissen & Steinberg, 1988). Moreover, statistical analysis using IRT allows us to assess the 
degree of severity represented by each item in a measure, and the strength of the relationship between the 
item and the underlying construct being measured (Steinberg, Thissen, Shrout, & Fiske, 1995). The 
primary assumption of IRT models is that responses to symptom queries are a function of individual 
variation along a single underlying dimension. All IRT models follow three essential ideas: That the 
variable being measured is unobserved, or latent (Stouffer et al., 1950); That items have parameters that 
place them on the same scale as the variable being measured (Thurstone, 1925); and that the unobserved 
variable accounts for the observed interrelationships among the item responses (Stouffer et al., 1950). 
Response probability is predicted using: (a) properties of individuals (Theta); and (b) properties of items 
(difficulty and discrimination). Whereas statistics associated with classic test theory often confound item 
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discrimination with difficulty or severity, IRT models provide information on the power of an item to 
discriminate between groups separately from its difficulty or severity (Steinberg et al., 1995). 
Although IRT has been developed throughout the last century, it has only recently begun to gain 
momentum in the investigation of its application across a wide range of psychological contexts. 
Historically IRT analyses were believed to require substantial sample sizes in order to provide robust 
results (Fayers, 2004; He & Wheadon, 2013; van der Linden & Hambleton, 2013). Initially, perhaps 
because of these requirements, IRT methods were primarily used for the analysis of data from large scale 
standardised achievement and aptitude tests (Harvey & Hammer, 1999; Holman, Glas, & de Haan, 2003) 
and were not considered for smaller scale application. More recent research has shown that IRT analyses 
are possible and reliable with much smaller sample sizes than originally thought. However, it should be 
noted that the best methods of conducting IRT analyses with these smaller sample sizes is still being 
researched (Blanchin et al., 2015; Guilleux, Blanchin, Hardouin, & Sébille, 2014). 
The limited range of application of IRT analyses historically may also in part be explained by the 
demanding computational nature of IRT models which would have limited their accessibility prior to the 
widespread availability of affordable computer hardware and software (Harvey & Hammer, 1999). There 
are now many diverse IRT models available and more readily accessible, and these models are 
increasingly being applied to attitude, personality and similar inventories (Embretson & Reise, 2004; 
Harvey & Hammer, 1999). For example, IRT has been applied to analyses using the SADS-C to identify 
the level of information each symptom provides in terms of syndrome severity in bipolar mania (Cheniaux 
et al., 2014). It has also been used to develop understanding of comorbidity among anxiety and unipolar 
mood disorders (Krueger & Finger, 2001), compare measures of depressive symptomatology (Olino et al., 
2012), and to identify differences in depressive symptoms between patients with unipolar and bipolar 
depression (Weinstock et al., 2009).   
Method	
Participants	
This study was conducted in association with a larger longitudinal study with the approval of the 
University of New South Wales Human Research Ethics Committee (HREC Protocol 09/104), and the 
South Eastern Sydney Illawarra Health Service HREC (Protocol 09/097) in Sydney, Australia. The overall 
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methodology of the longitudinal study and each of its components have been reported in detail elsewhere 
(Breakspear et al., 2015; McCormack et al., 2016; Perich et al., 2015; Perich et al., 2013; Perich et al., 
2014). Methodology reported here will primarily be that relevant to the current study. A total of n = 186 
participants were included in the final analyses. Age of participants ranged from 12 to 22yrs, with a mean 
age of 17.26 (SD = 3.2). Male participants comprised 48.5% of the sample; 77% were Caucasian, 9.2% 
Asian, 2.6% reported mixed cultural background, and for 11.2% ethnicity was not recorded. 
Participants were categorized as follows: those with a diagnosis of bipolar disorder (Bipolar 
Disorder group; n = 18), those considered at genetic risk of developing bipolar disorder but without a 
current diagnosis (At Risk group; n = 105), and Controls (n = 63). Control participants were defined as 
those who did not have a first degree relative with current or past history of BD, recurrent major 
depression, schizophrenia, schizoaffective disorder; or past psychiatric hospitalisation; or a second degree 
relative with a history of psychosis or mood disorder related hospitalisation. Participants in the At Risk 
group were those with an identified first degree relative, either parent or sibling with a confirmed DSM-
IV-TR diagnosis of Bipolar I or II disorder. Participants in the Bipolar Disorder group had a current 
diagnosis of Bipolar I or II disorder confirmed via semi-structured interview and medical records where 
available.  
The majority of participants included in both the At Risk and Bipolar groups were recruited via 
distribution of print and electronic media. Recruitment also included local university and community 
noticeboards, mental health consumer clinicians and organisations, and families who had participated in 
previous research studies. Control participants were recruited primarily via local university and 
community noticeboards and distribution of print and electronic media. Written informed consent for 
participation in an ongoing longitudinal study was obtained from all participants and additional parental 
consent was also obtained for all participants under 16yrs of age.  
Participants were included in the AR group with confirmed proband best-estimate consensus 
diagnosis based on information collected via the Diagnostic Interview for Genetic studies (DIGs v.4) 
(Nurnberger et al., 1994), The Family Interview for Genetic Studies (FIGS) (Maxwell, 1992) and medical 
records where available. Based on an ecological approached similar to that used in other studies involving 
high risk groups (Nurnberger et al., 2011), for both AR and Control groups, participants with reported 
lifetime or current psychiatric symptoms (with the exception of the occurrence of BD) were not excluded 
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from participating in the study. This approach is believed to provide greater ecological validity in the 
sampling and therefore improved generalisability.  
Materials	/	Measures	
The Schedule for Affective Disorders and Schizophrenia for School-Age Children – Present and 
Lifetime Version (K-SADS-PL)(Kaufman et al., 1997) is a semi-structured diagnostic interview designed 
to assess symptoms of psychopathology in children and adolescents, both current and past episodes, 
according to DSM-III and IV criteria. The primary diagnoses assessed with the K-SADS-PL include but 
are not restricted to: major depression, mania, hypomania, cyclothymia, bipolar disorders, anxiety 
disorders, schizoaffective disorders, and schizophrenia. The K-SADS-PL is administered by interviewing 
one or both parents as well as the participating child. Probes and objective criteria are provided to rate 
individual symptoms, and summary ratings are compiled including all sources of information collected.  
The Diagnostic Interview for Genetic Studies (DIGS) is a semi-structured clinical interview 
developed by the National Institute of Mental Health (NIMH) Genetics Initiative, especially constructed 
for the assessment of major mood and psychotic disorders and their spectrum conditions (Nurnberger et 
al., 1994). The DIGS provides a retrospective lifetime description of BD and other axis I disorders, and is 
intended to be useful as part of archival data gathering for genetic studies of major affective disorders, 
schizophrenia, and related conditions. 
The Family Interview for Genetic Studies (FIGS) is a guide developed by principal investigators 
in the NIMH Schizophrenia and Bipolar Disorder Genetics Initiatives for the systematic collection of 
diagnostic information about relatives in family / genetic studies (Maxwell, 1992). Unlike the DIGS, the 
FIGS does not collect self-report data but asks participants to provide information about their relatives. 
The diagnostic information collected using the FIGS is pooled with other data collected using the DIGS 
and medical records to provide more comprehensive information on each individual relative (Maxwell, 
1992). There are three components of the FIGS: The general screening questions are intended to gather the 
most general information about all known relatives regardless of how distantly they are related; The face 
sheet is to collect information about first degree relatives, and any affected relatives about whom the 
interviewee can provide information; and symptom checklists are used to collect diagnostic details to 
assist with best estimate diagnoses (Maxwell, 1992). 
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Procedure	
To determine eligibility for the study, Clinical interviews were administered to all potential adult 
participants, parents of younger participants, and Bipolar Disorder probands to assess family history, and 
confirm proband diagnoses. At least one parent of participants in the 12-21yr age group was required to be 
available in addition to their participating child to complete the FIGS interview and the Kiddie-Schedule 
for Affective Disorders and Schizophrenia – Present and Lifetime version (KSADS-PL) about their child. 
The KSADS-PL was administered separately to both parent and child, after which ratings from both 
interviews were used to determine summary ratings for each symptom measure. All clinical interviewers 
were extensively trained by the principal investigator or study coordinator. Each possessed a minimum of 
an honours level degree in psychology, some also possessing graduate level degrees in psychology and / 
or psychology related fields. Where possible the same interviewer conducted interviews with both parent 
and child for continuity of data collection. 
Analytic	Plan	
As is consistent with previous IRT studies, factor analysis was used to test that the required 
assumptions for IRT analysis were met. Exploratory Factor Analysis (EFA) was conducted using 
Statistical Package for the Social Sciences (SPSS) software 22.0 for Windows. IRT analyses were 
conducted in R using the latent trait models (ltm) package (Rizopoulos, 2006) GRM function. As response 
options were not consistent across all scales, item responses were first re-coded to provide a consistent 
scale for all items that represented: No endorsement (1), Endorsement at a sub-threshold level (2), and 
Endorsement at threshold level (3). An EFA was conducted to identify underlying latent variables required 
for the IRT analysis. Participants were removed from a dataset for a particular scale if they had any 
missing data for that scale.   
One critical component for deciding which IRT model to use for analysis is the response format of 
items included in the measure being analysed. Models for items with dichotomous responses include: The 
Rasch Model, and One and Two parameter Logistic models. As their name suggests, the logistic IRT 
models are based on the logistic distribution (Embretson & Reise, 2013). One-parameter and Rasch 
Models, estimate the probability of a response (for example, endorsement of a symptom) based on trait 
level and item difficulty (severity) information. Items differ only in difficulty (or severity) and the value 
for item discrimination is estimated as a constant. The two-parameter model adds item discrimination 
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parameters which allow for differences in the relationship between individual items and the latent trait. In 
other words, the two parameter model is more appropriate for measures where individual items may not be 
equally related to the latent trait. Other types of models such as the nominal model, and the Graded 
Response Model (Samejima, 1969, 1997) can be used for items with polytomous response data.  
Samejima’s Graded Response Model (GRM) is a two parameter (2PL) IRT model that is often applied to 
the analysis of item responses such as those in Likert rating scales where the assumption of ordinal 
response levels is plausible (Embretson & Reise, 2004). In the GRM each item in a scale is described by 
one slope (discrimination) parameter α, and a number of between category threshold parameters β equal to 
the number of possible response categories minus 1. The β threshold parameters represent the trait level 
necessary to respond above a given response threshold with 0.50 probability. In the current study, 
Samejima’s two-parameter Graded Response Model (GRM), was used for all IRT analyses. The two 
parameters estimated in the model for each item were: (a) severity; or location along the continuum of the 
latent trait, and (b) discrimination; or the ability of the item to differentiate between those scoring high and 
low on each domain. 
Results	
Factor	Analysis	
Maximum likelihood extraction with Promax Rotation (Kappa 4) was conducted on all items in 
the clinical interview measure, and then constrained to 5 factors and 6 factors for comparison on the basis 
of examination of the scree plot (Appendix B). Total variance explained for the five and six factor models 
was 51.15% and 54.04% respectively. For both models, KMO statistic was fair at 0.881, and Bartlett’s 
Test of Sphericity was significant (p < 0.001). Examination of the pattern matrices suggested that the five 
factor model was theoretically a better fit with factors that appeared to represent the following clusters: 
depression items, mania items, anxiety items, externalizing items and attention deficit hyperactivity items. 
Items that loaded weakly on all five factors (i.e. coefficients under 0.3) were excluded from further 
analyses. Excluded items were: aches and pains; psychomotor agitation, increased appetite and self-harm 
from the Depression scale; and hypersexuality from the Mania scale. Following removal of these items 
KMO statistic improved and Bartlett’s Test of Sphericity remained significant (0.891, p < 0.001). The five 
factor solution accounted for 52.9% of total variance with only 24% non-redundant residuals over 0.05 
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resulting in five separate unidimensional scales. Cronbach’s Alpha was calculated for each of the 
symptom scales. Alpha values for Depression, Mania, Anxiety, Externalising and ADHD scales were 
0.95, 0.94, 0.87, 0.85 and 0.90 respectively. 
GRM		Analysis	
Item Response Theory Analyses were performed separately for factors identified in the EFA 
directly relevant to BD, i.e. Depression and Mania. Three parameters were estimated for each item: two 
severity (between category) threshold values and one item discrimination value. The estimates for 
category threshold and discrimination parameters can be found in Tables 3 and 4. 
The threshold parameter between item responses 1 and 2, or the level of the latent trait theta at 
which an individual has a 50% chance of endorsing response 2 or higher is represented by β1. β2 represents 
the threshold parameter between a response of 2, endorsing subthreshold level of a symptom, and 3, 
endorsing a symptom at its highest, or threshold level. Alpha (α) is the discrimination parameter, which 
represents how well an item discriminates between someone scoring high and someone scoring low on the 
latent trait. Model fit was assessed by comparing the fit of the two-parameter model to that of the one-
parameter model, where the discrimination parameter is held constant between items. This was conducted 
using the likelihood ratio test, using a p-value of <0.01 as indicator of a significantly better fit of the two-
parameter over the one-parameter model.  
We present two types of plot to facilitate interpretation of results: category response curves, 
which show for each item the levels of the latent trait at which each response is most likely; and item 
information function and test information function curves provide information on the level of the latent 
trait at which the item provides the most precision of measurement (the test information function curves is 
the sum of the item information curves). The complete array of plots can be found in Appendices C to F 
with select plots provided in the main text for illustration. In the category response curves, the position of 
the curves on the x-axis indicates threshold locations, and discrimination is indicated by the steepness of 
the curves. The graphs included in Figures 8 and 10 are chosen to illustrate the differences that can be seen 
in these parameters between individual items on the depression and mania scales. 
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Depression	items	
Parameter estimates for depression items can be found in Table 3. Across the items in the 
depression scale, those with the highest discrimination parameter (α) were Anhedonia, Hopelessness, and 
Thoughts of Death. The least discriminating items in the depression scale were Insomnia, and Irritability.  
Items with the lowest location values (β1) were Depressed Mood, Irritability, Negative Self Image, and 
Rejection Sensitivity. Items endorsed at sub-threshold levels at higher severity of the latent trait included 
Leaden Paralysis, and Anorexia. Insomnia and Thoughts of death were the items most likely to be 
endorsed at the threshold level at higher severity of the latent trait (β2), whereas, items such as Fatigue, 
Depressed mood and Negative Self-image were most likely to be endorsed at the threshold level at lower 
severity.  
Table 3: Parameter Estimates for Depression Scale Items 
Depression Items Parameter Estimates 
Item β1 β2 α 
Depressed Mood -0.64 1.57 2.74 
Irritability -0.11 2.40 1.45 
Excessive Guilt 0.89 2.41 2.10 
Negative Self Image -0.24 1.60 2.70 
Hopelessness 0.14 1.73 3.37 
Anhedonia 0.17 1.61 3.88 
Fatigue 0.26 1.46 2.74 
Difficulty Concentrating 0.21 1.76 2.87 
Psychomotor Retardation 0.95 2.26 2.68 
Social Withdrawal 0.07 1.79 2.29 
Insomnia 0.38 3.75 1.02 
Hypersomnia 0.87 1.95 1.69 
Anorexia 1.01 2.44 1.74 
Leaden Paralysis 1.57 2.28 2.70 
Rejection Sensitivity -0.27 1.85 2.42 
Thoughts of Death 0.71 2.55 3.06 
Suicidal Ideation 0.98 2.43 2.63 
 
Included in Figure 8 are category response curves that illustrate clear differences in threshold 
locations, and discrimination between individual depression items. For example: Although the 
discrimination information (steepness of curve) is very similar for Depressed Mood and Thoughts of 
Death, the latter is endorsed at a sub-threshold level at a higher severity of the latent trait (position of 
curves). In comparison, both Insomnia and Leaden Paralysis provide much less discrimination 
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information.  Further, as perhaps could be expected, Leaden Paralysis presents almost as a dichotomous 
item that is either present or absent with little endorsement at the sub-threshold level (middle curve). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Response Category Curves for Depression Symptoms: Depressed Mood, Insomnia, Leaden 
Paralysis and Thoughts of Death. 
 
The item information curve (see Figure 9) for depression items indicates that although symptoms 
such as Irritability, and Insomnia, appear to provide more consistent information across the levels of the 
latent trait, overall the information they provide is minimal (i.e. the curves are uniform but low). The 
information statistics support this, showing that these two items together provide only 5.8% of the total 
information provided by the scale, compared with Hopelessness, Anhedonia, and Thoughts of Death 
which account for 26% of the total information. Comparison of one- and two- parameter models indicate 
that the two-parameter model fits significantly better than the one-parameter model (p<0.001). 
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Figure 9: Information Curve for Depression Items 
	
Mania	Items			
A number of the mania items included in the scale following exploratory factor analysis, were 
required to be removed from the IRT analysis as they had not been endorsed by participants across the full 
range of responses. Mania items 13 through 16 (Inappropriate Laughing, People Seeking, Increased 
Productivity, and. Increased Creativity) were not endorsed at the highest (threshold) level of symptoms by 
any participants and as a result the analysis was not able to be completed with these items included.  
Parameter estimates for mania items can be found in Table 4. In the mania scale Elevated Mood, 
Racing thoughts, Increased Energy, Hyperactivity, and Pressured Speech showed the highest 
discrimination capacity. Those with the lowest discrimination capacity were Mood Lability, and, as with 
the depression items, Irritability. Looking at the Category response curves and parameter estimates we can 
see that although racing thoughts and increased energy both have steep peaks representing good 
discrimination, Racing thoughts is more informative at greater severity levels (i.e. has a higher second 
threshold), whereas increased energy is more informative at lower levels of the latent trait (see Figure 10). 
Interestingly, Irritability and Distractibility are items most likely to be endorsed at threshold at the highest 
	64	
	
levels of the latent trait, whereas, items such as Increased Energy, and Hyperactivity, are more likely to be 
endorsed at threshold at much lower severity. This may suggest that these symptoms are more easily 
recognized as unusual or out of the ordinary for individuals than changes in irritability or ability to focus. 
 
Table 4: Parameter Estimates for Mania Scale Items 
Mania Items Parameter Estimates 
Item β1 β2 α 
Elevated Mood 0.38 1.74 3.41 
Irritability 0.84 3.54 1.38 
Mood Lability 0.56 2.75 1.98 
Decreased Sleep 1.05 2.08 2.37 
Racing Thoughts 0.43 2.09 3.06 
Energetic 0.37 1.48 3.94 
Increased Goal Activity 0.59 1.67 2.98 
Hyperactivity 0.34 1.55 3.59 
Grandiosity 0.89 2.50 2.80 
Pressured Speech 0.36 2.11 3.15 
Poor Judgement 0.96 2.60 2.00 
Distractibility 0.47 3.09 2.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Response Category Curves for Mania Items Increased Energy, Racing Thoughts, Irritability, 
and Distractibility. 
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Examination of the item information curve (Figure 11.) suggests that the symptom Irritability 
provides minimal information across the latent trait continuum (low flat curve). This is supported by the 
information statistics that show that Irritability accounts for only 4% of the total information accounted for 
by the scale whereas the most informative item, Increased Energy accounted for 12%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Information Curve for Mania Items 
 
Comparison of constrained and unconstrained models showed that the 2 parameter GRM model 
demonstrated a significantly better fit than the 1PL constrained model (p<0.007). 
Discussion	
The aim of this study was to identify the specific symptoms of BD that may be most clinically 
informative in the assessment of risk during adolescence and early adulthood. Diagnostic interviews were 
conducted with individuals with a diagnosis of BD, those considered at increased genetic risk, and those 
with no diagnosis of mood disorder, for endorsement of experiences of clinical and sub-threshold level 
symptoms. IRT analysis was then conducted on these patterns of endorsement to identify which individual 
symptoms were most informative with regard to discrimination and severity. As expected, individual 
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symptoms differed in their capacity to discriminate between individuals scoring high and low on 
underlying latent traits representing Depression and Mania. They also differed in the amount of 
information they could provide in relation to severity on these underlying traits. Moreover, symptoms 
found to be most informative at lower levels of severity were different to those found to be most 
informative at higher levels of severity. 
Across both scales, symptoms commonly thought to be informative in the prediction of risk in 
young people, but that are also found across a variety of different presentations, for example: irritability, 
provided the least discriminatory information. The symptoms found to provide the most information in 
terms of discriminating between those scoring high and low on Depression and Mania were those more 
specific to the underlying trait being examined. For example, across depressive symptoms, losing interest 
in previously enjoyed activities, a sense of hopelessness, and thoughts of death and suicide, all symptoms 
highly representative of, and specific to, depression were found to have most discrimination capacity. For 
mania, it was increased energy and activity, elevated mood, and racing thoughts. These results support 
hypotheses proposed by Faedda et al. (2015) and Van Meter, Burke, Youngstrom, Faedda, and Correll 
(2016) that individual symptoms more specific to manic and depressive presentations would be more 
informative in the identification of risk than other key symptoms that are associated with more heterotypic 
outcomes. 
These findings are also consistent with those of a previous IRT study that demonstrated the 
importance of energy and activity as an indicator of severity in mania (Cheniaux et al., 2014). Although 
the results of the study included in this thesis show a much more even distribution of information from 
mania items in comparison to the Cheniaux et al. (2014) study, the symptom Increased Energy still clearly 
stands out as the most informative item. Differences in results between the current study and that of 
Cheniaux and colleagues may relate to sampling differences. The Cheniaux (2014) study was restricted to 
include only participants with a diagnosis of BD, whereas the present study included a broader range 
including at risk and control participants. It is nevertheless interesting to see for both studies a similar 
pattern of results which may indicate that unusual increases in energy and hyperactivity are clinically 
meaningful at both diagnostic and lower threshold levels, and in both adolescent and young adult age 
groups.  
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These findings can be seen to have various implications for conceptualizations of childhood-onset 
BD. Due to the difficulties identifying and differentiating core symptoms such as elevated mood and 
grandiosity in younger children, irritability has been proposed as a potential key diagnostic indicator for 
BD in children (Leibenluft, Charney, Towbin, Bhangoo, & Pine, 2003; Wozniak et al., 1995; Wozniak et 
al., 2005). The results of the current study do not support this. In a sample comprised primarily of younger 
individuals, irritability was found to be the least informative of all symptoms across both depression and 
mania items. This would suggest that although irritability may be a symptom associated with both of these 
presentations, it does not demonstrate sufficient specificity to be a reliable indicator of clinical risk. The 
overall prevalence of irritability in children and adolescence, combined with this lack of specificity 
indicate that irritability is unreliable as a diagnostic marker. The broadening of diagnostic criteria to 
include irritability over and above other clinical markers in BD risks incorporating a range of 
heterogeneous presentations thereby risking over-diagnosis and inappropriate treatment.  
The results of this study should be interpreted with certain limitations in mind. Historically, the 
use of IRT analyses have required large sample sizes to general accurate parameter estimates (Embretson 
& Reise, 2004; Embretson & Reise, 2013; Fayers, 2004). This is, however, dependent on the type of 
analysis conducted and number of parameters estimated. Although previous studies have demonstrated 
effective use of IRT analysis with sample sizes similar to that used in the current study, analysis using a 
larger sample size may provide more robust results. Moreover, the sample size in the current study was 
not sufficient to run separate analyses comparing parameter estimates between At Risk, Control and 
Bipolar groups. Future research using larger samples may provide further insight into whether there are 
identifiable patterns of differences in information provided by individual symptoms between these groups, 
and as such, which symptoms are most clinically useful for each group. Further, future research comparing 
individual symptom patterns between more restricted age groups, i.e. pre-adolescent / adolescent / early 
adult, may provide greater insight into which symptoms are most indicative of risk at different 
developmental stages.  
Finally, despite the range of presentations included in the sample, it was necessary to remove 
certain symptoms from the IRT analysis due to a lack of endorsement across levels of the symptoms, 
particularly at the threshold level. This means that these items were not able to be assessed as part of the 
latent traits investigated, and in terms of the level of information they may have provided. However, the 
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fact that these items were not endorsed at the threshold level by any participants, even those with a 
diagnosis of BD, suggests that these items are relatively uninformative in relation to diagnosis or future 
risk of BD.  
Despite these limitations, this is one of few studies investigating the potential of individual and 
sub threshold clinical symptoms to explore their usefulness as developmentally appropriate indicators of 
risk in adolescents and young adults. The results of this study provide information that is potentially useful 
for clinicians in the identification of at risk individuals who may benefit from early monitoring, support 
and intervention. Further, identification of the most and least informative symptoms, in conjunction with 
existing knowledge of genetic and environmental risk factors, provides a basis for the development of 
developmentally appropriate clinical screening tools which may help differentiate normal adolescent stress 
from clinically relevant risk. It also informs areas to target in the development of early intervention 
programs for young people. From a theoretical perspective, this information may be useful in informing 
developmentally specific models of BD in terms of symptom structure; and it identifies key risk markers 
that may benefit from future research with adolescent populations. Finally, this is one of a limited number 
of studies to apply IRT principles in a clinical context. 
Conclusions	
The results of this empirical study support the potential usefulness of individual diagnostic 
symptoms, and sub-threshold level symptoms, in the identification of risk and assessment of severity in 
BD. Further, results indicate that not all symptoms are equal in the level of information they provide. This 
has implications for the application and scoring of clinical measures that simply sum the number of 
endorsed symptoms with little regard for differences in the level of information each symptom provides. 
Understanding and applying the additional information provided by individual symptoms with regard to 
severity and discrimination capacity may enhance the accuracy and efficacy of current diagnostic 
instruments. This information may also inform the development of brief screening scales including only 
those symptoms that provide the greatest levels of information. The results of this study support previous 
findings impacting the theoretical conceptualisation of core features of mania that question the focus on 
elevated mood over activation, and call into question the reliability of using irritability as a key symptom 
in the identification of BD in younger individuals. They also highlight the potential usefulness of novel 
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analytical approaches based on IRT in clinical research. IRT has much to offer clinical research and the 
development of more accessible and affordable means for conducting these types of analyses, means that 
there are fewer barriers for researchers wanting to apply them. Further research using similar analyses 
with larger samples would be helpful both to improve the robustness of results, and allow separate 
analyses with more cohesive groups (i.e. At Risk only, control only; specific age ranges) that may identify 
the most clinically meaningful symptoms for these populations. 
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Chapter	4:	General	Discussion	
As outlined in the previous chapters, bipolar disorder (BD) is a chronic psychiatric illness 
associated with significant, pervasive and enduring functional impairment (Coryell et al., 1993b; Fagiolini 
et al., 2013; World Health Organisation, 2001). The empirical evidence suggests that there are long delays 
to diagnosis in BD (Drancourt et al., 2013; Schneck, 2011a), particularly for those who experience onset at 
an earlier age (Joslyn et al., 2016), and that these delays in diagnosis and appropriate treatment are 
associated with poorer long term outcomes for those with BD (Goldberg & Ernst, 2002c). Reliable early 
identification is imperative to improving outcomes in BD, yet may be complicated by difficulties 
distinguishing symptoms of BD in adolescence from the emotional difficulties that are developmentally 
typical during this period. Research into BD has attempted to identify a specific prodrome following the 
success of a similar approach in schizophrenia research. As yet, no clear prodromal features have been 
found that span the BD spectrum. Progress has been made in the identification of genetic markers (Adams 
et al., 1998; McQueen et al., 2005; Segurado et al., 2003), and structural and functional brain differences 
associated with BD (Strakowski, Delbello, & Adler, 2005), however, there has been limited research into 
the clinical utility of sub-threshold psychological symptoms that may provide useful information in the 
indication of risk.  
The aims of this thesis were threefold. The first aim was to synthesise, summarise and critically 
evaluate current empirical and theoretical literature related to BD, with a focus on difficulties in diagnosis, 
and impact on outcomes. The second was to systematically review and analyse empirical research into the 
impact of age of onset on prognosis and outcomes for those with BD; and the final aim was to empirically 
investigate the potential clinical utility of individual symptoms from a standard clinical interview in the 
assessment of risk of BD. 
Summary	of	Findings	
Chapter 2 comprised a published systematic review and meta-analysis that examined existing 
empirical research investigating the adverse outcomes associated with an early onset of BD. Of 2629 
Papers identified, fifteen met inclusion criteria and were entered into the meta-analysis. Results confirmed 
that there are a number of adverse clinical characteristics more prevalent for those with an earlier onset of 
BD. However, not all characteristics previously believed to be associated with early onset were supported. 
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There was insufficient evidence to support commonly reported associations between an early onset of BD 
and clinical characteristics indicative of greater severity of illness. These characteristics, such as psychotic 
symptoms and mixed episodes (as defined by DSM-IV) have been thought to result in greater treatment 
resistance in BD and, as such, particularly poor long term outcomes. Contrary to popular belief, the results 
of the current meta-analysis indicated that such poor outcomes are not inevitable with earlier onset of BD.  
The clinical features that were found to have the strongest relationship with an earlier age of onset 
were those that may potentially be amenable to intervention, for example: comorbid anxiety, substance 
use, and treatment delay. Awareness of these relationships may provide promise for recognising 
comorbidity early and providing appropriate intervention to minimise negative outcomes. Moreover, these 
results emphasise the need for continued efforts to find clear indicators of BD and BD risk in younger 
individuals to reduce delays to appropriate treatment. The results of this meta-analysis provide a hopeful 
message for those who develop BD at an earlier age and provide potential areas of focus for the 
development of early intervention. They also highlight the importance of early identification for improved 
prognoses.  
As reported in Chapter 3, an empirical study was conducted that was designed to investigate the 
potential clinical usefulness of relevant individual symptoms in the assessment of risk of psychopathology, 
particularly BD. The main objective of the study was to evaluate whether individual symptoms differed in 
their capacity to discriminate between individuals scoring high and low on underlying latent traits 
representing Depression and Mania. It also investigated differences in the amount of information 
individual symptoms could provide in relation to severity on these underlying traits.   
In both depression and mania scales, the symptoms that were found to be most informative were 
those that could be considered most representative of the underlying trait being examined. For example, of 
depressive symptoms, losing interest in previously enjoyed activities, a sense of hopelessness, and 
thoughts of death and suicide, all symptoms highly representative of, and specific to, depression were 
found to have most discrimination capacity. Similarly, for mania, increased energy and activity, elevated 
mood, and racing thoughts showed the greatest capacity for discrimination. Perhaps understandably, 
symptoms that could be considered more common to a variety of presentations e.g. irritability, provided 
the least discriminatory information on both scales. These results support hypotheses proposed by (Faedda 
et al., 2015; Van Meter et al., 2016) that individual symptoms more specific to manic and depressive 
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presentations would be more informative in the identification of risk than other key symptoms that are 
associated with more heterotypic outcomes.  
Interestingly, Irritability and Distractibility were symptoms most likely to be endorsed by 
individuals as meeting clinical threshold at much higher levels of severity in the mania scale. On the other 
hand, items such as Increased Energy, Hyperactivity, and Elevated Mood were more likely to be endorsed 
at much lower levels of severity. This may suggest that changes in mood and energy levels are more easily 
recognized by individuals as a departure from the norm than changes in irritability or ability to focus. 
Alternatively, it may be that changes in mood, energy and activity levels are more easily identified at 
lower levels of severity and more difficult to identify at higher levels. A recent study by da Silva and 
colleagues investigating insight in bipolar mania, found that individuals with BD demonstrated less insight 
into changes in their own activity and energy levels (da Silva, Mograbi, Bifano, Santana, & Cheniaux, 
2016) compared to their overall insight about their illness, and the consequences of previous episodes. 
This lower level of insight into specific symptoms was significantly correlated with greater severity of 
agitation and increased energy. However, it also appeared to be associated with greater severity of illness 
overall. 
The results of the current empirical study also fit with previous research findings to indicate that 
although irritability is highly correlated with BD, it is by no means specific to BD, and that chronic 
irritability does not appear to be pathognomonic for BD (Stringaris et al., 2010). Findings such as this are 
important in the context of the controversial argument in favour of paediatric BD. Given the difficulties in 
recognizing or identifying particular key diagnostic indicators of BD such as grandiosity and elated mood 
in children, chronic irritability has been proposed as a more appropriate indicator for paediatric BD 
(Leibenluft et al., 2003; Wozniak et al., 1995; Wozniak et al., 2005). When taken with the findings of 
previous studies, the results of the current study suggest that irritability is not an appropriate symptom on 
which to base a diagnosis of BD. As a diagnostic indicator, irritability has high sensitivity and low 
specificity, and as previously suggested by Stringaris and Youngstrom (2014a), using such a non-specific 
symptom as a core diagnostic indicator for BD is likely to lead to over-diagnosis.  
Over several decades researchers have argued that variables related to activation rather than mood 
states are more central in the phenomenology of mania (Bauer et al., 1991; Beigel & Murphy, 1971; 
Johnson, Gershon, & Starov, 2015). For example, in their 1971 study, Biegel and Murphy identified 
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several symptoms they believed to be representative of core characteristics of mania (Beigel & Murphy, 
1971). These included increased motor behaviour, increased verbal production and increased rapidity of 
thought processes. Similarly, the results of a study by (Bauer et al., 1991) led them to conclude that mania 
was primarily a disorder of activation rather than mood. Results of the French multi-site EPIMAN study 
(Akiskal et al., 2001) prompted recommendations that activation should be included as one of the stem 
criterion for the diagnosis of mania, a change that was integrated into the development of DSM-5 
(American Psychiatric Association, 2013b). More recently, a study by Perry, McIlwain, Kloezeman, 
Henry, and Minassian (2016) found increased energy to be a distinguishing feature of bipolar mania, 
particularly energy related to specific and goal directed exploration activity. Interestingly, a study 
published last year by Johnson et al. (2015) found that high energy in BD was not associated with high 
mood, leading them to suggest that general shifts in activation may be problematic to use as an indicator 
of impending mania. It should be noted, however, that the researchers themselves identified a number of 
significant limitations to this study and highlighted the need for replication of results in a more robust 
design. 
The findings of the current empirical study provide further support for the theory that symptoms 
of increased energy and activation may be more clinically useful in the identification of mania than 
changes in mood. These findings are also consistent with those of a previous IRT study that demonstrated 
the importance of energy and activity as an indicator of severity in mania (Cheniaux et al., 2014). It is 
interesting to note the consistency in these findings, particularly given the age of the sample included in 
the current study, and the high proportion of sample participants identified as “At Risk”. This may indicate 
that unusual increases in energy and activity are clinically useful in the identification of risk of BD, 
particularly for younger individuals. However, results of longitudinal follow up studies would be 
necessary to support this.  
Theoretical	implications	
With the development of DSM-5 (American Psychiatric Association, 2013b), there has been a 
shift in the structure of diagnostic classification of BD to include increased energy and activation along 
with elevated and expansive mood as core diagnostic criteria. The results of the current empirical study 
support the importance of increased energy and activation in identifying and assessing the severity of 
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manic symptoms. Further, they suggest that such increases in activation and energy may even be more 
informative than mood variability in the assessment of risk of later psychopathology in adolescents and 
young adults. 
Moreover, results of the IRT analysis highlight the fact that individual symptoms do not all 
provide the same level of information with regard to discriminating between groups and levels of severity 
of disorder. This has important implications for development and use of standardized diagnostic 
instruments. Many current diagnostic tools have been designed to fit within a categorical diagnostic 
system whereby numbers of endorsed symptoms are summed to assess whether an individual reaches a 
diagnostic threshold. The results of the empirical study included in this thesis show that all individual 
symptoms are not equal in the information they provide and therefore should not necessarily be equally 
weighted in diagnostic assessments. To do so risks minimizing the potential information garnered from 
these assessments and may result in a trend toward over or under-diagnosis. 
 Further, results of the empirical paper do not support the use of irritability as a key diagnostic 
indicator for BD in younger populations. Despite the difficulties identifying clinical levels of other core 
criteria such as grandiosity and elevated mood in younger individuals, the prevalence of increased 
irritability in these populations, combined with the lack of specificity associated with such symptoms 
indicate that it is unreliable as a diagnostic marker. The broadening of diagnostic criteria to include 
irritability over and above other clinical markers in BD risks incorporating a range of heterogeneous 
presentations thereby risking over-diagnosis and inappropriate treatment.  
Clinical	Implications	
The outcomes of studies included in this thesis also have potentially important clinical 
implications. Despite mixed evidence in the empirical literature, it has commonly been reported that an 
earlier onset of BD is an indicator of greater severity of illness and poorer prognosis, offering little hope 
for those who develop BD at an earlier age and their treating clinicians. However, there have previously 
been no published reviews or meta-analyses critically evaluating whether the evidence is in support of 
these reports. The review included herein is the first published meta-analysis investigating this 
relationship, the results of which support some, but not all, of the commonly reported claims. Although 
adverse outcomes associated with an earlier onset of BD were identified, these outcomes do not suggest as 
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poor prognosis as previously believed. Clinical features associated with greater severity of illness in BD, 
and often thought to increase treatment resistance, were not found to be associated with an earlier onset. 
Features found to have the strongest association with an earlier age of onset were those that may be 
amenable to intervention if reliably identified and treated appropriately. For example, evidenced based 
psychological treatment targeting anxiety and substance abuse may be helpful in addressing identified 
comorbidities that add to the burden of illness and often result in poorer outcomes.  
The results of the empirical study provide information useful to clinicians working with young 
people in mental health and other clinical settings relating to identification of at risk populations. The 
recognition of key symptoms, particularly in combination with a positive family history, may help identify 
individuals who are likely to benefit from early support, increased monitoring, and implementation of 
early intervention strategies. Moreover, areas of focus for the development of early intervention programs 
for individuals considered at risk are identified. Psychological strategies that have been found to be helpful 
in identifying early warning signs, minimising severity of mood episodes, and reducing anxiety around 
relapse for those with BD, with some adaptation, may also be useful for those considered at risk. Of 
course, whether early intervention can lead to prevention and improved prognoses in mental health 
remains to be seen. However, the benefit of psychologically based interventions as opposed to early 
pharmacological treatment is the reduce risk of harm in the case of false positives. The information 
included in this thesis provides a more hopeful outlook and supports the need for development and 
evaluation of early intervention strategies for youth at risk of psychopathology. It provides the beginning 
of a basis for the creation of developmentally appropriate clinical screening tools to assist in 
differentiating normal adolescent stress from clinically relevant risk.  
Strengths,	Limitations,	and	Future	Directions	
The results of the studies included in this thesis should be interpreted with certain limitations in 
mind. Many of the samples included in the meta-analysis were comprised primarily of outpatient 
participants and as such may not be representative of the more general population of those with BD. 
Moreover, not all individual studies included in the meta-analysis incorporated the full range of diagnostic 
subgroups of BD which again may affect the generalizability of the results. Unfortunately, insufficient	
information	on	the	breakdown	of	BD	diagnoses	was	available	in	the	original	articles	to	conduct	analyses	
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stratified	 by	 diagnostic	 status.	 Given	 the	 recognized	 differences	 between	 BDI	 and	 BDII	 in	 terms	 of	
severity	 and	 prognostic	 factors,	 conducting	 the	 analysis	 in	 this	 way	 may	 have	 provided	 additional	
information	relating	to	differences	between	ages	of	onset.	Provided	samples	have	sufficient	power	to	do	
so,	 future	 research	 may	 benefit	 from	 breaking	 BD	 groups	 down	 further	 in	 this	 way	 for	 analysis.		
Moreover,	 despite the controversy surrounding early diagnosis of BD, if studies include cases with onset 
as early as 12yrs, future research investigating differences between pre-adolescent and adolescent onset 
groups is warranted. Such research may identify severity or prognostic indicators not clearly delineated in 
this meta-analysis due to the compression of these age groups. 
Although the majority of studies included in the meta-analysis used adequate definitions of Age at 
onset (AAO) (Egeland et al., 1987), differences in the measurement and definition of AAO between 
studies may have impacted the synthesis of the data. An EAO cut-off of 18 – 20yrs was used as this age 
cut-off is reflective of the broader literature. Although this method has been used in a number of previous 
studies (Coryell et al., 2013; Drancourt et al., 2013), recent research using admixture analysis has shown 
that the theoretical model that best accounts for observed distributions of AAO is consistent with the 
existence of three AAO subgroups with average onset ages of 17years, 25years and 38years (Azorin et al., 
2013; Bellivier et al., 2001b; Tozzi et al., 2011b). In addition, the impact of potential confounding factors 
such as duration of untreated illness on the results of the meta-analysis should not be underestimated. A 
number of the factors found to be associated with earlier age of onset, such as greater comorbidity and 
increased likelihood of suicide attempts, have previously been found to be associated with longer duration 
of untreated illness, which itself has been linked to earlier age of onset. As such, the true nature of many 
of the relationships identified in the meta-analysis is not clear. Follow up data from longitudinal studies 
may offer opportunities to investigate this more thoroughly.  
In the empirical study, due to the large number of items included in the factor analysis, the sample 
included was not large enough to conduct exploratory and then confirmatory factor analyses as one might 
do in a factory analytic study. As the primary purpose of the factor analysis for this study, was to test the 
assumption of unidimensionality for the IRT analyses, however; and as the procedure followed in the 
study is in line with previous empirical research using IRT analyses, it was felt that using exploratory 
factor analysis alone was appropriate.  
	77	
	
In order to generate accurate parameter estimates using IRT analyses, large sample sizes are 
typically required. This is, however, dependent on the type of analysis conducted and number of 
parameters estimated. Although previous studies have demonstrated effective use of IRT analysis with 
sample sizes similar to that used in the current study, analysis using a larger sample size may provide 
more robust results. Moreover, the sample size in the current study was not sufficient to run separate 
analyses comparing parameter estimates between At Risk, Control and Bipolar groups. Future research 
using larger samples may provide further insight into whether there are identifiable patterns of differences 
between these groups, and as such, which symptoms are most clinically useful for each group. Further, 
future research comparing individual symptom patterns between more restricted age groups, i.e. pre-
adolescent / adolescent / early adult, may also provide greater insight into which symptoms are most 
indicative of risk at different developmental stages.  
Despite the limitations highlighted, the papers included in this thesis also carry significant 
strengths. The Meta-Analysis included in chapter 2 is the first published paper that has critically evaluated 
and statistically analysed the evidence for what is often reported as “common knowledge” in the bipolar 
disorder literature. By investigating the specifics of the relationship between earlier onset of BD and 
outcomes, this paper has provided a more positive message for those who develop BD at a younger age, 
and the clinicians who work with them. Moreover, it identifies specific areas that warrant further research 
in younger ‘at risk’ populations and that may be useful in informing development of early intervention 
programs.  
The empirical study is one of few studies investigating the potential of individual and sub 
threshold clinical symptoms to explore their usefulness as developmentally appropriate indicators of risk 
in adolescents and young adults. It is also one of the few studies to apply a novel statistical approach based 
on IRT principals in a clinical context. The results of this study provide information that is potentially 
useful for clinicians in the recognition of at risk individuals who may benefit from increased monitoring 
and support, the first step toward early identification and intervention. This study also identifies key risk 
markers that may benefit from future research with adolescent populations and provides information that 
may be useful in informing developmentally specific models of BD in terms of symptom structure. The 
identification of the most clinically relevant symptoms, in conjunction with existing knowledge of genetic 
and environmental risk factors, provides a basis for the creation of developmentally appropriate screening 
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tools which may help differentiate normal adolescent stress from clinically relevant risk. Finally, these 
results inform areas to target in the development and trial of early intervention programs for young people 
who may be at risk of later psychopathology.  
Conclusions	
This thesis explored and presented a range of evidence supporting the importance of early identification in 
bipolar disorder. In addition, it identifies areas of potential usefulness for further investigation with 
adolescent and young adult populations; and for development of early intervention strategies for 
individuals identified as at increased risk of later psychopathology. The results of the empirical study 
support the potential usefulness of individual diagnostic symptoms, and sub-threshold level symptoms, in 
the identification of risk and assessment of severity in BD. Further, results indicate that not all individual 
symptoms are equal in the level of information they provide. This has implications for the scoring 
methods of clinical measures that simply sum the number of endorsed symptoms in a scale with little 
regard for differences in the level of information provided by each symptom. Understanding and making 
use of the additional information provided by individual symptoms with regard to severity and 
discrimination capacity may enhance the accuracy and efficiency of current diagnostic instruments. In 
addition, this information may help inform the development of brief screening scales including only those 
symptoms that provide the greatest levels of information. These results also support previous findings that 
question the focus on elevated mood over activation as core features of mania and call into question the 
reliability of using irritability as a key symptom in the identification of BD in younger individuals. Finally, 
the empirical study highlights the potential usefulness of novel analytical approaches based on IRT in 
clinical research. IRT has much to offer clinical research. Moreover, the development of more accessible 
and affordable means for conducting these types of analyses means that there are fewer barriers for 
researchers wanting to apply them. Further research using similar analyses with larger samples would be 
helpful both to improve the robustness of results. In addition, it would allow for separate analyses with 
more cohesive, homogenous samples that may identify the most clinically meaningful symptoms for these 
populations. 
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APPENDIX	A:	HREC	Approval	Letter	
 
	
Human Research Ethics Committee (HREC) 
	
30-Apr-2014 
	
Dear Scientia Professor Mitchell, 
	
	
 
HREC Ref: # HC14128 
 
Identifying the determinants and early manifestations of bipolar disorder 
 
	
The Human Research Ethics Committee considered the above protocol at its meeting held on 
29-Apr-2014 and is pleased to advise it is satisfied that this protocol meets the requirements as 
set out in the National Statement on Ethical Conduct in Human Research*. Having taken into 
account the advice of the Committee, the Deputy Vice-Chancellor (Research) has approved the 
project to proceed. 
	
Would you please note:- 
	
	
• approval is valid  from 29-Apr-2014 to 28-Apr-2019; 
	
	
• you will be required to provide annual reports on the study’s progress to the HREC, as 
recommended by the National Statement; 
	
	
• you are required to immediately report to the Ethics Secretariat anything which might 
warrant review of ethical approval of the protocol (National Statement 3.3.22, 5.5.7: 
http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/e72.pdf) including: 
	
§ serious or unexpected outcomes experienced by research participants (using the 
Serious Adverse Event proforma on the University website at 
http://research.unsw.edu.au/human-ethics-forms- and-proformas ; 
	
	
§ proposed changes in the protocol; and 
	
	
§ unforeseen events or new information (eg. from other studies) that might affect 
continued ethical acceptability of the project or may indicate the need for 
amendments to the protocol; 
	
• any modifications to the project must have prior written approval and be ratified by any 
other relevant Human Research Ethics Committee, as appropriate; 
• if there are implantable devices, the researcher must establish a system for tracking the 
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participants with implantable devices for the lifetime of the device (with consent) and report 
any device incidents to the TGA; 
	
	
• if the research project is discontinued before the expected date of completion, the researcher 
is required to inform the HREC and other relevant institutions (and where possible, research 
participants), giving reasons. For multi-site research, or where there has been multiple 
ethical review, the researcher must advise how this will be communicated before the 
research begins (National Statement 3.3.22, 5.5.7: 
http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/e72.pdf); 
	
	
• consent forms are to be retained within the archives of the PSYCEN - Sch of 
Psychiatry and made available to the Committee upon request. 
 
 
*** Please Note: As your application has now been approved, a new reference number has 
been issued: HC14128. Please use this number in all future correspondence in relation to 
Project Title: Identifying the determinants and early manifestations of bipolar disorder. 
Project number HC09097 has been deactivated. *** 
	
	
Sincerely, 
	
	
 
	
Professor 
Heather 
Worth 
Presiding 
Member 
Human Research Ethics Committee 
	
	
* http://www.nhmrc.gov.au 
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APPENDIX	B:	Scree	Plot	–	Exploratory	Factor	Analysis	
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APPENDIX	C:	Category	Response	Curves	Depression	
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APPENDIX	C:	Category	Response	Curves	Depression	continued	
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APPENDIX	C:	Category	Response	Curves	Depression	continued	
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APPENDIX	C:	Category	Response	Curves	Depression	continued	
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APPENDIX	C:	Category	Response	Curves	Depression	continued	
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APPENDIX	C:	Category	Response	Curves	Depression	continued	
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APPENDIX	C:	Category	Response	Curves	Depression	continued	
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APPENDIX	C:	Category	Response	Curves	Depression	continued	
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APPENDIX	D:	Category	Response	Curves	Mania	
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APPENDIX	D:	Category	Response	Curves	Mania	continued	
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APPENDIX	D:	Category	Response	Curves	Mania	continued	
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APPENDIX	D:	Category	Response	Curves	Mania	continued	
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APPENDIX	D:	Category	Response	Curves	Mania	continued	
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APPENDIX	D:	Category	Response	Curves	Mania	continued	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	113	
	
APPENDIX	E:	Item	Information	Curves	
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APPENDIX	F:	Test	Information	Curves	
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APPENDIX	G:	Example	Script	for	IRT	analysis	–	Depression	variables		
(#	denotes	description	of	what	the	subsequent	script	does)	
#	open	library	for	read	command	
library(foreign)	
library(ltm)	
	
	
#read	the	spss	file	to	access	data	
KSADS	<-	read.spss("R:\\Data\\SPSS	Files\\Separated	Data	Files	for	IRT\\KSADS_IRT_Depression.sav",	use.value.labels	=	TRUE,	
to.data.frame	=	TRUE)	
	
	
#create	a	dataset	using	chosen	variables	
Myvars_depression	<-	KSADS[c("Dx1_DepressedMood",	"Dx2_Irritability",	"Dx5_ExcessiveGuilt",	"Dx6_NegSelf_Image",	
"Dx7_Hopelessness",	"Dx9_Anhedonia",	"Dx10_Fatigue",	"Dx11_DiffConcentrate",	"Dx13_PsychomotRetardation",	
"Dx14_SocialWithdrawal",	"Dx15_Insomnia",	"Dx17_Hypersomnia",	"Dx18_Anorexia",	"Dx23_LeadenParalysis",	
"Dx24_RejectionSensitive",	"Dx25_ThoughtsDeath",	"Dx26_Suicidal_Ideation",	"Dx30_SelfHarm")]	
	
	
#fit	GRM	to	that	dataset	
Fit1	<-	grm(Myvars_depression)	
	
	
#Show	coefficients	/	results	of	grm	analysis	
Fit1	
	
	
#Produce	graphics	and	information	statistics	from	GRM	analysis	
	
par(mfrow	=	c(1,	1))	
plot(Fit1,	type	=	"IIC",	lwd	=	2,	cex	=	1.2,	legend	=	TRUE,	cx	=	"topleft",	xlab	=	"Depression",	cex.main	=	1.5,	cex.lab	=	1.3,	cex.axis	
=	1.1)	
plot(Fit1,	type	=	"IIC",	items	=	0,	lwd	=	2,	xlab	=	"Depression",	cex.main	=	1.5,	cex.lab	=	1.3,	cex.axis	=	1.1)	
plot(Fit1,	lwd	=	2,	cex	=	1.2,	legend	=	TRUE,	cx	=	"left",	xlab	=	"Latent	Trait",	cex.main	=	1.5,	cex.lab	=	1.3,	cex.axis	=	1.1)	
	
info1	<-	information(Fit1,	c(-4,	0))	
info2	<-	information(Fit1,	c(0,	4))	
	
text(-1.9,	8,	labels	=	paste("Information	in	(-4,	0):",	paste(round(100	*	info1$PropRange,	1),	"%",	sep	=	""),	"\n\nInformation	in	
(0,	4):",paste(round(100	*	info2$PropRange,	1),	"%",	sep	=	"")),	cex	=	1.2)	
information(Fit1,	c(-4,	4),	items	=	c(1))	
information(Fit1,	c(-4,	4),	items	=	c(2))	
information(Fit1,	c(-4,	4),	items	=	c(3))	
information(Fit1,	c(-4,	4),	items	=	c(4))	
information(Fit1,	c(-4,	4),	items	=	c(5))	
information(Fit1,	c(-4,	4),	items	=	c(6))	
information(Fit1,	c(-4,	4),	items	=	c(7))	
information(Fit1,	c(-4,	4),	items	=	c(8))	
information(Fit1,	c(-4,	4),	items	=	c(9))	
information(Fit1,	c(-4,	4),	items	=	c(10))	
information(Fit1,	c(-4,	4),	items	=	c(11))	
information(Fit1,	c(-4,	4),	items	=	c(12))	
information(Fit1,	c(-4,	4),	items	=	c(13))	
information(Fit1,	c(-4,	4),	items	=	c(14))	
information(Fit1,	c(-4,	4),	items	=	c(15))	
information(Fit1,	c(-4,	4),	items	=	c(16))	
information(Fit1,	c(-4,	4),	items	=	c(17))	
information(Fit1,	c(-4,	4),	items	=	c(18))	
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APPENDIX	H:	Participant	Information	and	Consent	Forms:	AR,	C,	BD	16-22yrs.	
	
	
	
	
PARTICIPANT	INFORMATION	STATEMENT	AND	CONSENT	FORM	
Bipolar	Kids	and	Sibs	Study	
Approval	No	(HREC	09097)				
THE	UNIVERSITY	OF	NEW	SOUTH	WALES		
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM 
 
Below	are	some	questions	that	you	might	like	to	ask	about	the	study.	We	will	happily	explain	further	or	
answer	any	other	questions	that	you	might	have.	
What	is	the	study	about?	
 You	are	being	invited	to	take	part	in	a	longitudinal	study	to	examine	the	genetic	and	
environmental	risk	factors	for	bipolar	disorder.	
 We	hope	to	learn	about	risk	factors	for	bipolar	disorder	and	use	this	data	to	develop	better	ways	
to	intervene	early	in	those	at	risk	for	bipolar	disorder.	
	
Why	have	I	been	asked	to	take	part?	
You	were	selected	as	a	possible	participant	in	this	study	because	either	you	or	a	member	of	your	family	
has	a	history	of	bipolar	disorder.	
How	long	does	the	study	last?	
Identifying	risk	factors	requires	information	to	be	collected	over	many	years	and	so	we	would	like	to	
keep	in	contact	with	you	for	5	–	10	years.	Over	that	period	we	will	get	in	touch	every	12	months	and	ask	
you	some	questions.	
What	are	you	asking	me	to	do?	
 We	will	be	interviewing	you	to	find	out	about	symptoms	you	experience	now	and	also	those	you	
may	have	experienced	when	you	were	younger.	
 You	will	also	be	asked	to	undertake	a	mood	interview,	fill	in	some	self-report	questionnaires	(you	
will	be	given	the	option	of	completing	these	questionnaires	online),	complete	a	series	of	simple	
neuropsychological	computerised	tasks,	give	some	blood,	and	undertake	a	brain	scan.	
 After	the	initial	interview	we	would	like	to	contact	you	every	12	months	to	do	shorter	
assessments.	
 So	the	first	thing	we	need	is	your	permission	to	use	these	assessments	in	our	research.	
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How	long	will	it	take?	
 The	initial	assessment	will	be	conducted	in	a	morning	and	afternoon	session	over	the	course	of	a	
day,	or	over	two	days	if	preferred.			
 The	questions	to	be	done	every	12	months	will	take	approximately	3-4	hours.	
	
Genetic	testing	
 The	genetic	testing	will	only	be	done	once.	We	will	take	20	ml	of	blood	from	a	vein	in	your	arm.		
 The	blood	will	be	used	to	look	for	genes	that	may	increase	your	risk	of	developing	bipolar	
disorder.	As	it	is	now	considered	likely	that	many	genes	–	which	each	individually	play	a	small	
role	–	are	involved	together	in	causing	bipolar	disorder,	we	will	test	for	many	genes	at	once	
when	we	analyse	your	blood	sample.	
 When	 researchers	understand	how	genes	 are	 involved	 in	 the	development	of	 bipolar	disorder	
they	have	a	better	chance	of	designing	better	methods	to	diagnose,	treat	or	cure	that	disease.	
	
Brain	imaging	
 We	will	be	inviting	some	of	the	participants	to	be	involved	in	a	brain	imaging	study.		If	you	are	
asked	to	be	involved	in	this,	you	will	be	provided	with	a	separate	information	sheet	and	consent	
form.	
	
What	will	you	be	asking	me	every	12	months?	
There	will	be	an	interview	asking	you	about	any	symptoms	you	have	experienced	over	the	previous	
twelve	months.	You	will	also	complete	some	self-report	questionnaires	and	sometimes	a	series	of	
neuropsychological	tests.	The	questions	are	a	lot	like	the	ones	you	are	answering	for	the	first	
assessment.		
What	are	the	advantages	and	disadvantages	of	being	involved	in	the	study?	
 We	don’t	anticipate	any	risks	to	you	from	being	involved	in	the	study.	However,	we	acknowledge	
that	the	assessments	are	lengthy	and	that	involvement	in	the	study	will	mean	setting	aside	time	
to	complete	them.		
 The	main	advantage	is	early	detection	of	any	symptoms	of	bipolar	disorder	or	psychosis.	If	we	
notice	symptoms	we	can	help	you	get	the	appropriate	treatment.	
 The	blood	draw	may	cause	some	mild	discomfort	or	bruising.	
	
How	is	the	blood	sample	used?	
 The	blood	sample	will	be	submitted	to	Genetic	Repositories	Australia	(GRA),	a	research	resource	
located	at	Neuroscience	Research	Australia,	for	subsequent	processing.	Your	sample	will	be	de-
identified	and	only	be	tracked	by	a	code	number.	
 Genetic	material	will	be	extracted	from	your	blood	sample.	In	order	to	ensure	ongoing	source	of	
DNA,	white	blood	cells	 (lymphocytes)	are	cultured	and	kept	growing	 in	 the	 laboratory	as	a	cell	
line,	which	allows	a	source	of	genetic	material	without	having	to	obtain	another	blood	sample.	
These	cell	lines	can	be	stored	indefinitely.	
 GRA	collects,	stores,	and	distributes	DNA	samples	and	cell	lines.	All	researchers	wishing	to	access	
the	genetic	material	stored	by	GRA	must	first	have	approval	from	the	relevant	Human	Research	
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Ethics	 Committee	 for	 their	 projects.	 Those	 researchers	must	 then	 apply	 in	writing	 to	 the	GRA	
Management	Committee,	describing	the	intended	use	for	the	samples	for	approval	for	access	to	
the	 samples.	 Researchers	may	be	 from	non-profit	 research	 institutes,	 universities,	 etc	 or	 from	
commercial	organisations	from	Australia	or	overseas.	
 Research	using	your	blood,	in	combination	with	samples	from	many	other	people,	may	result	in	
discoveries	that	could	lead	to	commercial	developments.	These	developments	may	include	new	
understanding	about	the	cause	of	the	disease,	new	diagnostic	tests,	new	treatments,	and	new	
ways	to	prevent	diseases.	In	this	respect,	it	should	be	noted	that	it	is	the	whole	collection	of	
many	samples	that	is	of	value	and	that	each	individual	sample	probably	has	no	commercial	value	
on	its	own.	You	agree	to	waive	any	future	claim	to	ownership	rights	for	financial	benefit	through	
participation	in	this	research.		
	
Issues	about	online	data	entry	for	self-report	questionnaires	
 The	security	of	your	personal	 information	 is	 important	 to	us.	 	We	use	a	 third	party	web-based	
service	operated	by	QuestionPro	in	the	USA	for	conducting	surveys.	The	data	remains	controlled	
by	 us.	 	 QuestionPro	 follows	 generally	 accepted	 industry	 standards	 to	 protect	 personal	
information	 and	 uses	 secure	 socket	 layer	 technology.	 	More	 information	 on	 QuestionPro	 and	
their	Privacy	Policy	is	available	on	their	website	at	www.questionpro.com.	However,	no	method	
of	 transmission	over	 the	 internet,	or	method	of	electronic	 storage	 is	100%	secure.	 	 Therefore,	
while	we	strive	to	use	commercially	acceptable	means	to	protect	your	personal	information,	we	
cannot	guarantee	its	absolute	security.			
 By	 using	 this	 service	 you	 understand	 that	we	 use	 the	QuestionPro	 service	 and	 consent	 to	 the	
transfer	of	relevant	data	to	the	USA	based	system.		We	also	encourage	you	to	take	responsibility	
for	the	security	of	your	own	computer	system.	
	
Who	gets	told	how	I	answer	the	questions?	
 The	researcher	who	asks	you	questions	will	know,	but	they	will	keep	all	information	confidential.	
 When	we	do	our	research	your	name	and	your	answers	are	kept	apart,	so	no	one	except	the	
researcher	responsible	for	you	can	find	out.	
 Apart	from	that	we	don’t	tell	anyone	else	(unless	the	law	requires	us	to).	
	
What	if	I	change	my	mind	and	don’t	want	to	go	on	with	the	study?	
 That’s	OK.	You	can	pull	out	of	the	study	at	any	time	—	just	sign	the	form	and	tell	us.		
 	If	you	decide	to	withdraw	from	the	study,	GRA	will	follow	the	directions	of	the	Chief	Investigator	
to	either	destroy	your	sample	or	to	allow	your	sample	to	continue	to	be	used	based	on	your	
decision	as	detailed	in	the	attached	revocation	of	consent	form.		
So	it	is	all	confidential?	
 Any	information	that	is	obtained	in	connection	with	this	study	and	that	can	be	identified	with	
you	will	remain	confidential	and	will	be	disclosed	only	with	your	permission,	except	as	required	by	
law.	
 All	clinical	details	—	and	any	other	confidential	information	we	collect	—	will	be	available	only	to	
the	member	of	the	research	team	responsible	for	you.	
 Blood	samples	will	be	given	a	unique	identification	number	to	protect	your	privacy.	Genetic	
Repositories	Australia	will	not	give	out	any	personal	information	that	can	identify	you	to	the	
scientists	who	are	approved	to	receive	the	samples.		
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 If	you	give	us	your	permission	by	signing	this	document,	we	plan	to	discuss/publish	the	results	at	
scientific	conferences	and	in	scientific	journals.	In	any	discussion	or	publication,	information	will	be	
provided	in	such	a	way	that	you	cannot	be	identified.	
	
Can	I	complain	about	the	study?	
Complaints	may	be	directed	to	the:	
								Ethics	Secretariat,	
								The	University	of	New	South	Wales,	
								SYDNEY	2052	AUSTRALIA	
								Phone	9385	4234,	Fax	9385	6648,	email	ethics.sec@unsw.edu.au.	
		
Any	complaint	you	make	will	be	treated	in	confidence	and	investigated,	and	you	will	be	informed	of	the	
outcome.	
	
What	if	the	questions	upset	me?	
If	you	find	that	the	questioning	is	upsetting	or	if	you	just	want	to	talk	about	the	questions,	please	call	
Gloria	Roberts	on	1800	352	292.	So	that	we	can	ensure	your	usual	GP	or	psychiatrist	is	urgently	informed	
on	your	condition	we	will	need	you	to	provide	us	with	emergency	contact	details	for	these	doctors.	
Why	do	I	have	to	sign	a	consent	form?	
It	is	important	that	no	research	is	done	without	your	permission	—	and	we	have	to	be	able	to	prove	that	
you	said	“yes.”	
	
Tell	me	again	what	I	am	consenting	to.	
By	signing	the	Consent	Form	you	are	giving	us	permission	to	
1. Use	the	answers	from	your	assessment	in	our	research;	and	
2. Contact	you	every	12	months	over	the	next	5-10	years,	ask	you	some	more	questions,	and	use	
those	answers	in	our	research.	
	
Your	consent	
Your	decision	whether	or	not	to	participate	will	not	prejudice	your	future	relations	with	The	University	of	
New	South	Wales.	If	you	decide	to	participate,	you	are	free	to	withdraw	your	consent	and	to	discontinue	
participation	at	any	time	without	prejudice.	
If	you	have	any	questions,	please	feel	free	to	ask	us.	If	you	have	any	additional	questions	later	Gloria	
Roberts	will	be	happy	to	answer	them	(Ph	1800	352	292,	email	bipolar-kidsandsibs@unsw.edu.au	).	
	
You will be given a copy of this form to keep.  
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Please	tick	and	 initial	each	part	of	 the	study	procedures	to	show	your	agreement	to	participate.	 If	you	do	
not	wish	to	participate	in	a	specific	procedure	simply	do	not	tick	or	initial	it.	
																																																																																																																														Yes							No	 Initials	
I	consent	to	my	information	being	entered	as	part	of	the	study	records	 	 	 	 	 	
	 	 	 	 	 	
I	consent	to	provide	a	blood	sample	for	genetic	testing	 	 	 	 	 	
	 	 	 	 	 	
I	consent	to	be	contacted	every	12	months	for	a	period	of	5-10	years	 	 	 	 	 	
	 	 	 	 	 	
I	consent	to	be	contacted	regarding	future	studies	of	bipolar	disorder	 	 	 	 	 	
	
Sharing	data	across	studies	of	bipolar	disorder	and	mental	illness	allows	for	researchers	to	pool	resources	
and	make	the	most	of	our	data,	maximising	the	benefits	of	the	research.		Research	studies	conducted	by	
the	 Australian	 Schizophrenia	 Research	 Bank	 (ASRB)	 or	 the	 Sydney	 Bipolar	 Disorders	 Clinic	 at	 the	 Black	
Dog	 Institute,	 use	 the	 same	 cognitive	 and	 genetic	 analyses	 that	 we	 are	 conducting.	 Do	 you	 give	 us	
permission	to	share	your	de-identified	data	(i.e.	no	name,	address	or	other	identifying	information	will	be	
provided)	with	these	researchers?	
																																																																																																																														Yes							No	 Initials	
I	consent	to	have	my	de-identified	(cognitive/genetic/MRI)	data,		 	 	 	 	 	
made	available	for	use	in	research	by	other	studies	approved	by	 	 	 	 	 	
the	UNSW	human	research		ethics	committee.	 	 	 	 	 	
	 	 	 	 	 	
I	would	be	interested	in	receiving	information	via	mail	or	email		 	 	 	 	 	
about	other	potential	mental	health	research	studies.	I	understand		 	 	 	 	 	
that	this	would	not	oblige	me	to	take	part	in	these	studies.			 	 	 	 	 	
 
In providing a blood sample, I understand that the following is involved:  
• Blood samples will be collected for DNA extraction and/or generation of cell lines for research, 
and that my sample will be processed and stored by Genetic Repositories Australia  
• My samples will be stored indefinitely  
• My non-identifiable samples may be shared with approved researchers from academic institutions 
or companies from Australia or internationally  
• Data gathered from my sample may be published, provided that I cannot be identified  
• I will not receive any routine results  
• I will not receive any financial benefit from my participation  
• I will not receive or be able to claim any payment, compensation, royalty or any other financial 
benefit which may result from this research  
• Should I wish to withdraw from the study and have my samples destroyed, I may do so by 
contacting Professor Mitchell  
• In the event that any clinically significant result is found that has a significant probability of 
impacting on my health or that of my children, I wish to be advised how to access that information 
through established medical channels which will include genetic counselling and information 
provision via an appropriate clinical specialist:……  YES          NO        Initials   
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		THE	UNIVERSITY	OF	NEW	SOUTH	WALES	and	PRINCE	OF	WALES	HOSPITAL		
	
PARTICIPANT	INFORMATION	STATEMENT	AND	CONSENT	FORM	(continued)	
Bipolar	Kids	and	Sibs	Study	
You	are	making	a	decision	whether	or	not	 to	participate.	 	Your	signature	 indicates	 that,	having	read	
the	Participant	Information	Statement,	you	have	decided	to	take	part	in	the	study.	
	
…………………………	.…………																																				………………………………………….	
Signature	of	Research	Participant																																																					Signature	of	Witness	
	 	 	 	 	 	
	
	
……………….……………………	 	 	 	 ……………………………….	
	(Please	PRINT	name)	 	 	 	 	 											(Please	PRINT	name)	
	
	
	
…………….………………………	 	 	 	 …………………………….	
Date	 	 	 	 	 	 	 																									Nature	of	Witness	
	
	
……………………………………………………																																															
Signature(s)	of	Investigator(s)	
	
	
.…………………………………………………….	
Please	PRINT	Name	
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REVOCATION	OF	CONSENT	
Bipolar	Kids	and	Sibs	Study	
I	 hereby	wish	 to	WITHDRAW	my	 consent	 to	participate	 in	 the	 research	proposal	described	above	and	
understand	 that	 such	 withdrawal	WILL	 NOT	 jeopardise	 any	 treatment	 or	 my	 relationship	 with	 The	
University	of	New	South	Wales.	
	
___	I	hereby	wish	to	withdraw	my	consent	to	participate	in	the	study.	
	
Tick	and	initial	which	aspects	of	the	study	you	wish	to	withdraw	from:	
	 																																																																																																																			Yes					No	 Initials	
1.	 I	request	that	I	no	longer	be	contacted	regarding	this	research	but	I	
agree	that	the	data	and	samples	already	collected	to	continue	to	be	
used	
	 	
	 	
	
	 	 	 	 	 	 	
2.	 I	request	that	my	data	and	blood	sample	be	destroyed	
	 	
	 	
	
	 	 	 	 	 	 	
	 	 	 	 	 	 	
	
	
…………….………………………	 	 	 	 …………………………….	
Signature	 	 	 	 	 	 																														Date	
	
	
	
……………………………………………………																																															
Please	PRINT	Name	
	
The	section	for	Revocation	of	Consent	should	be	forwarded	to	Professor	Philip	Mitchell,	The	Black	Dog	
Institute,	Prince	of	Wales	Hospital,	RANDWICK	NSW	2031.	
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APPENDIX	I:	Participant	Information	and	Consent	Forms:	AR,	C,	BD	Under	16	–	Parent	for	child.	
	
	
	
PARTICIPANT	INFORMATION	STATEMENT	AND	CONSENT	FORM	
Bipolar	Kids	and	Sibs	Study	
Approval	No	(HREC	09097)	
THE	UNIVERSITY	OF	NEW	SOUTH	WALES	
INFORMATION STATEMENT AND CONSENT FORM 
For	parents	to	consent	for	12-16	year	old	children		
What	is	the	study	about?	
 Your	child	is	being	invited	to	take	part	in	a	longitudinal	study	to	examine	the	genetic	and	
environmental	risk	factors	for	bipolar	disorder.	
 We	hope	to	learn	about	risk	factors	for	bipolar	disorder	and	use	this	data	to	develop	better	ways	
to	intervene	early	in	those	at	risk	for	bipolar	disorder.		
	
Why	has	your	child	been	asked	to	take	part?	
Your	child	has	been	selected	as	a	possible	participant	because	your	child	has	been	diagnosed	with	
bipolar	disorder,	or	a	parent	or	sibling	of	your	child	has	been	diagnosed	with	bipolar	disorder.	
How	long	does	the	study	last?	
Identifying	risk	factors	requires	information	to	be	collected	over	many	years	and	so	we	would	like	to	
keep	in	contact	with	your	child	for	5-10	years.	Over	that	period	we	will	get	in	touch	every	12	months	and	
ask	your	child	some	questions.	
What	are	you	asking	my	child	to	do?	
 We	will	be	interviewing	your	child	to	find	out	about	symptoms	they	are	currently	experiencing	
and	also	any	they	may	have	experienced	when	they	were	younger.	We	may	also	ask	you	to	
participate	in	the	interview.		
 Your	child	will	be	asked	to	undertake	a	mood	interview,	fill	in	some	self-report	questionnaires	
(you	will	be	given	the	option	of	completing	these	questionnaires	online),	complete	a	series	of	
simple	neuropsychological	computerised	tasks,	give	some	blood,	and	undertake	a	brain	scan.	
 	After	the	initial	interview	we	would	like	to	contact	your	child	every	12	months	to	do	shorter	
assessments.	
 So	the	first	thing	we	need	is	your	permission	to	use	these	assessments	in	our	research.	
	
How	long	will	it	take?	
 The	initial	assessment	will	be	conducted	in	a	morning	and	afternoon	session	over	the	course	of	a	
day,	or	over	two	days	if	preferred.		
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 The	assessment	to	be	conducted	every	12	months	will	take	approximately	3-4	hours.		
	
Genetic	testing	
 The	genetic	testing	will	only	be	done	once.	We	will	take	20	ml	of	blood	from	a	vein	in	their	arm.		
 The	blood	will	be	used	to	look	for	genes	that	may	increase	your	child’s	risk	of	developing	bipolar	
disorder.	As	it	is	now	considered	likely	that	many	genes	–	which	each	individually	play	a	small	
role	–	are	involved	together	in	causing	bipolar	disorder,	we	will	test	for	many	genes	at	once	
when	we	analyse	your	blood	sample.	
 When	 researchers	understand	how	genes	 are	 involved	 in	 the	development	of	 bipolar	disorder	
they	have	a	better	chance	of	designing	better	methods	to	diagnose,	treat	or	cure	that	disease.	
	
Brain	imaging	
 We	will	be	inviting	some	of	the	participants	to	be	involved	in	a	brain	imaging	study.	If	your	child	
is	asked	to	be	involved	in	this,	you	will	be	provided	with	a	separate	information	sheet	and	
consent	form.	
	
What	will	you	be	asking	my	child	every	12	months?		
 The	interview	asks	them	about	any	symptoms	they	have	experienced	over	the	previous	twelve	
months.	They	also	fill	in	some	self-report	questionnaires	and	sometimes	complete	some	
neuropsychological	tests.		
	
What	are	the	advantages	and	disadvantages	of	my	child	being	involved	in	the	study?	
 We	don’t	anticipate	any	risks	to	your	child	from	being	involved	in	the	study.	However,	we	
acknowledge	that	the	assessments	are	lengthy	and	that	involvement	in	the	study	will	mean	
setting	aside	time	to	complete	them.		
 The	main	advantage	is	early	detection	of	any	symptoms	of	bipolar	disorder	or	psychosis.	If	we	
notice	symptoms	we	can	help	your	child	get	the	appropriate	treatment.	
 The	blood	draw	may	cause	some	mild	discomfort	or	bruising.	
	
How	is	the	blood	sample	used?	
 The	blood	sample	will	be	submitted	to	Genetic	Repositories	Australia	(GRA),	a	research	resource	
located	at	Neuroscience	Research	Australia,	for	subsequent	processing.	Your	child’s	sample	will	
be	de-identified	and	only	be	tracked	by	a	code	number.	
 Genetic	material	will	 be	extracted	 from	your	 child’s	 blood	 sample.	 In	order	 to	ensure	ongoing	
source	of	DNA,	white	blood	cells	(lymphocytes)	are	cultured	and	kept	growing	in	the	laboratory	
as	a	cell	 line,	which	allows	a	source	of	genetic	material	without	having	to	obtain	another	blood	
sample.	These	cell	lines	can	be	stored	indefinitely.	
 GRA	collects,	stores,	and	distributes	DNA	samples	and	cell	lines.	All	researchers	wishing	to	access	
the	genetic	material	stored	by	GRA	must	first	have	approval	from	the	relevant	Human	Research	
Ethics	 Committee	 for	 their	 projects.	 Those	 researchers	must	 then	 apply	 in	writing	 to	 the	GRA	
Management	Committee,	describing	the	intended	use	for	the	samples	for	approval	for	access	to	
the	 samples.	 Researchers	may	be	 from	non-profit	 research	 institutes,	 universities,	 etc	 or	 from	
commercial	organisations	from	Australia	or	overseas.	
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 Research	using	your	child’s	blood,	in	combination	with	samples	from	many	other	people,	may	
result	in	discoveries	that	could	lead	to	commercial	developments.	These	developments	may	
include	new	understanding	about	the	cause	of	the	disease,	new	diagnostic	tests,	new	
treatments,	and	new	ways	to	prevent	diseases.	In	this	respect,	it	should	be	noted	that	it	is	the	
whole	collection	of	many	samples	that	is	of	value	and	that	each	individual	sample	probably	has	
no	commercial	value	on	its	own.	You	agree	to	waive	any	future	claim	to	ownership	rights	for	
financial	benefit	through	participation	in	this	research.		
	
Issues	about	online	data	entry	for	self-report	questionnaires	
 The	security	of	your	personal	 information	 is	 important	 to	us.	 	We	use	a	 third	party	web-based	
service	operated	by	QuestionPro	in	the	USA	for	conducting	surveys.	The	data	remains	controlled	
by	 us.	 	 QuestionPro	 follows	 generally	 accepted	 industry	 standards	 to	 protect	 personal	
information	 and	 uses	 secure	 socket	 layer	 technology.	 	More	 information	 on	 QuestionPro	 and	
their	Privacy	Policy	is	available	on	their	website	at	www.questionpro.com.	However,	no	method	
of	 transmission	over	 the	 internet,	or	method	of	electronic	 storage	 is	100%	secure.	 	 Therefore,	
while	we	strive	to	use	commercially	acceptable	means	to	protect	your	personal	information,	we	
cannot	guarantee	its	absolute	security.			
 By	 using	 this	 service	 you	 understand	 that	we	use	 the	QuestionPro	 service	 and	 consent	 to	 the	
transfer	of	relevant	data	to	the	USA	based	system.		We	also	encourage	you	to	take	responsibility	
for	the	security	of	your	own	computer	system.	
	
Who	sees	the	information	my	child	provides?	
 The	researcher	who	asks	your	child	the	questions	will	know,	but	they	must	keep	all	information	
confidential.	
 When	we	do	our	research	your	child’s	name	and	answers	are	kept	apart,	so	no	one	except	the	
researcher	responsible	for	them	can	find	out.	
 Apart	from	that	we	don’t	tell	anyone	else	(unless	the	law	requires	us	to).	
	
What	if	I	change	my	mind	and	don’t	want	them	to	go	on	with	the	study?	
 That’s	OK.	You	can	pull	your	child	out	of	the	study	at	any	time	—	just	sign	the	form	and	tell	us.		
 	If	you	decide	to	withdraw	your	child	from	the	study,	GRA	will	follow	the	directions	of	the	Chief	
Investigator	to	either	destroy	your	child’s	sample	or	to	allow	your	child’s	sample	to	continue	to	
be	used	based	on	your	decision	as	detailed	in	the	attached	revocation	of	consent	form.		
	
So	it	is	all	confidential?	
 Any	information	that	is	obtained	in	connection	with	this	study	and	that	can	be	identified	with	
you	and	your	child	will	remain	confidential	and	will	be	disclosed	only	with	your	permission,	except	as	
required	by	law.	
 All	clinical	details	—	and	any	other	confidential	information	we	collect	—	will	be	available	only	to	
the	member	of	the	research	team	responsible	for	your	child.	
 Blood	samples	will	be	given	a	unique	identification	number	to	protect	your	child’s	privacy.	
Genetic	Repositories	Australia	will	not	give	out	any	personal	information	that	can	identify	you	or	
your	child	to	the	scientists	who	are	approved	to	receive	the	samples.		
 If	you	give	us	your	permission	by	signing	this	document,	we	plan	to	discuss/publish	the	results	at	
scientific	conferences	and	in	scientific	journals.	In	any	discussion	or	publication,	information	will	be	
provided	in	such	a	way	that	you	and	your	child	cannot	be	identified..	However,	we	cannot	and	do	not	
guarantee	or	promise	that	your	child	will	receive	any	benefits	from	the	study	directly.	
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Can	I	complain	about	the	study?	
Complaints	may	be	directed	to	the	
								Ethics	Secretariat,	
								The	University	of	New	South	Wales,	
								SYDNEY	2052	AUSTRALIA	
								Phone	9385	4234,	Fax	9385	6648,	email	ethics.sec@unsw.edu.au.	
	
Any	complaint	you	make	will	be	treated	in	confidence	and	investigated,	and	you	will	be	informed	of	the	
outcome.	
What	if	the	questions	upset	me	or	my	child?	
If	you	find	that	the	questioning	is	upsetting	or	if	you	just	want	to	talk	about	the	questions,	please	call	
Gloria	Roberts	on	1800	352	292.	So	that	we	can	ensure	your	usual	GP	or	psychiatrist	is	urgently	informed	
on	your	condition	we	will	need	you	to	provide	us	with	emergency	contact	details	for	these	doctors.	
	
Why	do	I	have	to	sign	a	consent	form?	
It	is	important	that	no	research	is	done	without	your	permission	—	and	we	have	to	be	able	to	prove	that	
you	said	“yes.”	
	
Tell	me	again	what	I	am	consenting	to:	
By	signing	the	consent	form	you	will	be	giving	us	permission	to:	
1. Use	the	answers	from	your	child’s	assessment	and	your	questions	in	our	research;	and	
2. Contact	you	and	your	child	every	12	months	over	the	next	5-10	years,	ask	your	child	some	more	
questions,	and	use	those	answers	in	our	research.	
	
Your	consent	
Your	decision	whether	or	not	to	participate	will	not	prejudice	your	future	relations	with	The	University	of	
New	South	Wales.	If	you	decide	to	participate,	you	are	free	to	withdraw	your	consent	and	to	discontinue	
participation	at	any	time	without	prejudice.	
If	you	have	any	questions,	please	feel	free	to	ask	us.	If	you	have	any	additional	questions	later	Gloria	
Roberts	will	be	happy	to	answer	them	(Ph	1800	352	292,	email	bipolar-kidsandsibs@unsw.edu.au	).	
	
You will be given a copy of this form to keep.  
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Please	tick	and	 initial	each	part	of	 the	study	procedures	to	show	your	agreement	to	participate.	 If	you	do	
not	wish	to	participate	in	a	specific	procedure	simply	do	not	tick	or	initial	it.	
																																																																																																																														Yes							No	 Initials	
I	consent	to	my	child’s	information	being	entered	as	part	of	the	study		 	 	 	 	 	
records	 	 	 	 	 	
	 	 	 	 	 	
I	consent	to	my	child	providing	a	blood	sample	for	genetic	testing	 	 	 	 	 	
	 	 	 	 	 	
I	consent	to	be	contacted	every	12	months	for	a	period	of	5-10	years	 	 	 	 	 	
	 	 	 	 	 	
I	consent	to	be	contacted	regarding	future	studies	of	bipolar	disorder	 	 	 	 	 	
	
Sharing	data	across	studies	of	bipolar	disorder	and	mental	illness	allows	for	researchers	to	pool	resources	
and	make	the	most	of	our	data,	maximising	the	benefits	of	the	research.		Research	studies	conducted	by	
the	 Australian	 Schizophrenia	 Research	 Bank	 (ASRB)	 or	 the	 Sydney	 Bipolar	 Disorders	 Clinic	 at	 the	 Black	
Dog	 Institute,	 use	 the	 same	 cognitive	 and	 genetic	 analyses	 that	 we	 are	 conducting.	 Do	 you	 give	 us	
permission	to	share	your	de-identified	data	(i.e.	no	name,	address	or	other	identifying	information	will	be	
provided)	with	these	researchers?	
																																																																																																																														Yes							No	 Initials	
I	consent	to	have	my	child’s	de-identified	(cognitive/genetic/MRI)		 	 	 	 	 	
data,	made	available	for	use	in	research	by	other	studies	approved	by	 	 	 	 	 	
the	UNSW	human	research	ethics	committee.	 	 	 	 	 	
	 	 	 	 	 	
I	would	be	interested	in	receiving	information	via	mail	or	email		 	 	 	 	 	
about	other	potential	mental	health	research	studies.	I	understand		 	 	 	 	 	
that	this	would	not	oblige	me	to	take	part	in	these	studies.			 	 	 	 	 	
	
In providing consent for my child to provide a blood sample, I understand that the 
following is involved:  
• Blood samples will be collected for DNA extraction and/or generation of cell lines for research, 
and that my child’s sample will be processed and stored by Genetic Repositories Australia  
• My child’s samples will be stored indefinitely  
• My child’s non-identifiable samples may be shared with approved researchers from academic 
institutions or companies from Australia or internationally  
• Data gathered from my child’s sample may be published, provided that my child cannot be 
identified  
• My child will not receive any routine results  
• My child will not receive any financial benefit from my participation  
• My child will not receive or be able to claim any payment, compensation, royalty or any other 
financial benefit which may result from this research  
• Should I wish to withdraw my child from the study and have my child’s samples destroyed, I may 
do so by contacting Professor Mitchell  
• In the event that any clinically significant result is found that has a significant probability of 
impacting on my health or that of my children, I wish to be advised how to access that information 
through established medical channels which will include genetic counselling and information 
provision via an appropriate clinical specialist:……  YES          NO        Initials   
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THE	UNIVERSITY	OF	NEW	SOUTH	WALES	
PARTICIPANT	INFORMATION	STATEMENT	AND	CONSENT	FORM	(continued)	
Bipolar	Kids	and	Sibs	Study	
	
You	are	making	a	decision	whether	or	not	to	permit	your	child	to	participate.		
Your	signature	indicates	that,	having	read	the	attached	Parental	(or	Guardian)	Information	Statement	
and	 Participant	 Information	 Statement,	 you	 have	 decided	 to	 take	 part	 in	 the	 study	 and	 you	 have	
decided	to	permit	your	child	to	take	part	in	the	study.				
	
	
.………………………………	…		 	 	 ………………………………………..	
Signature	of	Parent/Guardian		 	 	 	Signature	of	Witness	
	 	 	 	 	 	
	
	.…………………………………		 	 	 ……………………………………….	
	(Please	PRINT	name)	 	 	 	 	(Please	PRINT	name)	
	
	
	.…………………………………		 	 	 ………………………………………..			
Date	 	 	 	 	 	 	Nature	of	Witness	
	
	
……………………………………………………																																															
Signature(s)	of	Investigator(s)	
	
	
.…………………………………………………….	
Please	PRINT	Name	
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Approval	No	(HREC	09097)	
REVOCATION	OF	CONSENT	
Bipolar	Kids	and	Sibs	Study	
	
I	hereby	wish	to	WITHDRAW	my	consent	for	my	child/ward	and	myself	to	participate	in	the	research	
proposal	described	above	and	understand	that	such	withdrawal	WILL	NOT	jeopardise	any	treatment,	or	
my	child/ward’s	relationship,	with	The	University	of	New	South	Wales.	
	
___	I	hereby	wish	to	withdraw	my	child’s	consent	to	participate	in	the	study.	
	
Tick	and	initial	which	aspects	of	the	study	you	wish	to	withdraw	from:	
	 																																																																																																																			Yes					No	 Initials	
1.	 I	request	that	my	child	no	longer	be	contacted	regarding	this	research	
but	I	agree	that	the	data	and	samples	already	collected	to	continue	to	
be	used	
	 	 	 	 	
	 	 	 	 	 	 	
2.	 I	request	that	my	child’s	data	and	blood	sample	be	destroyed	 	 	 	 	 	
	 	 	 	 	 	 	
	 	 	 	 	 	 	
	
……………………………………										 	 	 ………………………………….																																		
Signature	of	Parent/Guardian			 	 	 	 	 										Date	
	
	
……………………………………………………																																															
Please	PRINT	Name	
	
The	section	for	Revocation	of	Consent	should	be	forwarded	to	Professor	Philip	Mitchell,	Black	Dog	
Institute,	Prince	of	Wales	Hospital,	RANDWICK	NSW	2031.	
	
	130	
	
APPENDIX	J:	Participant	Information	and	Consent	Forms:	AR,	C,	BD	Under	16	–	Child	for	self.	
 
 
 
 
 
 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM 
 
Bipolar Kids and Sibs Study 
 
Approval No (HREC 09097)    
 
THE UNIVERSITY OF NEW SOUTH WALES  
 
 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM 
 
 
Below are some questions that you might like to ask about the study. We will happily explain 
further or answer any other questions that you might have. 
 
What is the study about? 
 You are being invited to take part in a study that will take part at different time points to 
examine the genetic and environmental risk factors for bipolar disorder. 
 We hope to learn about risk factors for bipolar disorder and use this data to develop better 
ways to provide early help to those at risk for bipolar disorder. 
 
Why have I been asked to take part? 
You were selected as a possible participant in this study because you or a member of your family 
have a history of bipolar disorder. 
 
How long does the study last? 
Identifying risk factors requires information to be collected over many years and so we would 
like to keep in contact with you for 5 – 10 years. Over that period we will get in touch every 12 
months and ask you some questions. 
 
What are you asking me to do? 
 We will be interviewing you to find out about symptoms you experience now and also 
those you may have experienced when you were younger. 
 You will also be asked to undertake a mood interview, fill in some self-report 
questionnaires (you will be given the option of completing these questionnaires online), 
complete a series of simple neuropsychological computerised tasks, give some blood, and 
undertake a brain scan. 
 After the initial interview we would like to contact you every 12 months to do shorter 
assessments. 
 So the first thing we need is your permission to use these assessments in our research. 
 
How long will it take? 
 The initial assessment will be conducted in a morning and afternoon session over the 
course of a day, or over two days if preferred.   
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 The questions to be done every 12 months will take approximately 3-4 hours. 
 
Genetic testing 
 The genetic testing will only be done once. We will take 20 ml of blood from a vein in 
your arm.  
 The blood will be used to look for genes that may increase your risk of developing bipolar 
disorder. As it is now considered likely that many genes – which each individually play a 
small role – are involved together in causing bipolar disorder, we will test for many genes 
at once when we analyse your blood sample. 
 When researchers understand how genes are involved in the development of bipolar 
disorder they have a better chance of designing better methods to diagnose, treat or cure 
that disease. 
 
Brain imaging 
 We will be inviting some of the participants to be involved in a brain imaging study.  If 
you are asked to be involved in this, you will be provided with a separate information 
sheet and consent form. 
 
What will you be asking me every 12 months? 
There will be an interview asking you about any symptoms you have experienced over the 
previous six months. You will also complete some self-report questionnaires and sometimes a 
series of psychological tests. The questions are a lot like the ones you are answering for the first 
assessment.  
 
What are the advantages and disadvantages of being involved in the study? 
 We don’t anticipate any risks to you from being involved in the study. However, we 
acknowledge that the assessments are lengthy and that involvement in the study will mean 
setting aside time to complete them.  
 The main advantage is early detection of any symptoms of bipolar disorder or other 
mental disorders. If we notice symptoms we can help you get the appropriate treatment. 
 The blood draw may cause some mild discomfort or bruising. 
 
How is the blood sample used? 
 The blood sample will be submitted to Genetic Repositories Australia (GRA), a research 
resource located at Neuroscience Research Australia, for subsequent processing. Your 
sample will be de-identified and only be tracked by a code number. 
 Genetic material will be extracted from your blood sample. In order to ensure ongoing 
source of DNA, white blood cells (lymphocytes) are cultured and kept growing in the 
laboratory as a cell line, which allows a source of genetic material without having to 
obtain another blood sample. These cell lines can be stored indefinitely. 
 GRA collects, stores, and distributes DNA samples and cell lines. All researchers wishing 
to access the genetic material stored by GRA must first have approval from the relevant 
Human Research Ethics Committee for their projects. Those researchers must then apply 
in writing to the GRA Management Committee, describing the intended use for the 
samples for approval for access to the samples. Researchers may be from non-profit 
research institutes, universities, etc or from commercial organisations from Australia or 
overseas. Research using your blood, in combination with samples from many other 
people, may result in discoveries that could lead to commercial developments. These 
developments may include new understanding about the cause of the disease, new 
diagnostic tests, new treatments, and new ways to prevent diseases. In this respect, it 
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should be noted that it is the whole collection of many samples that is of value and that 
each individual sample probably has no commercial value on its own.  You agree to waive 
any future claim to ownership rights for financial benefit through participation in this 
research.  
 
Issues about online data entry for self-report questionnaires 
 The security of your personal information is important to us.  We use a separate web-
based service operated by QuestionPro in the USA for conducting surveys. The data 
remains controlled by us.  QuestionPro does what is accepted business practice to protect 
personal information, using what is called ‘secure socket layer technology’.  More 
information on QuestionPro and their Privacy Policy is available on their website at 
www.questionpro.com. However, no method of answering questions over the internet, or 
method of storing data electronically is 100% secure.  Therefore, while we strive to use 
acceptable means to protect your personal information, we cannot guarantee that it’s 
absolutely safe.   
 By using this service you understand that we use the QuestionPro service and consent to 
the transfer of relevant data to the USA based system.  We also encourage you to take 
responsibility for your own computer system’s safety and protection. 
 
Who gets told how I answer the questions? 
 The researcher who asks you questions will know, but they will keep all information 
private. 
 When we do our research your name and your answers are kept apart, so no one except 
the researcher responsible for you can find out. 
 Apart from that we don’t tell anyone else (unless the law requires us to). 
 
What if I change my mind and don’t want to go on with the study? 
 That’s OK. You can pull out of the study at any time — just sign the form and tell us.  
  If you decide to withdraw from the study, GRA will follow the directions of the Chief 
Investigator to either destroy your sample or to allow your sample to continue to be used 
based on your decision as detailed in the attached revocation of consent form.  
 
So it is all private? 
 Any information that is obtained in connection with this study and that can be identified 
with you will remain private, except as required by law. 
 All the information we collect — will be available only to the member of the research 
team responsible for you. 
 Blood samples will be given a unique identification number to protect your privacy. 
Genetic Repositories Australia will not give out any personal information that can identify 
you to the scientists who are approved to receive the samples.  
 If you give us your permission by signing this document, we plan to discuss/publish the 
results at scientific meetings and in scientific journals. In any discussion or publication, 
information will be provided in such a way that you cannot be identified. 
 
Can I complain about the study? 
Complaints may be directed to the 
        Ethics Secretariat, 
        The University of New South Wales, 
        SYDNEY 2052 AUSTRALIA 
        Phone 9385 4234, Fax 9385 6648, email ethics.sec@unsw.edu.au. 
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Any complaint you make will be treated in confidence and investigated, and you will be told 
about the outcome. 
 
What if the questions upset me? 
If you find that the questioning is upsetting or if you just want to talk about the questions, please 
call Gloria Roberts on 1800 352 292. So that we can ensure your usual GP or psychiatrist is 
urgently informed on your condition we will need you to provide us with emergency contact 
details for these doctors. 
 
Why do I have to sign a consent form? 
It is important that no research is done without your permission — and we have to be able to 
prove that you said “yes.” 
 
Tell me again what I am consenting to. 
By signing the Consent Form you are giving us permission to 
3. Use the answers from your assessment in our research; and 
4. Contact you every 12 months over the next 5-10 years, ask you some more questions, and 
use those answers in our research. 
 
Your consent 
Your decision whether or not to participate will not affect your future relations with The 
University of New South Wales. If you decide to participate, you are free to withdraw your 
consent and to discontinue participation at any time without any consequences. 
 
If you have any questions, please feel free to ask us. If you have any additional questions later 
Gloria Roberts will be happy to answer them (Ph 1800 352 292, email bipolar-
kidsandsibs@unsw.edu.au ). 
 
 
You will be given a copy of this form to keep.  
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Please tick and initial each part of the study procedures to show your agreement to participate. 
If you do not wish to participate in a specific procedure simply do not tick or initial it. 
 
                                                                                                                              Yes       No Initials 
I consent to my information being entered as part of the study records      
      
I consent to provide a blood sample for genetic testing      
      
I consent to be contacted every 12 months for a period of 5-10 years      
      
I consent to be contacted regarding future studies of bipolar disorder      
 
Sharing data across studies of bipolar disorder and mental illness allows for researchers to pool 
resources and make the most of our data, maximising the benefits of the research.  Research 
studies conducted by the Australian Schizophrenia Research Bank (ASRB) or the Sydney Bipolar 
Disorders Clinic at the Black Dog Institute, use the same cognitive and genetic analyses that we 
are conducting. Do you give us permission to share your de-identified data (i.e. no name, address 
or other identifying information will be provided) with these researchers? 
 
                                                                                                                              Yes       No Initials 
I consent to have my de-identified (cognitive/genetic/MRI) data,       
made available for use in research by other studies approved by      
the UNSW human research ethics committee.      
      
I would be interested in receiving information via mail or email       
about other potential mental health research studies. I understand       
that this would not oblige me to take part in these studies.        
 
In providing a blood sample, I understand that the following is involved:  
• Blood samples will be collected for DNA extraction and/or generation of cell lines for research, 
and that my sample will be processed and stored by Genetic Repositories Australia  
• My samples will be stored indefinitely  
• My non-identifiable samples may be shared with approved researchers from academic institutions 
or companies from Australia or internationally  
• Data gathered from my sample may be published, provided that I cannot be identified  
• I will not receive any routine results  
• I will not receive any financial benefit from my participation  
• I will not receive or be able to claim any payment, compensation, royalty or any other financial 
benefit which may result from this research  
• Should I wish to withdraw from the study and have my samples destroyed, I may do so by 
contacting Professor Mitchell  
• In the event that any clinically significant result is found that has a significant probability of 
impacting on my health or that of my children, I wish to be advised how to access that information 
through established medical channels which will include genetic counselling and information 
provision via an appropriate clinical specialist:……  YES          NO        Initials   
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  THE UNIVERSITY OF NEW SOUTH WALES and PRINCE OF WALES HOSPITAL  
 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM (continued) 
Bipolar Kids and Sibs Study 
 
You are making a decision whether or not to participate.  Your signature indicates that, 
having read the Participant Information Statement, you have decided to take part in the 
study. 
 
 
 
………………….…………………    …………………………………. 
Signature of Research Participant                                                     Signature of Witness 
      
 
 
…………………….………………    ……………………………………. 
 (Please PRINT name)               (Please PRINT name) 
 
 
 
…………………….………………    ……………………………………. 
Date                               Nature of Witness 
 
 
 
……………………………………………………                                               
Signature(s) of Investigator(s) 
 
 
 
.……………………………………………………. 
Please PRINT Name 
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REVOCATION OF CONSENT 
Bipolar Kids and Sibs Study 
 
I hereby wish to WITHDRAW my consent to participate in the research proposal described 
above and understand that such withdrawal WILL NOT jeopardise any treatment or my 
relationship with The University of New South Wales. 
 
 
 
___ I hereby wish to withdraw my consent to participate in the study. 
 
 
Tick and initial which aspects of the study you wish to withdraw from: 
 
                                                                                                                    Yes     No Initials 
1. I request that I no longer be contacted regarding this research but I 
agree that the data and samples already collected to continue to be used 
  
  
 
  
 
     
2. I request that my data and blood sample be destroyed 
  
  
 
       
       
 
 
…………………….………………    ……………………………………. 
Signature                                            Date 
 
 
 
……………………………………………………                                               
Please PRINT Name 
 
 
The section for Revocation of Consent should be forwarded to Professor Philip Mitchell, The 
Black Dog Institute, Prince of Wales Hospital, RANDWICK NSW 2031. 
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APPENDIX	K:	Participant	Information	and	Consent	Forms:	16-22yrs	–Proband	Parent.	
 
 
 
 
 
 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM 
 
Bipolar Kids and Sibs Study 
 
Approval No (HREC 09097) 
 
THE UNIVERSITY OF NEW SOUTH WALES 
 
 
INFORMATION STATEMENT AND CONSENT FORM 
 
For parents to consent for themselves.  
 
Below are some questions that you might like to ask about the study. We will happily explain 
further or answer any other questions that you might have. 
 
What is the study about? 
 You are being invited to take part in a longitudinal study to examine the genetic and 
environmental risk factors for bipolar disorder. 
 We hope to learn about risk factors for bipolar disorder and use this data to develop better 
ways to intervene early in those at risk for bipolar disorder. 
 
Why have I been asked to take part? 
You were selected as a possible participant in this study because a parent or sibling of your child 
has been diagnosed with bipolar disorder. 
 
How long does the study last? 
Identifying risk factors requires information to be collected over many years and so we would 
like to keep in contact with you for 5 – 10 years. Over that period we will get in touch every 12 
months and ask you some questions. 
 
What will I be asked for? 
 As a parent we will be interviewing you to find out about symptoms experienced by your 
child now and also those that he/she may have experienced at a younger age.  
 For the initial assessment you will undertake a mood interview about your child, fill in 
some questionnaires about yourself in addition to questionnaires about your children who 
are participating in this study (you will be given the option of completing these 
questionnaires online), and give some blood. You will also be asked will undertake a 
mood interview about yourself. After the initial interview we would like to contact the 
parent every 12 months to do shorter assessments. 
 
How long will it take? 
 The initial assessment about your child will be conducted in a morning or afternoon 
session, or over two days if preferred. The questionnaires can be completed during this 
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session or else online prior to mood interviews. If you are also undertaking a mood 
interview about yourself this will take an additional morning or afternoon session that will 
be conducted prior to the interview about your child.  
 The questions and mood interviews to be done every twelve months will take 
approximately 3-4 hours. 
 
Genetic testing 
 The genetic testing will only be done once. We will take 20 ml of blood from a vein in 
your arm.  
 The blood will be used to look for genes that may increase your risk of developing bipolar 
disorder. As it is now considered likely that many genes – which each individually play a 
small role – are involved together in causing bipolar disorder, we will test for many genes 
at once when we analyse your blood sample. 
 When researchers understand how genes are involved in the development of bipolar 
disorder they have a better chance of designing better methods to diagnose, treat or cure 
that disease. 
 
What will you be asking every 12 months? 
 There will be an interview asking you about any symptoms your child may have 
experienced over the previous twelve months. You will also complete some self-report 
questionnaires. The questions are a lot like the ones being answered for the first 
assessment.  
 
What are the advantages and disadvantages of being involved in the study? 
 We don’t anticipate any risks to you from being involved in the study. However, we 
acknowledge that the assessments are lengthy and that involvement in the study will mean 
setting aside time to complete them.  
 The main advantage is early detection of any symptoms of bipolar disorder or psychosis 
in your child. If we notice symptoms we can help your child get the appropriate treatment. 
 
How is the blood sample used? 
 The blood sample will be submitted to Genetic Repositories Australia (GRA), a research 
resource located at Neuroscience Research Australia, for subsequent processing. Your 
sample will be de-identified and only be tracked by a code number. 
 Genetic material will be extracted from your blood sample. In order to ensure ongoing 
source of DNA, white blood cells (lymphocytes) are cultured and kept growing in the 
laboratory as a cell line, which allows a source of genetic material without having to 
obtain another blood sample. These cell lines can be stored indefinitely. 
 GRA collects, stores, and distributes DNA samples and cell lines. All researchers wishing 
to access the genetic material stored by GRA must first have approval from the relevant 
Human Research Ethics Committee for their projects. Those researchers must then apply 
in writing to the GRA Management Committee, describing the intended use for the 
samples for approval for access to the samples. Researchers may be from non-profit 
research institutes, universities, etc or from commercial organisations from Australia or 
overseas. 
 Research using your blood, in combination with samples from many other people, may 
result in discoveries that could lead to commercial developments. These developments 
may include new understanding about the cause of the disease, new diagnostic tests, new 
treatments, and new ways to prevent diseases. In this respect, it should be noted that it is 
the whole collection of many samples that is of value and that each individual sample 
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probably has no commercial value on its own. You agree to waive any future claim to 
ownership rights for financial benefit through participation in this research.  
 
Issues about online data entry for self-report questionnaires 
 The security of your personal information is important to us.  We use a third party web-
based service operated by QuestionPro in the USA for conducting surveys. The data 
remains controlled by us.  QuestionPro follows generally accepted industry standards to 
protect personal information and uses secure socket layer technology.  More information 
on QuestionPro and their Privacy Policy is available on their website at 
www.questionpro.com. However, no method of transmission over the internet, or method 
of electronic storage is 100% secure.  Therefore, while we strive to use commercially 
acceptable means to protect your personal information, we cannot guarantee its absolute 
security.   
 By using this service you understand that we use the QuestionPro service and consent to 
the transfer of relevant data to the USA based system.  We also encourage you to take 
responsibility for the security of your own computer system. 
 
Who gets told how I answer the questions? 
 The researcher who asks you questions will know, but they will keep all information 
confidential. 
 When we do our research your name and your answers are kept apart, so no one except 
the researcher responsible for you can find out. 
 Apart from that we don’t tell anyone else (unless the law requires us to). 
 
What if I change my mind and don’t want to go on with the study? 
That’s OK. You can pull out of the study at any time — just sign the form and tell us. 
 
So it is all confidential? 
 Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission, except as 
required by law. 
 All clinical details — and any other confidential information we collect — will be 
available only to the member of the research team responsible for you. 
 If you give us your permission by signing this document, we plan to discuss/publish the 
results at scientific conferences and in scientific journals. In any discussion or publication, 
information will be provided in such a way that you cannot be identified. 
 
 
Can I complain about the study? 
Complaints may be directed to the 
        Ethics Secretariat, 
        The University of New South Wales, 
        SYDNEY 2052 AUSTRALIA 
        Phone 9385 4234, Fax 9385 6648, email ethics.sec@unsw.edu.au. 
  
Any complaint you make will be treated in confidence and investigated, and you will be informed 
of the outcome. 
 
What if the questions upset me? 
If you find that the questioning is upsetting or if you just want to talk about the questions, please 
call Gloria Roberts on 1800 352 292. So that we can ensure your usual GP or psychiatrist is 
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urgently informed on your condition we will need you to provide us with emergency contact 
details for these doctors. 
 
Why do I have to sign a consent form? 
It is important that no research is done without your permission — and we have to be able to 
prove that you said “yes.” 
 
Tell me again what I am consenting to. 
By signing the Consent Form you are giving us permission to 
5. Use the answers from your assessment in our research; and 
6. Contact you every 12 months over the next 5-10 years, ask you some more questions, and 
use those answers in our research. 
 
Your consent 
Your decision whether or not to participate will not prejudice your future relations with The 
University of New South Wales. If you decide to participate, you are free to withdraw your 
consent and to discontinue participation at any time without prejudice. 
 
If you have any questions, please feel free to ask us. If you have any additional questions later 
Gloria Roberts will be happy to answer them (Ph 1800 352 292, email bipolar-
kidsandsibs@unsw.edu.au ). 
 
You will be given a copy of this form to keep.  
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  THE UNIVERSITY OF NEW SOUTH WALES and PRINCE OF WALES HOSPITAL  
 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM (continued) 
Bipolar Kids and Sibs Study 
 
You are making a decision whether or not to participate.  Your signature indicates that, 
having read the Participant Information Statement, you have decided to take part in the 
study. 
 
 
 
…………………… .……………    ………………………………………. 
Signature of Research Participant                                                           Signature of Witness 
      
 
 
…………………………………     ………………………………………. 
 (Please PRINT name)                      (Please PRINT name) 
 
 
 
…………………….……………    ………………………………………. 
Date                                     Nature of Witness 
 
 
 
……………………………………………………                                               
Signature(s) of Investigator(s) 
 
 
 
.……………………………………………………. 
Please PRINT Name 
 
 
Do you agree to be contacted every 12 months for a period of 5-10 years?  
yes               no 
 
Sharing data across studies of bipolar disorder and mental illness allows for researchers to pool 
resources and make the most of our data, maximising the benefits of the research.  Research 
studies conducted by the Australian	 Schizophrenia	 Research	 Bank	 (ASRB)	 or	 the	 Sydney	Bipolar	Disorders	Clinic	at	 the	Black	Dog	 Institute, use the same cognitive and genetic analyses 
that we are conducting. Do you give us permission to share your de-identified data (i.e. no name, 
address or other identifying information will be provided) with these researchers? 
	
___ I	consent	to	have	my	de-identified	(cognitive/genetic/MRI)	data,	made	available	
for	use	in	research	by	other	studies	approved	by	the	UNSW	ethics	committee.	
 
___ I would be interested in receiving information via mail or email about other potential 
mental health research studies. I understand that this would not oblige me to take part in 
these studies.  	
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REVOCATION OF CONSENT 
Bipolar Kids and Sibs Study 
 
I hereby wish to WITHDRAW my consent to participate in the research proposal described 
above and understand that such withdrawal WILL NOT jeopardise any treatment or my 
relationship with The University of New South Wales. 
 
 
___ I hereby wish to withdraw my consent to participate in the study. 
 
___ I do not want to be contacted in the future.  
 
 
…………………….……………    ………………………………………. 
Signature                                            Date 
 
 
 
……………………………………………………                                               
Please PRINT Name 
 
 
The section for Revocation of Consent should be forwarded to Professor Philip Mitchell, The 
Black Dog Institute, Prince of Wales Hospital, RANDWICK NSW 2031. 
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APPENDIX	L:	Participant	Information	and	Consent	Forms:	Under	16yrs	–Proband	Parent.	
 
 
 
 
 
 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM 
 
Bipolar Kids and Sibs Study 
 
Approval No (HREC 09097) 
 
THE UNIVERSITY OF NEW SOUTH WALES 
 
 
INFORMATION STATEMENT AND CONSENT FORM 
For parents to consent for themselves.  
 
 
Below are some questions that you might like to ask about the study. We will happily explain 
further or answer any other questions that you might have. 
 
What is the study about? 
 You are being invited to take part in a longitudinal study to examine the genetic and 
environmental risk factors for bipolar disorder. 
 We hope to learn about risk factors for bipolar disorder and use this data to develop better 
ways to intervene early in those at risk for bipolar disorder. 
 
Why have I been asked to take part? 
You were selected as a possible participant in this study because your child has been diagnosed 
with bipolar disorder or a parent or sibling of your child has been diagnosed with bipolar 
disorder. 
 
How long does the study last? 
Identifying risk factors requires information to be collected over many years and so we would 
like to keep in contact with you for 5 – 10 years. Over that period we will get in touch every 12 
months and ask you some questions. 
 
What will I be asked for? 
 As a parent we will be interviewing you to find out about symptoms experienced by your 
child now and also those that he/she may have experienced at a younger age.  
 For the initial assessment you will undertake a mood interview about your child, fill in 
some questionnaires about yourself in addition to questionnaires about your children who 
are participating in this study (you will be given the option of completing these 
questionnaires online). You will also be asked will undertake a mood interview about 
yourself. After the initial interview we would like to contact the parent every 12 months to 
do shorter assessments. 
 
How long will it take? 
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 The initial assessment about your child will be conducted in a morning or afternoon 
session, or over two days if preferred. The questionnaires can be completed during this 
session or else online prior to mood interviews. If you are also undertaking a mood 
interview about yourself this will take an additional morning or afternoon session that will 
be conducted prior to the interview about your child.  
 The questions and mood interviews to be done every twelve months will take 
approximately 3-4 hours. 
 
Genetic testing 
 The genetic testing will only be done once. We will take 20 ml of blood from a vein in 
your arm.  
 The blood will be used to look for genes that may increase your risk of developing bipolar 
disorder. As it is now considered likely that many genes – which each individually play a 
small role – are involved together in causing bipolar disorder, we will test for many genes 
at once when we analyse your blood sample. 
 When researchers understand how genes are involved in the development of bipolar 
disorder they have a better chance of designing better methods to diagnose, treat or cure 
that disease. 
 
What will you be asking every 12 months? 
 There will be an interview asking you about any symptoms your child may have 
experienced over the previous twelve months. You will also complete some self-report 
questionnaires. The questions are a lot like the ones being answered for the first 
assessment.  
 
What are the advantages and disadvantages of being involved in the study? 
 We don’t anticipate any risks to you from being involved in the study. However, we 
acknowledge that the assessments are lengthy and that involvement in the study will mean 
setting aside time to complete them.  
 The main advantage is early detection of any symptoms of bipolar disorder or psychosis 
in your child. If we notice symptoms we can help your child get the appropriate treatment. 
  
How is the blood sample used? 
 The blood sample will be submitted to Genetic Repositories Australia (GRA), a research 
resource located at Neuroscience Research Australia, for subsequent processing. Your 
sample will be de-identified and only be tracked by a code number. 
 Genetic material will be extracted from your blood sample. In order to ensure ongoing 
source of DNA, white blood cells (lymphocytes) are cultured and kept growing in the 
laboratory as a cell line, which allows a source of genetic material without having to 
obtain another blood sample. These cell lines can be stored indefinitely. 
 GRA collects, stores, and distributes DNA samples and cell lines. All researchers wishing 
to access the genetic material stored by GRA must first have approval from the relevant 
Human Research Ethics Committee for their projects. Those researchers must then apply 
in writing to the GRA Management Committee, describing the intended use for the 
samples for approval for access to the samples. Researchers may be from non-profit 
research institutes, universities, etc or from commercial organisations from Australia or 
overseas. 
 Research using your blood, in combination with samples from many other people, may 
result in discoveries that could lead to commercial developments. These developments 
may include new understanding about the cause of the disease, new diagnostic tests, new 
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treatments, and new ways to prevent diseases. In this respect, it should be noted that it is 
the whole collection of many samples that is of value and that each individual sample 
probably has no commercial value on its own. You agree to waive any future claim to 
ownership rights for financial benefit through participation in this research.  
 
Issues about online data entry for self-report questionnaires 
 The security of your personal information is important to us.  We use a third party web-
based service operated by QuestionPro in the USA for conducting surveys. The data 
remains controlled by us.  QuestionPro follows generally accepted industry standards to 
protect personal information and uses secure socket layer technology.  More information 
on QuestionPro and their Privacy Policy is available on their website at 
www.questionpro.com. However, no method of transmission over the internet, or method 
of electronic storage is 100% secure.  Therefore, while we strive to use commercially 
acceptable means to protect your personal information, we cannot guarantee its absolute 
security.   
 By using this service you understand that we use the QuestionPro service and consent to 
the transfer of relevant data to the USA based system.  We also encourage you to take 
responsibility for the security of your own computer system. 
 
Who gets told how I answer the questions? 
 The researcher who asks you questions will know, but they will keep all information 
confidential. 
 When we do our research your name and your answers are kept apart, so no one except 
the researcher responsible for you can find out. 
 Apart from that we don’t tell anyone else (unless the law requires us to). 
 
What if I change my mind and don’t want to go on with the study? 
That’s OK. You can pull out of the study at any time — just sign the form and tell us. 
 
So it is all confidential? 
 Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission, except as 
required by law. 
 All clinical details — and any other confidential information we collect — will be 
available only to the member of the research team responsible for you. 
 If you give us your permission by signing this document, we plan to discuss/publish the 
results at scientific conferences and in scientific journals. In any discussion or publication, 
information will be provided in such a way that you cannot be identified. 
 
 
Can I complain about the study? 
Complaints may be directed to the 
        Ethics Secretariat, 
        The University of New South Wales, 
        SYDNEY 2052 AUSTRALIA 
        Phone 9385 4234, Fax 9385 6648, email ethics.sec@unsw.edu.au. 
  
Any complaint you make will be treated in confidence and investigated, and you will be informed 
of the outcome. 
 
What if the questions upset me? 
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If you find that the questioning is upsetting or if you just want to talk about the questions, please 
call Gloria Roberts on 1800 352 292. So that we can ensure your usual GP or psychiatrist is 
urgently informed on your condition we will need you to provide us with emergency contact 
details for these doctors. 
 
Why do I have to sign a consent form? 
It is important that no research is done without your permission — and we have to be able to 
prove that you said “yes.” 
 
Tell me again what I am consenting to. 
By signing the Consent Form you are giving us permission to 
7. Use the answers from your assessment in our research; and 
8. Contact you every 12 months over the next 5-10 years, ask you some more questions, and 
use those answers in our research. 
 
Your consent 
Your decision whether or not to participate will not prejudice your future relations with The 
University of New South Wales. If you decide to participate, you are free to withdraw your 
consent and to discontinue participation at any time without prejudice. 
 
If you have any questions, please feel free to ask us. If you have any additional questions later 
Gloria Roberts will be happy to answer them (Ph 1800 352 292, email bipolar-
kidsandsibs@unsw.edu.au ). 
 
You will be given a copy of this form to keep.  
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  THE UNIVERSITY OF NEW SOUTH WALES and PRINCE OF WALES HOSPITAL  
 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM (continued) 
Bipolar Kids and Sibs Study 
 
You are making a decision whether or not to participate.  Your signature indicates that, 
having read the Participant Information Statement, you have decided to take part in the 
study. 
 
 
 
…………………… .……………    ………………………………………. 
Signature of Research Participant                                                           Signature of Witness 
      
 
 
…………………………………     ………………………………………. 
 (Please PRINT name)                      (Please PRINT name) 
 
 
 
…………………….……………    ………………………………………. 
Date                                     Nature of Witness 
 
 
 
……………………………………………………                                               
Signature(s) of Investigator(s) 
 
 
 
.……………………………………………………. 
Please PRINT Name 
 
 
Do you agree to be contacted every 12 months for a period of 5-10 years?  
yes               no 
 
Sharing data across studies of bipolar disorder and mental illness allows for researchers to pool 
resources and make the most of our data, maximising the benefits of the research.  Research 
studies conducted by the Australian	 Schizophrenia	 Research	 Bank	 (ASRB)	 or	 the	 Sydney	Bipolar	Disorders	Clinic	at	 the	Black	Dog	 Institute, use the same cognitive and genetic analyses 
that we are conducting. Do you give us permission to share your de-identified data (i.e. no name, 
address or other identifying information will be provided) with these researchers? 
	
___ I	consent	to	have	my	de-identified	(cognitive/genetic/MRI)	data,	made	available	
for	use	in	research	by	other	studies	approved	by	the	UNSW	ethics	committee.	
 
___ I would be interested in receiving information via mail or email about other potential 
mental health research studies. I understand that this would not oblige me to take part in 
these studies.  	
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REVOCATION OF CONSENT 
Bipolar Kids and Sibs Study 
 
I hereby wish to WITHDRAW my consent to participate in the research proposal described 
above and understand that such withdrawal WILL NOT jeopardise any treatment or my 
relationship with The University of New South Wales. 
 
 
___ I hereby wish to withdraw my consent to participate in the study. 
 
___ I do not want to be contacted in the future.  
 
 
…………………….……………    ………………………………………. 
Signature                                            Date 
 
 
 
……………………………………………………                                               
Please PRINT Name 
 
 
The section for Revocation of Consent should be forwarded to Professor Philip Mitchell, The 
Black Dog Institute, Prince of Wales Hospital, RANDWICK NSW 2031. 
 
 
	
